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The human papillomavirus (HPV) represents the most common sexually 
transmitted disease, however the development of the HPV vaccine, Gardasil, protects 
women from becoming infected. The current study examined attitudes toward the HPV 
vaccine in 150 college-age women who had received the vaccine and 58 college-age 
women who had not. Data were collected using an online survey and correlations and 
regression analyses were run to assess for relationships between the variables of interest. 
Using the Health Belief Model (HBM), predictor variables included perceived benefits, 
barriers, susceptibility and severity regarding HPV infection and vaccination. Additional 
psychosocial variables were also explored. Results indicate that for unvaccinated women, 
perceived benefits accounted for unique variance in predicting vaccine intentions. 
Moreover, self-efficacy, cues to action and subjective norms all accounted for unique 
variance in differentiating vaccinated from unvaccinated women. In summary, women’s 
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 In recent years, prevention research has gained a stronger presence among 
counseling psychologists (Romano & Netland, 2008). The demands of the 21
st
 century, 
such as cost containment and a focus on prevention rather than remediation, as well as 
individual and institutional needs have fueled the growth of prevention science. Critical 
issues that impact the health of individuals and communities require a preventative 
perspective, as opposed to remediating the problems after they develop. Counseling 
psychology represents an ideal field to promote this perspective since it has roots in 
prevention, education, and the promotion of human development across the lifespan.   
Part of prevention research involves exploring which factors influence 
individual’s health decisions and behaviors. Research indicates that strong and consistent 
individual differences exist in health behaviors (Armitage & Conner, 2000). While some 
of these individual differences are attributable to sociodemographic variables, other 
differences have been found to relate to social cognitive variables such as perceived 
benefits and barriers to taking action. Researchers have generally focused on social 
cognitive variables to explain differences in health behavior since they are potentially 
more amenable to change. The present study explored how social cognitive factors within 
the Health Belief Model influenced an individual’s decision to receive a vaccine that 
prevents infection of the human papillomavirus (HPV), a widespread sexually transmitted 
disease with potentially serious consequences. 
 The Health Belief Model (HBM) represents a useful framework for understanding 
how individuals form health decisions that subsequently influence health behavior. 
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Originally designed to explain participation in disease prevention programs, this theory 
has also been used to explain the change and maintenance of health behavior as well as 
guide health behavior interventions (Strecher & Rosenstock, 1997). For instance, the 
HBM has been used to predict heart disease preventive behaviors, dietary compliance, 
and vaccine acceptance (Ali, 2002; Becker, Maiman, Kirscht, Haefner, & Drachman, 
1977; Chapman & Coups, 1999). As a value-expectancy theory, the HBM contains two 
health representations, threat perception which involves susceptibility and severity of an 
illness and behavioral evaluation which involves benefits and barriers of taking action 
(Sheeran & Abrahan, 1996). Therefore, individuals are expected to take action to prevent 
illness if they perceive themselves as susceptible to a condition that has potentially 
serious consequences and believe that a course of action would be beneficial as well as 
outweigh any barriers (Strecher, Champion, & Rosenstock, 1997).  
 While the four main components of the HBM provide a valuable foundation for 
understanding health behavior, other social cognitive variables have been added by some 
researchers to augment the model. One variable that has been used on occasion in health 
studies includes cues to action.  These cues include a range of internal and external 
triggers that can promote or discourage health protective behaviors (Sheeran & Abrahan, 
1996). For example, in one study, physician advice or recommendation represented a 
successful cue to action that influenced individuals to receive the flu vaccine (Cummings 
et al., 1979). When combined with the appropriate beliefs, cues to action can promote 
health behavior (Sheeran & Abrahan, 1996). Thus, if the perceived threat of disease is 
high and the perceived benefits outweigh perceived barriers, then a positive cue to action 
can prompt behavior to avoid the illness (Strecher et al., 1997). 
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Self-efficacy has also been added to the Health Belief Model in many studies to 
increase the theory’s explanatory power (Rosenstock, Strecher, & Becker, 1988). 
Bandura (1977, p.79) described self-efficacy as ―the conviction that one can successfully 
execute the behavior required to produce the outcomes‖. In the case of health behavior, 
the desired outcome is generally preventing an illness or living a healthier lifestyle. 
Research supports the importance of self-efficacy in predicting initiation and 
maintenance of behavioral change, especially for more complex and long-term changes 
(Bandura, 1986; Strecher, DeVellis, Becker, & Rosenstock, 1986; Strecher et al., 1997). 
Self-efficacy has been used to explain health behaviors such as eating, drinking, 
exercising, smoking, and sexual practices (Strecher et al., 1997). Therefore, the HBM 
combined with self-efficacy theorizes that successful behavior change depends upon a 
high perception of threat, belief that change will be beneficial and come at an acceptable 
cost, and confidence in the ability to overcome perceived barriers to taking action.  
The social cognitive variables previously described focus solely on the individual, 
however, most people do not make health decisions in isolation. One factor that considers 
the influence of others on health behavior is subjective norms. This construct assesses 
whether an individual perceives that his or her social network expects and approves of the 
behavior and whether the individual’s social contacts perform the behavior themselves 
(Fishbein & Azjen, 1975). Traditionally associated with the Theory of Planned Behavior, 
subjective norms have been found to influence protective sexual intentions and behavior 
among college students. Higher subjective norms positively influenced condom use, 
getting tested for HIV, and receiving the HPV vaccine (Munoz-Silva, Sanchez-Garcia, 
Nunes, & Martins, 2007; King, 2006, Boehner et al., 2003; Jones & Cook, 2008; Costar, 
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2008). Thus, the behavior of peers and the approval of significant others appear to play 
an important role in health decisions and behaviors.  
While social cognitive variables are more amenable to change, certain 
sociodemographic variables can still provide important information regarding health 
decisions. For instance, knowledge about a disease or behavioral risk factors for a disease 
can influence whether an individual engages in behaviors to protect against the disease. 
Some studies indicate that higher human papillomavirus (HPV) knowledge and certain 
sexual risk factors for HPV increase intentions to receive a vaccine that protects against 
HPV (Jones & Cook, 2008; Allen Mohllajee, Shelton, Othus, Fontenot, & Hanna, 2009; 
Gerend & Magloire, 2008; Jones & Cook, 2008; Boehner, Howe, Bernstein, & Rosenthal, 
2003; Costar, 2008; Buchanan, 2008). Moreover, knowledge and behavioral risk factors 
are more changeable than other sociodemographic characteristics and can be modified 
through interventions. For instance, HPV educational interventions have been found to 
increase knowledge about the human papillomavirus (Lambert, 2001; Dempsey, Zimet, 
Davis, & Koutsky, 2003; Chan, Cheung, Lo, & Chung, 2007). Therefore, these variables 
were included as factors that could influence health decisions about receiving the HPV 
vaccine.  
The human papillomavirus (HPV) represents an important disease to study since 
it affects a large majority of the population. As many as 75% of sexually active men and 
women will become infected with HPV in their lifetime (Cates, 1999; Koutsky, 1997). 
Young adults between the ages of 15 and 25 are particularly affected since peak 
prevalence and the highest rate of new infections occur in this age group (NIH, 1996; 
Weinstock, Berman & Cates, 2004). Although HPV is often harmless and asymptomatic, 
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it can cause bothersome consequences in both men and women such as genital warts as 
well as deadly diseases such as oral, cervical and anogenital cancers (Graziottin & 
Serafini, 2009). Detecting HPV is problematic since many people are unaware that they 
are infected. Moreover, the virus passes through genital skin-to-skin contact, making it 
easily transmissible between sexual partners (Cates et al., 1999). Although awareness of 
HPV has grown in recent years, misunderstandings about this sexually transmitted 
disease still persist (Lambert, 2001). 
In the past, HPV prevention efforts focused on promoting Pap smear screenings, 
condom use and abstinence, none of which fully protect against HPV. While Pap smear 
tests can detect cervical HPV infection in women, not all sexually active females receive 
regular screenings (Fletcher & Bryden, 2005). Moreover, Pap smears do not prevent HPV 
and once the virus is acquired, treatments to remove precancerous lesions can be painful 
and may result in complications (American Society for Colposcopy and Cervical 
Pathology, 2006). Condoms also do not fully protect against HPV since the virus is 
transmitted via skin-to-skin contact and areas not covered by the condom are vulnerable 
to infection (Winer et al., 2006). Finally, abstinence might not be a realistic option for 
some young adults and, although rare, virgins can still acquire HPV (Winer et al., 2003). 
Given the limitations of HPV prevention efforts, a new, more effective method is 
necessary in order to fully prevent HPV infection. 
In 2006, an HPV vaccine, Gardasil, was developed to protect females against four 
different strains of HPV. Two of the strains are associated with 90% of genital warts and 
two of the strains cause 70% of cervical cancers (Center for Disease Control and 
Prevention, 2008). In a randomized double-blind placebo-controlled trial, the HPV 
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vaccine reduced the incidence of the four HPV types by 90% (Villa et al., 2005). 
Therefore, the vaccine protects against infection of the four HPV types as well as the 
clinical sequelae of genital warts and cervical cancer. Prior research indicates that the 
majority of college-aged women are interested in the HPV vaccine and 85 to 88 percent 
of participants intend to become vaccinated (Gerend & Magloire, 2008; Jones & Cook, 
2008; Kahn, Rosenthal, Hamann & Bernstein, 2003). While some studies have explored 
how individual differences among women might affect their decision to receive the HPV 
vaccine, only one known study has focused on women who have already received the 
HPV vaccine. Including vaccinated women increases the understanding of which factors 
positively influence vaccination and which factors serve as barriers. 
Allen et al. (2009) conducted a study in 2007 illustrating the psychosocial factors 
associated with HPV vaccine adoption among college women ages 18 to 22. The study 
used the original Health Belief Model variables of perceived susceptibility, perceived 
severity, perceived benefits and perceived barriers as well as the additional variables of 
HPV knowledge, subjective norms and demographic characteristics including sexual 
activity. The outcome variable included stages of HPV vaccine adoption such as deciding 
not to receive the vaccine, being unaware of the vaccine, planning to receive the vaccine, 
starting the vaccine injections, and being fully vaccinated. Results of the study present 
evidence that the HBM as well as additional social cognitive factors significantly predict 
stages of vaccine adoption. These findings are useful in understanding how individual 
differences influence various stages of health decision-making and preventative behavior 
related to the HPV vaccine. The present study partially replicated and extended these 
research findings using the same health topic of vaccination against HPV. 
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 The present study had three purposes: 1) To explore sociodemographic and social 
cognitive variables among non-HPV vaccinated college-age women, 2) To explore 
sociodemographic and social cognitive variables among HPV vaccinated college-age 
women, and 3) To compare vaccinated and unvaccinated college-age women along 
sociodemographic and social cognitive dimensions. The first purpose of the study was 
accomplished by looking at predictors of unvaccinated college-age women’s intentions to 
receive the vaccine. The second purpose of the study was a relatively unexplored area 
that helped illuminate the reasons behind getting vaccinated. Finally, the third purpose of 
the study was important since the opportunity for HPV vaccination was available for 
several years suggesting that women who had not yet received the vaccine might be 
different from women who had received the vaccine.  
As with Allen et al.’s (2009) study, the Health Belief Model served as the social 
cognitive framework and other psychosocial variables, including subjective norms, HPV 
knowledge and HPV sexual risk factors, augmented the model. However, the present 
study made several important additions to the existing literature. Cues to action and self-
efficacy were included as psychosocial predictors of HPV vaccination behavior and 
intentions. These factors have often been added to the HBM to increase the explanatory 
power of the model and helped provide new insights into beliefs about the HPV vaccine. 
In addition, this study presented information about how women view the HPV vaccine 
after it has been available for three years. Most previous research, including Allen et al. 
(2009), took place prior to or directly after the availability of the vaccine when women 
may have known little about HPV vaccination. Women’s beliefs about the vaccine during 
the early phases of dissemination might be different from current views now that the 
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vaccine has been established. Finally, college-aged women were an important population 
to research since they were eligible for vaccination and possessed some of the highest 
rates of HPV. As few studies have examined variables related to HPV vaccination and 
























Review of the Literature 
 Human papillomavirus (HPV) represents a widespread sexually transmitted 
disease that can cause serious consequences for both women and men. These 
consequences include genital warts and cancers of the cervix, vulva, vagina, penis, anus 
and the oropharynx area of the mouth and throat. Although both men and women are 
affected by HPV, the focus of this study was on college-aged women who are particularly 
susceptible since peak HPV prevalence and a high rate of new infections occur in this age 
group (Cervical Cancer, 1996; Bauer et al., 1991; Weinstock et al., 2004). The 
development of the HPV vaccine Gardasil, however, protects women from becoming 
infected and from infecting their sexual partners. This vaccine represents an opportunity 
to eliminate health concerns caused by HPV which would have enormous public health 
benefits. However, since the HPV vaccine is not currently mandatory, the success of the 
vaccine depends upon an individual’s decision to become vaccinated. Understanding how 
women view the vaccine represents an important step in reducing the prevalence of HPV.  
 The HPV vaccine is recommended to be given to 11 and 12-year old girls before 
they engage in any skin-to-skin sexual contact, therefore most HPV studies have focused 
on parents’ attitudes and beliefs for vaccinating their daughters. However, women up to 
age 26 are eligible for a ―catch-up‖ vaccine and can still benefit from vaccination. The 
vaccine protects women from four different strains of HPV, therefore, even if a female is 
infected with one strain of HPV, the vaccine can still protect her from three other strains 
(Adams et al., 2009; Jones & Cook, 2008). Vaccinating college-aged women can greatly 
reduce the incidence of HPV infection for the woman getting the vaccine and can reduce 
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spreading the virus to partners. Few studies have explored college-age women’s beliefs 
regarding the HPV vaccine. Since college women are at the age where they, not their 
parents, will make the decision to become vaccinated, it is important to understand the 
factors that influence HPV vaccination in this population. The Health Belief Model 
(HBM) was used as the conceptual framework for this study and was augmented by 
additional constructs including cues to action, self-efficacy, subjective norms, HPV 
knowledge and sexual risk factors. 
 This literature review will begin by reviewing the clinical relevance of HPV for 
the general population and for college-age women specifically. A description of the 
virus’s prevalence and detection, physical and psychological consequences, and risk 
factors will be provided. The literature review will then focus on the development of the 
HPV vaccine and its acceptance among college-age women. Finally, factors that predict 
HPV vaccination will be explored, including the main components of the Health Belief 
Model (HBM) as well as additional factors such as cues to action, self-efficacy, 
subjective norms, HPV knowledge and sexual risk factors. Specifically, the review will 
discuss the model structure of the HBM, describe several meta-analyses and explain how 
the HBM has been used to predict HPV vaccine acceptance in general and among 
college-age women. Factors outside of this theoretical framework, such as subjective 
norms, HPV knowledge and sexual risk factors, and their relevance to HPV vaccination 







Prevalence and Detection 
Approximately 20 million people in the United States are infected with HPV, the 
most common sexually transmitted infection (Center for Disease Control and Prevention, 
2008). Research indicates that up to 75% of sexually active adults will become infected 
in their lifetime (Cates, 1999; Koutsky, 1997). Peak prevalence occurs in young adults 
between the ages of 22 and 25 and one study discovered HPV infection in 46% of college 
females (NIH, 1996; Bauer et al., 1991). Moreover, 74% of new HPV infections occur 
among 15-24 year-olds (Weinstock, Berman & Cates, 2004).  
HPVs are a small group of DNA viruses. Over 100 types of HPV exist and 
approximately one-third infect the genital tract (Graziottin & Serafini, 2009). The HPV 
types that infect the genital tract fall into either high risk or low risk categories. High risk 
types of HPV can cause anogenital and oral cancers, whereas low risk types of HPV can 
cause genital warts. Most HPV infections are cleared by the immune system or become 
latent (Graziottin & Serafini, 2009; Sellors et al., 2003). However, without a Pap smear it 
is impossible to know whether HPV is still present in the cervix (Costar, 2008). Pap 
smears test for unusual cell changes in the cervix caused by HPV. There is no FDA-
approved test to detect HPV in men or to determine a person’s overall HPV status for 
either men or women. The only way to detect HPV in men is through a biopsy of an 
HPV-related tumor in the oral pharyngeal or anogenital areas. HPV cannot be seen and 
most people do not develop symptoms, such as genital warts or cancerous lesions. 
Moreover, HPV can stay dormant in the body for years after acquisition of the virus. 
12 
 
Therefore, many people are not aware that they are infected and can easily transmit the 
virus to a partner.  
Unlike other sexually transmitted diseases that spread through fluid transmission, 
HPV is transmitted through genital skin-to-skin contact (Cates et al., 1999). Recent 
research indicates that consistent condom use among newly sexually active women can 
reduce the risk of HPV infection (Winer et al., 2006). However, condoms cannot fully 
protect against the virus since HPV can infect areas not covered by the condom. The only 
way to completely prevent HPV is to abstain from any sexual contact. Individuals in a 
monogamous relationship can also lower their risk of HPV infection if their partner has 
had no or few other sexual partners.  
Physical and Psychological Consequences 
HPV can have serious consequences for both women and men. Studies have 
found that HPV is the primary cause of cervical cancer and can also cause cancers of the 
anus, vulva, vagina, penis, and mouth (National Cancer Institute, 2009; Souza et al., 
2007). However, HPV is particularly associated with negative consequences for women’s 
health. Specifically, HPV types 16 and 18 are associated with approximately 70% of 
cervical cancers (Clifford, Smith, Plummer, Munoz & Franceschi, 2003; Munoz et al., 
2003; Bosch & Sanjose, 2003). Cervical cancer is the second most common cancer in 
women worldwide and a common cause of death in middle aged women from developing 
countries (Bosch & Sanjose, 2003). Although the availability of screening options has 
greatly reduced the incidence of invasive cervical cancer in developed countries, 
precursors to cervical cancer, such as lesions, remain a public health burden. HPV has 
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been detected in 95% to 100% of cervical cancer cases, supporting the claim that HPV is 
the first necessary cause of a human cancer ever identified (Walboomers et al., 1999).  
Much research and publicity has focused on HPV’s association with cervical 
cancer, however HPV is also associated with substantial proportion of anogenital and oral 
cancers. In fact, the number of HPV-related noncervical cancers diagnosed annually in 
the US approximately equals the number of cervical cancers (Gillison, Chaturvedi, & 
Lowy, 2008). HPV 16 accounts for the largest proportion of HPV-related oral, anal, 
penile, vulvar, and vaginal cancers. Specifically, HPV 16 was detected in 84% of anal 
cancer specimen, 84.2% of penile cancer specimen, 29.3% of vulvar cancer cases and 
55.4% of vaginal cancer cases (Frisch, 1997; Pascual, 2007; Smith, Backes, Hoots, 
Kurman, & Pimenta, 2009). In addition, HPV 16 infection precedes oral cancer 
development and is the necessary cause of as many as 72% of oral pharyngeal cancer 
cases (Souza et al., 2007; Mork et al., 2001). While the incidence of cervical cancer has 
been decreasing, the incidence of oral and anal cancers has been increasing in the US 
since the 1960’s and 70’s (Gillison, 2008; Chaturvedi, Engels, Anderson, & Gillison, 
2008; Melbye, Rabkin, Frisch, & Biggar, 1994). Anal cancer is usually underestimated in 
women, but is now higher in women than in men (Melbye, et al., 1994; Graziottin & 
Serafini, 2009). On the other hand, HPV-related oral cancer is higher in men than in 
women. Anal and oral cancers remain particularly serious since there are currently no 
effective or widely used screening procedures for these diseases (Gillison et al., 2008). 
Although the risks of particular types of HPV-related cancer may be more prevalent in 
one gender over the other, transmission of the virus by infected men and women can still 
cause cancer in their partner. Therefore, the HPV vaccine is one of the few current ways 
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to manage infection in both the women receiving the vaccine and in the women’s 
partners. 
Low risk HPV viruses can cause genital warts which, although benign, still cause 
significant physical and psychological distress (Graziottin & Serafini, 2009). Specifically, 
HPV types 6 and 11 are associated with nearly 90% of genital warts (Gissman et al., 
1983). Prevalence studies indicate that the incidence of genital warts has increased since 
the 1950s (Becker, Stone, & Alexander, 1987; Chuang, Perry, Kurland, Ilstrup, 1984). 
Currently in the United States, 5.6% of adults report ever having been diagnosed with 
genital warts, with higher percentages in women than in men (Dinh, Sternberg, Dunne, & 
Markowitz, 2008). Specifically, women between the ages of 25 and 34 years have the 
highest percentage. However, since this data relies on self-report rather than actual 
detection, the prevalence of genital warts might actually be higher. Genital warts are 
highly contagious and develop in about two-thirds of people who have sexual contact 
with someone who has the condition (Mayo Clinic, 2009). The infection can even be 
transmitted from mother to baby during pregnancy and can cause physical complications 
when giving birth (Mayo Clinic, 2009).  
Aside from causing physical problems such as pain and discomfort, genital warts 
can also cause psychological distress (Conaglen, Hughs, Conaglen, & Morgan, 2001; 
Maw, Reitano, & Roy, 1998; Ireland, Reid, Powell, & Petrie, 2005). Feelings of disgust, 
shame, and embarrassment are common (Maw et a., 1998). People with genital warts 
have a significant lower health-related quality of life due to pain/discomfort and 
anxiety/depression as compared to those without the condition (Woodhall et al., 2008). 
Moreover, the psychological impact of a diagnosis of genital warts may be greater for 
15 
 
women than for men. For instance, women’s perception of their health was worse than 
men’s after a genital warts diagnosis (Woodhall et al., 2008). Aside from the 
psychological consequences, genital warts also present a large economic burden costing 
more than $700 per 1000 person-years of enrollment (Insinga, Dasbach, & Myers, 2003). 
This economic burden is greatest among females aged 15-24 years.  
HPV infection can lead to serious consequences, not just physically but 
psychologically as well. Following diagnosis and treatment of HPV, women reported a 
decreased interest in sex, a worsening in the emotional relationship with their partner, and 
feelings of anxiety and fear of cervical cancer (Maggino et al., 2007; Filiberti et al., 1993; 
Linnehan & Groce, 1999). In addition, women who tested positive for HPV experienced 
significantly more anxiety and distress, and felt worse about past, current, and future 
sexual relationships as compared to HPV-negative women (McCaffrey et al., 2004). 
Moreover, college-based health providers who have diagnosed and treated HPV 
infections generally perceive HPV as having a significant psychosocial impact on college 
women (Linnehan & Groce, 1999). They agreed that HPV infection can cause feelings of 
anger, guilt, blame, and fear as well as raise concerns about self-image, sexuality, and 
sexual functioning among college women. The majority of providers also reported that 
addressing emotional and psychosocial issues was the most challenging aspect of 
managing HPV. Therefore, HPV appears have a substantial effect on women’s emotional, 
social, and sexual functioning.  
HPV and its clinical sequelae also present a significant economic burden. 
Treatment for genital warts and precancerous cervical lesions that result from HPV 
involve removing problematic cells, decreasing HPV viral load and watching for 
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recurrence (Graziottin & Serafini, 2009). These procedures are costly and consume 
significant health care resources. In fact, the annual health care costs of HPV-related 
conditions in the United States range from 2.25-4.6 billion dollars, making the burden of 
HPV second only to HIV for sexually transmitted diseases (Fleurence, Dixon, Milanova, 
& Beusterien, 2007). This is not surprising given that there are an estimated 6.2 million 
new cases of high risk HPV infection in the US each year (Trottier & Franco, 2006; 
Center for Disease Control and Prevention, 2008). In women under age 24 alone, the 
estimated total annual cost of HPV is 2.8 billion dollars (Chesson, Blandford, Gift, Tao, 
& Irwin, 2004). Therefore, HPV infection in young women comprises the majority of 
annual health care costs for HPV.  
Risk Factors 
Since HPV is primarily a sexually transmitted disease, risk for acquiring the 
infection is heavily influenced by sexual activity (Koutsky, 1997). Women who have a 
higher number of lifetime sexual partners and who engaged in intercourse at an early age 
are at higher risk for HPV (Kataja, et al., 1993; Pichichero, 2007; Winer et al., 2003). 
Specifically, women with five or more partners are more likely to become infected than 
women with one or no sexual partners (Kataja et al., 1993). Studies indicate that college 
women have an average number of between 1.8 and 5.6 sexual partners, however this 
information could be underreported (Winer et al., 2003; Gerend & Magliore, 2008; 
Reinisch, Sanders, Hill, Ziemba-Davis, 1992). A woman’s risk is also dependent on 
certain characteristics of her sexual partner. For instance, the likelihood of acquiring HPV 
increases if the male partner is uncircumcised, has an STD, or has had a higher number of 
sexual partners (Kataja, et al., 1993; Castellsague et al., 2002; Burk et al., 1996). 
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However, HPV infection is not strictly limited to those engaging in intercourse. Although 
rare, virgins can also become infected since any type of non-penetrative sexual contact 
can transmit the virus. One study found a prevalence rate of 7.9% in virginal women over 
the course of two years (Winer et al., 2003). Non-penetrative sexual contact was 
associated with increased risk of HPV infection among virgins, but not among sexually 
active women.  
Besides the risk factors already listed, studies focusing specifically on college 
females found additional characteristics associated with HPV. Ho, Bierman, Beardsley, 
Chang, and Burk (1998) discovered that Hispanic and African-American women were at 
increased risk for HPV as compared to Caucasian women. Although the age range was 
narrow, younger women had a higher likelihood of acquiring HPV than older women. 
Moreover, increased risk was associated with high frequencies of vaginal sex and alcohol 
consumption, anal sex, and a partner not currently in school. Some of these factors, such 
as anal sex and alcohol consumption might serve as a proxy for other risky sexual 
behavior. Finally, Winer et al. (2003) found that the presence of a new male sexual 
partner within the last eight months led to a higher likelihood of HPV infection. Given 
the high rate of sexual activity and alcohol consumption on college campuses, a large 
majority of college women are at high risk for acquiring HPV. Studies of sexually active 
college females indicate an average number of 1.8 to 5.6 sexual partners and high rates of 
unprotected sexual activity, as well as a lack of preventive measures such as getting a Pap 
smear (Reinisch et al., 1992; Vail-Smith & White, 1992; Burkett et al., 1992; Linnehan & 
Groce, 1999). Moreover, while a woman may have one or few partners, her risk is still 
based on the number of sexual partners that her partner(s) has had as well. The sexual 
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behaviors of college women and their partners can increase their risk of acquiring HPV 
and explain the high incidence of infection among this age group.   
Some studies have also found an association between HPV infection and 
nonsexual behaviors, such as oral contraceptive use and smoking (Kataja, et al., 1993; 
Winer et al., 2003). However, the literature remains inconclusive since other studies have 
not supported these findings. For instance, Mosciki et al. (2001) found that use of oral 
contraceptives actually had a significant protective effect against HPV.  Since oral 
contraceptives have been associated with cervical cancer, it has been hypothesized that 
use of oral contraceptives alter the progression of HPV rather than increase the risk of 
acquiring the infection (Koutsky, 1997; WHO, 1993). While the majority of previous 
research has failed to find an association between smoking and HPV, some evidence 
suggests that smoking is associated with cervical cancer (Mosciki et al., 2001; Barton et 
al., 1988). Therefore, it is possible that smoking could act in a similar manner as oral 
contraceptives and change the progression of the infection in individuals who have HPV.  
However, these studies are still in the preliminary stages and require additional research 
to ascertain the true nature of the association.  
HPV and its clinical sequelae present a large economic, physical and 
psychological burden. This highlights the importance of developing methods to reduce 
the incidence of HPV and thereby diminish the consequences of the virus. Current 
methods of HPV prevention, such as condom use and abstinence, present incomplete 
protection as well as other major limitations. As indicated previously, condom use does 
not completely protect against HPV since the virus gets transmitted through skin-to-skin 
contact.  Moreover, abstinence presents an unrealistic expectation for many college 
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women and, although rare, virgins can still acquire HPV. Current screening procedures, 
such as Pap smears, help detect the presence of HPV and reduce the risk of cervical 
cancer. However, these procedures do not prevent HPV infection or the development of 
precancerous lesions, which can result in psychological distress and unpleasant surgical 
procedures. Moreover, cervical screenings are not effective for women who fail to 
receive regular Pap smears. Finally, as indicated previously, widely used and effective 
screening procedures do not exist for other HPV-related cancers, such as anal and oral 
cancers. Due to these limitations, a vaccine that prevents the acquisition of HPV presents 
a more effective strategy for reducing HPV-related diseases in both men and women. 
HPV Vaccine 
  In 2006, the U.S. Food and Drug Administration approved Merck’s Gardasil, an 
HPV vaccine that protects females against HPV 6 and 11 which cause 90% of genital 
warts and HPV 16 and 18 which cause 70% of cervical cancers (Center for Disease 
Control and Prevention, 2008).  HPV 16 is also associated with oral, anal, penile, vulvar, 
and vaginal cancers. In a randomized double-blind placebo-controlled trial, the HPV 
vaccine reduced the incidence of HPV 6, 11, 16 and 18 by 90% (Villa et al., 2005). 
Moreover the vaccine reduced the incidence of clinical disease, including genital warts, 
vulvar, vaginal, and cervical precancerous cellular changes, and cancers associated with 
these types of HPV by 100% (Garland et al., 2007). In a separate double-blind placebo-
controlled trial, the HPV vaccine efficacy for preventing cervical lesions was 98% 
(Future II Study Group, 2007). Therefore, the HPV vaccine not only reduced the 
incidence of HPV, but also substantially reduced the incidence of HPV-related diseases 
and precancerous lesions.  
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Gardasil is administered via three injections costing about $125 each over six 
months and is currently licensed for females ages 9 to 26 years (Center for Disease 
Control and Prevention, 2008; Gardasil, 2009). While the vaccine is most effective for 
girls and women not yet infected with the vaccine-type HPV strains, women previously 
infected with the virus are no less immune to developing other related or unrelated types 
of HPV (Thomas et al., 2000). Therefore, even women previously exposed to HPV types 
6, 11, 16 or 18 may benefit from additional protection as a consequence of a vaccine-
induced antibody response (Adams, Jasani, & Fiander, 2009). The vaccine, however, 
does not treat existing HPV infections. Gardasil has recently been licensed for males and 
preliminary clinical trials suggest that an HPV 16/18 vaccine was effective and well 
tolerated in boys aged 10 to 18 years (Petaja et al., 2009). Research on vaccine strategies 
indicate that even after vaccinating 12-year-old boys and girls, a catch-up vaccine for 
women ages 12-24 can substantially reduce the disease in the short term (Elbasha, 
Dasbach, & Insinga, 2007). In fact, a vaccination strategy for 12-year-old boys and girls 
that did not include a catch-up program was less effective and more costly. Given that the 
peak prevalence of HPV infection occurs in women ages 22 through 25, vaccination in 
college-aged women is particularly important (NIH, 1996; Burak & Meyer, 1997). 
As of May 1, 2009, at least 24 million doses of Gardasil have been distributed in 
the United States (CDC, 2009). Since this time, there have been reports of adverse events 
from the vaccine, 93% of which have been considered non-serious. The most common 
reported side effects have included fainting, pain and swelling at the injection site, 
headache, nausea, and fever. Fainting after vaccines and injections is especially common 
in adolescents. While serious adverse events have also been reported, causal associations 
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cannot be made between these events and the vaccine. The reports merely mean that the 
event occurred sometime following vaccination. Overall, there have been 26 confirmed 
reports of death, several cases of a rare disorder, Guillain-Barré Syndrome, that causes 
muscle weakness, and few reports of blood clots among females who have received the 
vaccine (CDC, 2009). However, medical experts have not found any common medical 
patterns that would suggest that these events were caused by the vaccine. Moreover, the 
percentage of serious adverse events reported for Gardasil has been less than the overall 
average for other vaccines (CDC, 2008). Still, these reports have caused concerns among 
consumers and anti-vaccine groups about the safety of the vaccine (Houppert, 2007).  
However, the main controversy surrounding the HPV vaccine has focused on 
whether states should make the vaccine mandatory for preteen girls. Some people 
disapprove of a school mandate to vaccinate due to concerns over the drug’s cost, safety, 
and parents’ rights to refuse (National Conference of State Legislatures (NCSL), 2009). 
Since HPV is a sexually-contracted virus, Christian conservative groups who favor an 
abstinence-only approach have argued that Gardasil will increase promiscuity in young 
women (Houppert, 2007). Moreover, states must address funding issues if the vaccine 
becomes mandatory, including whether to require coverage by insurance plans. These 
debates are still on-going for the majority of state legislatures and will likely continue for 
the next several years.  
Despite the concerns and controversies surrounding Gardasil, college women tend 
to hold positive attitudes overall toward the HPV vaccine. The majority of college 
women are interested in Gardasil and 85 to 88 percent of participants intend to become 
vaccinated (Gerend & Magloire, 2008; Jones & Cook, 2008; Kahn, Rosenthal, Hamann 
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& Bernstein, 2003). However, studies conducted in 2007 indicate that only 12% of 
college-aged females have received at least one vaccine injection (Allen et al., 2009; 
Grant, Kravitz-Wirtz, Breen, Tiro & Tsui, 2009). While low vaccination rates can be 
expected during the first year after vaccine licensing, this rate is still well below the 
number of adolescents who received the vaccine. In 2009, the Center for Disease Control 
(CDC) conducted a national survey of vaccination coverage of adolescents and found that 
approximately 37% of 13 to 17-year old females had initiated the HPV vaccine series 
(CDC, 2009). However, only 18% received the three shots needed for full protection. 
Although the vaccine is administered over the course of six months, this time frame does 
not seem to fully account for the discrepancy between those who initiate the vaccine 
series and those who complete it. A national survey has not been conducted among 
college-aged women, therefore, it remains difficult to paint an accurate picture of HPV 
vaccine uptake among this population. Understanding the beliefs and attitudes regarding 
the HPV vaccine among college-age women represents an important step in creating a 
successful HPV vaccination program. College students will likely decide for themselves 
whether to receive the HPV vaccine, and their beliefs and attitudes can influence their 
acceptance. Determining which factors positively influence vaccination and which factors 
serve as barriers can help create health messages and other interventions to promote 
health protective decision-making. One theory that is often used in understanding health-
protective decision-making is the Health Belief Model (HBM). This theory includes 





Health Belief Model 
Model Structure 
 The HBM represents one of the most widely used conceptual frameworks in 
health behavior (Strecher & Rosenstock, 1997). As such, this model served as the 
framework for this study and was augmented with additional variables, including cues to 
action and self-efficacy. Developed by a group of social psychologists in the 1950s, 
HBM was originally used to explain the wide-spread failure of people to participate in 
programs to prevent disease.  Since this time, the model has been used to explain the 
change and maintenance of health behavior and has served as a guiding framework for 
health behavior interventions.  The HBM is a value-expectancy theory where value refers 
to the desire to avoid illness or to get well and expectancy refers to the belief that a 
specific health action would prevent illness (Strecher & Rosenstock, 1997). Two health 
representations, threat perception and behavioral evaluation, emerged as the central 
aspects of the model (Sheeran & Abrahan, 1996). Threat perception depends upon beliefs 
regarding the perceived susceptibility to illness and the anticipated severity of the illness. 
Behavioral evaluation encompasses two beliefs as well, those regarding the benefits of a 
recommended health behavior and those regarding the barriers or costs to enacting the 
behavior. Therefore, individuals are expected to take action to prevent illness if they 
perceive themselves as susceptible to the condition, believe that the condition has 
potentially serious consequences, believe that an available course of action would be 
beneficial and anticipate that the barriers to taking action would be outweighed by the 
benefits (Strecher, Champion, & Rosenstock, 1997).  
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 Perceived susceptibility, perceived severity, benefits and barriers comprise the 
four main components of the HBM. While the definition of these constructs has varied 
across research, Strecher et al. (1997) offers general descriptions of the model 
components. Specifically, perceived susceptibility refers to an individual’s subjective 
assessment of his or her risk for contracting an illness. Perceived severity, on the other 
hand, refers to an individual’s feelings about the seriousness of contracting an illness. 
This includes both medical aspects such as pain, and psychosocial consequences such as 
interference with social roles. Benefits refer to an individual’s beliefs regarding the 
effectiveness of a particular health action in reducing the disease threat. This can also 
involve both medical and psychosocial aspects. Finally, barriers refer to the potential 
negative aspects of a particular health action, and can involve both practical and 
psychological costs. Practical barriers could include aspects such as time, expense, 
availability and waiting time. Psychological barriers could include costs such as pain, 
embarrassment and threat to well-being.   
 Aside from the four main components of the model, other constructs have been 
used to augment the model in order to further explain a person’s health behavior. 
People’s health decisions generally involve a complex interplay of factors that might not 
be completely captured by a rational, cost-benefit model like the HBM. Cues to action 
were included in various early formulations of the HBM, but have not been 
systematically studied or included in the majority of health belief research (Strecher et 
al., 1997). These cues can represent internal triggers, such as perceptions of symptoms, as 
well as external triggers like social influence and health education campaigns. Since the 
HPV vaccine has received significant media attention, including advertisements, 
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incorporating cues to actions in the model seems particularly relevant for this study. 
When combined with the appropriate beliefs, cues to action can promote health behavior 
(Sheeran & Abrahan, 1996). If the perceived threat of disease is high and the perceived 
benefits outweigh perceived barriers, then a cue to action can prompt behavior to avoid 
the illness (Strecher et al., 1997). For instance, one study discovered that physician 
advice or recommendations represented successful cues to action for flu vaccination 
(Cummings et al., 1979).  However, cues to action can also discourage health behavior if 
an individual is reminded of potential costs or barriers associated with the action. In 
another flu vaccination study, knowing someone who experienced negative side effects 
from the vaccine negatively impacted inoculation behavior (Aho et al., 1979). The 
fleeting nature of cues to action makes this concept difficult to study, particularly in 
explanatory surveys (Strecher et al., 1997). In addition, Weinstein (1988) maintains that 
cues to action do not represent rational, expectancy-value components like the rest of the 
HBM. Furthermore, little research exists on the types of cues that are related to taking 
action or the number or frequency of cues. Therefore, cues to action represent an 
important component that has been largely neglected in research on the HBM.  
 In the 1970s, Bandura introduced the concept of self-efficacy, or the belief in 
one’s ability to successfully perform the behavior required to produce certain outcomes 
(Strecher et al., 1997). Rosenstock, Strecher, and Becker (1988) proposed adding self-
efficacy to the Health Belief Model in order to increase its explanatory power. They 
hypothesized that this new model would more fully account for health-related behavior as 
compared to the earlier model, and would lead to more effective behavioral interventions. 
Research suggests that self-efficacy accounts for a significant amount of initiation and 
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maintenance of behavioral change, especially for more complex and long-term changes 
(Strecher et al., 1997). Simple preventative actions that are easy to carry out, such as a 
one-shot immunization, might not depend as much on self-efficacy. However, self-
efficacy would likely be an important determinant for receiving the HPV vaccination 
which requires three shots over the course of six months. In addition, receiving the HPV 
vaccine requires that women acknowledge that they are sexually active or plan to become 
sexually active. This acknowledgement requires self-efficacy beyond simply arranging to 
receive the vaccine. Therefore, successful behavior change depends upon a high 
perception of threat, belief that change will be beneficial and come at an acceptable cost, 
and confidence in the ability to overcome perceived barriers to taking action.  
Meta-Analyses 
 Several meta-analyses have been conducted on studies utilizing the HBM. Janz 
and Becker (1984) reviewed 46 studies published between 1974 and 1984, and calculated 
significance ratios for susceptibility, severity, benefits, and barriers. The studies in the 
review focused on a variety of health behaviors such as influenza vaccination, breast self-
examinations and participation in genetic screening programs. The significance ratios 
calculated by Janz and Becker (1984) indicate the percentage of times each construct was 
statistically significant across all of the studies. Overall, susceptibility was significant in 
81% of the studies, severity in 65%, benefits in 78 %, and barriers in 89%. Therefore, the 
significance ratios support the importance of the HBM in predicting health behaviors 
with barriers as the most reliable predictor. In addition, the findings from prospective 
studies suggest that these health beliefs play a causal role. The meta-analysis results also 
indicate that the relative importance of the HBM’s components may vary based on the 
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health behavior. For instance, severity had only a moderate effect upon preventive 
behavior and clinic utilization, but it was the second most powerful predictor of the 
behavior of individuals recently diagnosed as ill (Janz & Becker, 1984; Sheeran & 
Abraham, 1996). Thus, severity might be more difficult to conceptualize when 
asymptomatic or when the health threat only occurs in the long term. This applies to the 
HPV vaccine since vaccination represents a preventative behavior and the consequences 
of HPV, such as cervical cancer, may occur long after infection. Therefore, severity 
might not represent a strong predictor of HPV vaccination behavior.  
 While Janz and Becker’s (1984) meta-analysis provides strong support for the 
HBM across a variety of health behaviors, the study contains several limitations. First, 
the significance ratios only indicate the frequency of significant HBM components rather 
than the size of their effect (Sheeran & Abraham, 1996). Moreover, these ratios give 
equal weight to all studies regardless of sample size which could bias the results. Finally, 
not all of the studies in the meta-analysis included all four main components of the HBM 
which could influence the significance of each individual predictor. These issues were 
addressed in a subsequent meta-analysis by Harrison, Mullen, and Green (1992). 
 Harrison et al. (1992) identified 234 published empirical studies of the HBM, 
however, only 16 measured all four main components and included reliability checks. 
This illustrates the large number of studies that fail to operationalize the full HBM model 
and provide psychometric tests of the measures. Pearson’s r effect sizes were calculated 
across the 16 studies and transformed into a weighted average for each component. 
Health behavior had an average 0.15 correlation with susceptibility, 0.08 with severity, 
0.13 with benefits, and -0.21 with barriers. While these correlations were statistically 
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significant, they represent small effect sizes and account for just between 1.5 and 4% of 
the variance in behavior. Moreover, the effect sizes displayed considerable variability 
across studies, indicating that study design, measurement, or conceptualization 
differences likely influenced the results. The researchers also found a difference in the 
importance of HBM components between retrospective and prospective studies. Benefits 
and barriers had significantly larger effect sizes for retrospective studies and severity had 
smaller effect sizes as compared to prospective studies. This suggests that when people 
think retrospectively about their health decisions, they perceive that benefits and barriers 
played a more important role and severity played a less important role than when they 
made the decision. 
 Both meta-analyses support the significance of susceptibility, severity, benefits, 
and barriers in predicting health behaviors. While Harrison et al. (1992) found only small 
effects for these components, several characteristics of the study might account for these 
findings (Sheeran & Abraham, 1996). First, the researchers used extremely strict criteria 
for inclusion in the review and thus their results are based on a relatively small group of 
participants. Second, the reported effect sizes reflect each individual component rather 
than the model as a whole. The combined effects of the HBM components might be 
greater than the sum of the individual effects, however the researchers did not report this 
information. Finally, the effect sizes varied greatly across studies which influenced the 
overall average effect sizes. Therefore, these factors should be taken into consideration 
when interpreting the small effect sizes reported in the review.  
 While the HBM meta-analyses contain limitations, they also reveal problems in 
the HBM literature which should be addressed by future research. One of the most 
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problematic aspects of the research on the HBM involves inconsistent measurement of 
HBM concepts (Harrison et al., 1992; Strecher et al., 1997). The large majority of studies 
use different ways to operationalize the constructs and fail to establish reliability or 
validity prior to testing the model. Even when studies use valid and reliability measures, 
these measures must be re-evaluated with each data collection since the psychometrics 
may change depending on the sample characteristics (Strecher et al., 1997). In addition, 
the review by Harrison et al. (1992) illustrates the infrequent inclusion of all four main 
components, much less the full HBM model. When the four components are 
incorporated, however, the relationships between these factors still remain unclear. Some 
researchers include these variables as independent predictors, whereas others test for 
moderation and mediation effects. Strecher et al. (1997) argues that the relationships 
among the HBM constructs represent complex, indirect associations rather than simple 
collections of variables. A study by Ronis and Harel (1989) highlighted this concept 
when they found that benefits mediated the effects of severity on breast examination 
behaviors. Moreover, Harrison et al. (1992) maintains that studies must develop weights 
and interaction terms to show how the four dimensions work together. In addition, the 
HBM is a cognitive model and relies on people to make logical and rational decisions. 
However, the cues to action component relies less on rational decision-making and 
represents a more complex factor in the model. Finally, the HBM only measures 
psychosocial variables which limit its ability to predict individual behaviors and can 
produce small effect sizes (Rosenstock, 1990). The next section of the review will 




HPV Vaccine Acceptance 
Despite the limitations of previous research, the HBM is one of the only models 
that has been used in the sparse vaccination behavior literature. Perceived susceptibility, 
perceived severity, perceived effectiveness of the vaccine, barriers, and cues to action 
have been found to significantly predict influenza vaccination behavior (Brewer, 
Chapman, Gibbons, Gerrard,  McCaul, & Weinstein, 2007; Chapman & Coups, 1999). 
The literature suggests that the HBM is also a useful model for HPV vaccine 
acceptability. A review by Brewer and Fazekas (2007) used the HBM to identify 
predictors of HPV vaccine acceptability in studies from 1995 through 2006. The 
researchers discovered 28 studies that met review criteria, all of which were conducted in 
the US prior to federal approval of the vaccine and none of which examined actual 
vaccine uptake. Most of the studies utilized cross-sectional designs and included small 
samples of parents and adults. The results indicate that higher perceived susceptibility of 
HPV infection and of getting cervical cancer was related to vaccine acceptability. On the 
other hand, higher perceived severity of HPV infection was not related to HPV vaccine 
acceptability, even though cervical cancer was perceived to have severe consequences. 
The review only explored one benefit, vaccine effectiveness, but found an association 
between higher perceived vaccine effectiveness and greater HPV vaccine intentions. 
Vaccine effectiveness referred to prevention of HPV infection, however none of the 
studies explored perceived effectiveness against genital warts or cervical cancer. Barriers 
such as low perceived vaccine safety, cost of the vaccine, and anticipated side effects 
predicted lower HPV vaccine acceptability. Finally, cues to action included school 
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mandates and physician recommendations to get the vaccine, both of which were 
associated with higher vaccine acceptance. 
Cross-sectional studies are highly prevalent within the HBM literature as 
indicated by the 22 out of 28 studies in the review that used this type of design. In a 
separate meta-analysis by Brewer et al. (2007) that examined risk perception and 
vaccination behavior, 28 out of 34 studies were cross-sectional. One concern with the 
cross-sectional design is the post hoc justification that can occur where participants 
inflate their sense of perceived severity, susceptibility, and benefits and deflate perceived 
barriers to justify their health behavior. As indicated previously, Harrison et al. (1992) 
found that benefits and barriers had significantly larger effect sizes for retrospective 
studies as compared to prospective studies. However, Harrison et al. (1992) and Brewer 
et al. (2007) found that effect sizes for severity and susceptibility were no greater in 
cross-sectional/retrospective than prospective vaccination studies, and in fact were 
smaller. This suggests that post hoc justification doesn’t necessarily occur for severity 
and susceptibility, but might occur for benefits and barriers in cross-sectional designs. 
The current study employed a cross-sectional design in order to compare HPV 
vaccinated women with non-HPV vaccinated women. Allen et al. (2009) conducted the 
only other known study to explore predictors of HPV vaccination status. Previous studies 
have generally focused on HPV vaccination intentions or acceptance as indicated in the 
review by Brewer and Fazekas (2007). The current study also explored HPV vaccination 
intentions among unvaccinated women, however the comparison of vaccinated and 
unvaccinated women provided important information not included in the previous 
literature. In order to study these differences, a cross-sectional design was employed.  
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College-Age Women and the HPV Vaccine  
Out of the 28 studies in the review of HBM predictors on HPV attitudes and 
vaccine acceptability, only three explored components of the HBM in college students 
(Boehner et al., 2003; Ramirez, Ramos, Clayton, Kanowitz, & Moscicki, 1997; Yacobi, 
Tennant, Ferrante, Pal, & Roetzheim, 1999).  While these three studies provide a basis 
for future research, they contain several limitations. First, they failed to include all four of 
the main HBM concepts and only one focused specifically on college women whereas the 
others included both men and women. Since men and women may hold different beliefs 
about HPV and the vaccine, the results of these studies might not apply specifically to 
college women. Moreover, the HPV vaccine was not yet available at the time these 
studies were conducted. Therefore two of the studies explored attitudes toward HPV and 
one study explored acceptance of a hypothetical HPV vaccine. As such, these studies did 
not investigate acceptance of the currently available HPV vaccine. Several subsequent 
studies conducted after the review have explored  acceptance of the Gardasil vaccine in 
college women, however, the paucity of research in this area remains surprising given the 
high prevalence of HPV in this population.  
According to the existing literature, perceived susceptibility to HPV infection is 
relatively low among undergraduates (Gerend & Magloire, 2008; Jones & Cook, 2008; 
Yacobi et al., 1999). One study found that only 21% of college students believed they 
were at risk for HPV infection (Yacobi et al., 1999). However, this number rose to 58% 
among sexually active women, suggesting that the risks of sexual activity become more 
salient once one becomes sexually active (Ramirez et al. 1997). Research indicates that 
lack of perceived susceptibility is associated with low vaccine acceptance, whereas, high 
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perceived susceptibility is associated with increased intention to receive the vaccine 
(Gerend & Magloire, 2008; Jones & Cook, 2008; Boehner, 2003).  
The finding that most college students do not perceive themselves to be at risk for 
HPV is concerning in light of the high prevalence of HPV infection in this population. A 
study by Ramirez et al. (1997) confirmed that college students’ perceived susceptibility 
was unrelated to their actual risk as indicated by an HPV positive test. Women who did 
not perceive themselves at risk had almost identical prevalence rates as those who did.  
Even more concerning, low perceived susceptibility might inhibit college women’s 
decision to receive the vaccine. However, it remains unknown to what extent this factor 
influences HPV vaccination. Determining this information will be important for assessing 
whether HPV vaccine health messages and interventions should emphasize HPV 
prevalence rates in college-age students.   
Perceived severity of HPV infection among college women has been explored in a 
limited number of studies. The preliminary results suggest that the majority of college 
students would be at least somewhat upset if infected with HPV (Boehner et al., 2003; 
Jones & Cook, 2008). While  perceived severity did not significantly predict HPV 
vaccine acceptance in several studies, Kahn, Rosenthal, Jin, Huang, Namakydoust and 
Zimet (2008) found that higher perceived severity of HPV and HPV-related disease was 
positively associated with intention to receive the vaccine (Boehner et al., 2003; Jones & 
Cook, 2008). Interestingly, one study that examined the stages of HPV vaccine adoption 
found lower perceived severity in college women who were undecided or contemplating 
the vaccine as compared to those who had decided against it (Allen et al., 2009). This 
suggests that a complex relationship could exist between HPV vaccination and perceived 
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severity. Previous research indicates that benefits might mediate the effects of severity on 
health behavior, however this relationship has not been explored for HPV vaccination 
(Ronis & Harel, 1989). Given the severe consequences that can result from HPV 
infection and the lack of research in this area, investigating the psychosocial factors that 
lead to refusal of the vaccine is important.  
Only one study to the author’s knowledge has explored the direct effects of 
perceived benefits on HPV vaccination in college women. As indicated previously, Allen 
et al. (2009) categorized college women according to their stage of HPV vaccine 
adoption using the transtheoretical model of change (Prochaska & DiClemente, 1984).  
They found that women who planned to be vaccinated within the next 30 days 
(preparation stage) or were already vaccinated (action stage) had higher perceived benefit 
scores than those in the precontemplation and contemplation stages. Benefit scores were 
based on the vaccine’s potential to stop the spread of HPV to partners and to prevent 
cervical cancer and genital warts. Another study on women aged 18 to 30 years found 
that most participants believed that getting the HPV vaccine would be a good idea, would 
be safe, would prevent cervical cancer and would prevent future acquisition of HPV 
(Kahn et al., 2003). Since only one study has investigated the association between 
perceived benefits and HPV vaccination among college-age women, the current study 
explored whether this factor influenced the uptake of the vaccine.  
As acknowledged previously, certain barriers can influence HPV vaccine 
acceptability among women. According to the literature, potential barriers to women 
receiving the vaccine might include cost of the vaccine, not knowing enough about the 
vaccine, fears that others might consider them promiscuous and concerns about the safety 
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of the vaccine (Constantine & Jerman, 2007; Friedman & Shepeard, 2007; Grant et al., 
2009). However, very few studies have explored barriers to HPV vaccination in college-
age women. Preliminary results on college students suggest that those who have lower 
perceived barriers are more likely to accept the vaccine. For instance, students who 
weren’t bothered by shots, believed that the vaccine was safe, or believed it was low cost 
had greater vaccine acceptance (Boehner et al., 2003). Conversely, a separate study found 
that having to pay $50 for the vaccine made 63% of participants much less likely to 
accept the vaccine (Jones & Cook, 2008). Finally, results indicate that women previously 
vaccinated have significantly lower perceived barriers than those who decided against 
vaccination (Allen et al., 2009).  
Assessing barriers to vaccination represents an important area of exploration since 
these factors could inhibit wide-spread receipt of the vaccine. As previous studies 
indicate, college women possess positive attitudes towards the HPV vaccine. However, if 
this population experiences factors that inhibit their ability to receive the vaccine, then 
not as many college women will become vaccinated. Understanding these barriers 
represents the first step in successfully implementing the HPV vaccine. Once the barriers 
have been identified, then future research can explore methods for overcoming these 
factors.  
Although cues to action are part of the full HBM, a limited number of studies 
have explored this construct. To the author’s knowledge only one study has investigated 
cues to action for the HPV vaccine in college women. Jones and Cook (2008) found that 
knowing a close friend or relative with HPV predicted intention to receive the vaccine. In 
addition, the availability of a free vaccine and a doctor’s recommendation for the vaccine 
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made participants much more likely to accept vaccination. This suggests that external 
cues are particularly salient for trigging vaccination behavior. However, cues that might 
discourage vaccination, such as knowing someone who had negative side effects from the 
vaccine, have not been studied. One study found that most college students heard about 
HPV through public media like TV, magazines, and radio (Gerend & Magloire, 2008). 
Campaigns have been advertising the HPV vaccine since it became available, however, it 
remains unknown what effect this media has on vaccination behavior. Moreover, Jones 
and Cook (2008) focused on external cues, but internal cues might also play a role in 
women’s decision to receive the vaccine. Since preliminary results suggest that cues to 
action influence HPV vaccination, future studies should explore a larger variety of 
triggers.  
Self-efficacy has been part of the HBM model ever since Rosenstock et al. 
recommended adding it in 1988. However, a surprising number of studies fail to include 
this construct when testing the HBM. The original HBM model included perceived 
barriers, benefits, severity and susceptibility, whereas the expanded model incorporates 
cues to action as well as self-efficacy. The few studies that have investigated college 
student’s self-efficacy to receive the HPV vaccine found that this construct significantly 
predicted vaccination intentions. In one study, self-efficacy uniquely predicted college 
women’s intentions to receive the vaccine as well as mediated the effects of message 
framing (Gerend, Shepherd, & Monday, 2008). A loss-framed message for a hypothetical 
one-shot HPV vaccine promoted the greatest self-efficacy and therefore the highest 
vaccine intentions. Moreover, a separate study on college men found that higher self-
efficacy to receive a hypothetical HPV vaccine predicted vaccine acceptance (Gerend & 
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Barley, 2008). While these studies examined hypothetical HPV vaccines, Buchanan 
(2008) investigated the association between self-efficacy and the currently available 
Gardasil vaccine. The results indicate that even after including constructs from both the 
HBM and the Theory of Planned Behavior, self-efficacy remained a significant predictor 
of college women’s intentions to receive the vaccine. Therefore, women’s belief in their 
ability to overcome the necessary barriers to receive the three HPV vaccine injections 
appears to play an important role in predicting HPV vaccination behavior.    
According to the limited number studies, the HBM appears to be a useful 
predictor of HPV vaccination intentions and vaccination status among college-age 
women. This study aimed to build upon this previous research and address some of the 
limitations in the literature. Most of the previous studies included only a few of the major 
HBM components instead of testing the full model. Even the studies that incorporated 
perceived susceptibility, perceived severity, benefits and barriers did not include other 
important components such as self-efficacy and cues to action. Thus, the HBM has not 
been adequately tested or operationalized within the HPV literature.  
In addition, most of the studies were conducted prior to US federal approval of 
the vaccine and only one examined actual vaccine uptake (Allen et al., 2009). Finally, 
only a small number of HPV vaccine studies have focused on college-age women, which 
represents the most at-risk population. This study addressed some of these weaknesses by 
testing the full HBM model in vaccinated and unvaccinated women after the HPV 






The HBM provides a useful framework for predicting health behavior, however, 
additional factors can also influence health decisions and should be explored as well. One 
factor that has been particularly influential among college-age women for receiving the 
HPV vaccine is subjective norms. This construct has traditionally been associated with 
the Theory of Planned Behavior and refers to how people important to the individual 
view the behavior (Fishbein & Azjen, 1975). Subjective norms assess two different 
dimensions, injunctive and descriptive. Injunctive refers to whether an individual’s social 
network expects and approves of the behavior and descriptive refers to whether the 
individual’s social contacts perform the behavior themselves. Preliminary evidence 
indicates that the addition of this construct to the HBM could improve the ability to 
predict HPV vaccination. Studies incorporating aspects from both the HBM and the 
Theory of Planned Behavior found that subjective norms remained a significant predictor 
of women’s intention to receive the HPV vaccine above and beyond the other constructs 
(Buchanan, 2008; Kahn et al., 2003).   
According to the literature, college-age women seem to be especially influenced 
by the important people in their life. Participants who believed their parents, doctors, 
friends, and partners would encourage vaccination were more likely to accept the HPV 
vaccine (Boehner et al., 2003; Jones & Cook, 2008; Costar, 2008). In one study, social 
norms (the perception that peers were planning to be vaccinated or already had been 
vaccinated) was the strongest predictor of HPV vaccine intentions, above and beyond the 
HBM constructs (Allen et al., 2009). College women who had already received the 
vaccine or were planning to receive the vaccine had significantly higher subjective norms 
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as compared to women who decided not to get the vaccine. Therefore vaccinated women 
and those preparing to get the vaccine received more vaccination support from significant 
others. These results highlight the importance of assessing subjective norms for the HPV 
vaccine in college-age women. Although the majority of college-age women will likely 
decide for themselves whether to receive the vaccine, they may seek advice and support 
from the people they trust. The behavior of peers and the approval of important people 
may be one of the most significant determining factors in whether a woman becomes 
vaccinated.  
HPV Knowledge 
 HPV knowledge has been a popular area of exploration even before the 
development of the HPV vaccine. Of the 28 studies in Brewer et al.’s (2007) review, 15 
assessed knowledge and awareness of HPV. Most of these studies focused on adult 
women, however knowledge of HPV among college students has received substantial 
research attention.  Awareness of HPV has appeared to increase over the last decade, 
perhaps as a result of publicity surrounding the HPV vaccine. One study from 1999 found 
that only 38% of college students had ever heard of HPV (Yacobi et al., 1999). However 
later studies found that more than 75% of college students had heard of HPV and 95% of 
college women had heard of genital warts (Gerend & Magaloire, 2008; Baer, Allen, & 
Braun, 2000). While current awareness of HPV is relatively high in this population, 
knowledge about the virus remains modest at best. HPV knowledge was particularly low 
in earlier studies, with average scores below the 68
th
 percentile in one study and a median 
score of three on a 13-item scale in another study (Ramirez et al., 1997; Yacobi et al., 
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1999).  Moreover, college students indicated they knew the least about HPV and felt that 
this STD had received the least amount of educational effort.  
Knowledge scores increased slightly in later studies, with participants answering 
45% of the questions correctly in one study, however, misunderstandings about HPV still 
persist (Lambert, 2001). The research indicates that most students are unaware that HPV 
can be silent, and can cause complications such as genital warts, although 92% correctly 
identified the causal link between HPV and cervical cancer (Yacobi et al., 1999; Baer et 
al., 2000; Allen et al., 2009; Gerend & Magaloire, 2008). Knowledge about the transient 
nature of most HPV infections, the role of Pap smears in HPV detection, and the lack of 
available HPV treatment remained low (Allen et al., 2009; Gerend & Magaloire, 2008). 
However, the most consistent misunderstanding across studies was the modes of 
transmission for both genital warts and HPV (Allen et al., 2009; Yacobi et al., 1999; Baer 
et al., 2000). The lack of knowledge regarding transmission is particularly disturbing 
since college-age students may unknowingly expose themselves to infection. For 
instance, students may hold the false assumption that using condoms will fully protect 
them against any STD including HPV. This false sense of security could lead to riskier 
sexual behaviors.  
 Findings have been mixed regarding which factors predict HPV knowledge. One 
study found that sexually experienced college women possessed higher knowledge scores 
than sexually inexperienced college women (Ramirez et al., 1997). However, another 
study found that sexual behaviors among college students, such as having multiple 
partners and not using condoms, predicted lower HPV knowledge and awareness (Yacobi 
et al., 1999). Therefore sexual behavior appears to be associated with HPV knowledge, 
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however the direction of the association remains unclear. In addition, few studies have 
explored whether an association exists between HPV knowledge and health beliefs. 
Perceived risk of HPV infection was not significantly associated with HPV knowledge in 
one study, however, further research is needed to explore the association between 
knowledge and the HBM constructs (Ramirez et al., 1997). Finally, college women 
appear to possess greater awareness and knowledge of HPV than college men, perhaps as 
a result of the HPV vaccine and its media campaign targeting women (Gerend & 
Magaloire, 2008). 
 Several studies have attempted to determine whether interventions can increase 
HPV knowledge and thereby enhance vaccine acceptance. Methods such as HPV 
educational interventions and information sheets have been found to heighten knowledge. 
A brief educational intervention on HPV transmission, prevention, and complications 
increased HPV knowledge by 34% among college women (Lambert, 2001). In addition, 
detailed information sheets that describe the epidemiology and potential clinical sequelae 
of HPV infection increased HPV knowledge relative to the control group (Dempsey, 
Zimet, Davis, & Koutsky, 2003). Information pamphlets regarding the effectiveness of 
the HPV vaccine on reducing HPV infection and thereby cervical cancer also heightened 
knowledge about the HPV vaccine (Chan, Cheung, Lo, & Chung, 2007). While these 
interventions improved HPV knowledge, this increased awareness has not been directly 
associated with HPV acceptance. Of the studies that used the HPV information sheets, 
Davis, Dickman, Ferris, Dias (2004) found greater vaccine acceptance and, Dempsey et 
al. (2006) did not. However, Davis et al. (2004) did not measure changes in HPV 
knowledge, therefore the results cannot be attributed to increased knowledge. Chan et al. 
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(2007) found higher acceptance rates after parents received an HPV vaccine information 
pamphlet, however increased acceptance was only associated with one knowledge item. 
Therefore, increasing HPV knowledge through interventions does not necessarily lead to 
vaccine acceptance. Moreover, most of the intervention studies have focused on parental 
acceptance of the vaccine for their daughters. As a result, it remains unknown whether 
HPV interventions would increase vaccine acceptance among college-age women.  
A substantial number of studies have included HPV knowledge as the key 
predictor of HPV vaccine acceptability, however, the findings from this research remain 
inconsistent. Several studies found that HPV knowledge was unrelated to acceptance of 
the vaccine among college students (Boehner et al., 2003; Gerend & Magaloire, 2008). 
Other studies have found a significantly positive relationship between HPV knowledge 
and vaccine acceptance. For instance, Jones and Cook (2008) discovered that college 
women who correctly answered two or three knowledge questions were eight times more 
likely to accept the vaccine than those who answered zero to one questions correctly. In 
addition, HPV knowledge appears to be positively associated with receiving the vaccine. 
One study found that HPV vaccinated women had significantly higher knowledge scores 
than those who decided against vaccination (Allen et al., 2009).  
Differences in the HPV knowledge measures might account for some of the 
variance in the findings. The number of knowledge items, topics covered, and level of 
difficultly varied greatly between studies (Boehner et al., 2003; Gerend & Magaloire, 
2008; Jones & Cook, 2008; Allen et al., 2009). Moreover, preliminary results suggest that 
there might be a difference between knowledge of the vaccine and knowledge of HPV. 
Costar (2008) found that college women’s reported knowledge of the vaccine was 
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significantly correlated with intention to become vaccinated, but their reported 
knowledge of HPV was not. Thus, future studies should differentiate between 
participants’ knowledge of HPV and their knowledge of the HPV vaccine. Since the role 
of knowledge remains unclear, additional research is required to determine extent that 
this construct contributes to college-age women’s decision to receive the HPV vaccine.  
Sexual Risk Factors 
 Since HPV is a sexually transmitted disease, certain sexual risk factors increase 
an individual’s chance of contracting the infection and are important to include in studies 
examining attitudes toward vaccines. As indicated previously, having a high number of 
lifetime sexual partners and engaging in intercourse at an early age increase the risk of 
HPV. While perceived susceptibility has been found to predict acceptance of the HPV 
vaccine, some studies have also explored whether actual risk for HPV increases the 
chances of receiving the vaccine.  The findings indicate that sexually active college 
women and those with a higher number of sexual partners had higher intentions of getting 
the HPV vaccine (Gerend & Magloire, 2008; Jones & Cook, 2008; Boehner et al., 2003; 
Costar, 2008; Buchanan, 2008). Participants who reported more than five partners were 
four times more likely to intend to receive the vaccine than those with no partners (Jones 
& Cook, 2008). One study did not find an association between sexual experience and 
vaccine acceptance, however this study used a hypothetical vaccine since the HPV 
vaccine was not yet available (Boehner et al., 2003). Therefore, women seem to be aware 
that sexual behavior increases their risk of contracting HPV and seek to protect 
themselves through the vaccine. Interestingly, women who were not yet sexually active 
expressed the least amount of interest in the vaccine (Gerend & Magloire, 2008). This 
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represents an important finding since the vaccine targets sexually inexperienced females 
and research indicates that this population can benefit the most from vaccination. These 
women might not perceive themselves at risk and therefore feel that the vaccine is 
unnecessary. Moreover, as opposed to adolescent girls, college-age women are more 
likely to make their own decision about becoming vaccinated.  
 Additional behaviors related to sexual activity also predict higher acceptance of 
the HPV vaccine. Several studies found that condom use with a committed partner as 
well as condom use with a new partner predicted higher intentions to get vaccinated 
against HPV (Costar, 2008; Buchanan, 2008). In addition, women who had been tested 
for HIV were more likely to accept the HPV vaccine (Gerend, Lee, & Shepherd, 2006). 
This suggests that women who tend to engage in health-protective behavior have higher 
vaccination intentions. While contracting HPV depends upon an individual’s sexual 
behavior, it also depends upon the partner’s sexual history. For instance, if a male partner 
is uncircumcised, has an STD, or has had a higher number of sexual partners, this 
increases a woman’s risk for HPV. However, research has not explored whether an 
association exists between a partner’s sexual behavior and vaccine acceptance. If women 
are aware that their partner’s sexual history can increase their risk of HPV, this might 
make them more likely to become vaccinated. Studies have not explored other sexual risk 
factors such as age of first intercourse and frequency of vaginal sex.  These factors might 
also have an influence on women’s intentions to receive the vaccine. While women seem 
to be aware that sexual behaviors can increase their risk of HPV infection, one study 
found that perceived susceptibility was unrelated to actual risk (Ramirez et al., 1997). 
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Therefore the association between perceived risk, actual risk, and vaccine acceptance 
requires further research.  
Summary 
Few studies have explored factors that could influence HPV vaccination among 
college-age women. When studies have researched this topic, they have generally 
grouped college-age men and women together in one sample or used a hypothetical HPV 
vaccine instead of the currently available Gardasil vaccine. The HBM provides a useful 
framework for exploring HPV vaccination intentions and vaccination status and has been 
viewed by many researchers as an intuitively appealing model of health-related 
behaviors. However the limitations of this theory reside in its operationalization since 
many studies have not adequately measured the HBM or tested the model in its entirety. 
This study aimed to address some of these limitations by exploring the relationship 
between the full HBM model and college-age women’s intentions to receive the HPV 
Gardasil vaccine. In addition, the study used the HBM to examine differences between 
vaccinated and unvaccinated women. Finally, other factors that could influence 











Statement of the Problem 
 Research on preventative health has focused on the factors that influence people’s 
decision to engage in health behaviors. This study used the Health Belief Model as well 
as additional constructs to explore how HPV vaccinated college-age women differ from 
college-age women who haven’t been vaccinated.  These same constructs were used to 
predict college-age women’s intentions to receive the HPV vaccine if they had not 
already been vaccinated. The original HBM framework includes perceived susceptibility, 
severity, benefits and barriers. The constructs of cues to action, self-efficacy and 
subjective norms were used to augment the original model. In addition, HPV knowledge 
and sexual risk factors for HPV were used to explore intentions to receive the vaccine as 
well as the difference between vaccinated and unvaccinated college-age women.  
The human papillomavirus is a widespread virus that can have serious health 
consequences such as genital warts and anogenital cancers (National Cancer Institute, 
2008; Souza et al., 2007). Women are particularly affected since HPV has been identified 
as the cause of cervical cancer, an illness developed by almost 12,000 women in the U.S 
(U.S. Cancer Statistics Working Group, 2009). While up to 75% of sexually active adults 
will become infected with HPV in their lifetime, college-aged women are particularly 
susceptible since a high rate of new infections occurs in this age group (Cates, 1999; 
Koutsky, 1997; Cervical Cancer, 1996; Bauer et al., 1991; Weinstock et al., 2004). The 
availability of a vaccine that protects against high risk strains of HPV has the potential to 
reduce HPV infection among women and prevent the spread of the virus to sexual 
partners. In order for the vaccine to successfully reduce the incidence of HPV, females 
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must choose to become vaccinated. Although parents will likely play a role in deciding 
whether or not their daughters receive the vaccine, college-aged females will likely have 
more autonomy than younger females in making this decision. Therefore, understanding 
which factors influence women in this age group to receive the vaccine is an important 
step in creating a successful vaccination program.  
The Health Belief Model serves as a useful framework for understanding factors 
that influence health decisions. Original components of the HBM, including perceived 
susceptibility, severity, benefits and barriers, have been widely used to predict a range of 
health preventative behaviors. For instance, the HBM significantly predicted influenza 
vaccination in several studies (Brewer et al., 2007; Chapman & Coups, 1999). Research 
suggests that the HBM is also a useful model for HPV vaccine acceptability. In a review 
of 28 HPV studies, Brewer and Fazekas (2007) found that most of the HBM components 
predicted acceptance of the HPV vaccine. While several studies have used the HBM to 
explore college-age women’s attitudes and beliefs regarding the HPV vaccine, many have 
used only parts of the model rather than all four main components. The exclusion of one 
of these components could result in the omission of potentially important information 
regarding women’s decision to become vaccinated. This study aimed to test all four main 
components of the HBM.  
 Aside from the original HBM components, research indicates that other factors, 
such as cues to action, self-efficacy and subjective norms, can also influence health 
decisions. Several HBM studies have incorporated cues to action in order to augment the 
predictive utility of the original theory. For instance, both positive and negative cues have 
been found to significantly influence flu vaccination behavior (Cummings et al., 1979; 
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Aho et al., 1979). One study explored cues to action specific to the HPV vaccine and 
discovered that certain cues increased intentions to become vaccinated (Jones & Cook, 
2008). Given that the HPV vaccine has been featured in media advertisements, cues to 
action seem particularly relevant for this health decision. Ever since Bandura introduced 
the concept in the 1970’s, self-efficacy has been included in numerous HBM studies 
(Stretcher et al., 1997). Preliminary research on the HPV vaccine suggests that self-
efficacy represents an influential factor in deciding whether to become vaccinated. Self-
efficacy significantly predicted intentions to receive the vaccine in two studies on 
hypothetical HPV vaccines and one study on the Gardasil vaccine (Gerend & Magliore, 
2008; Gerend et al., 2008; Buchanan, 2008). While cues to action and self-efficacy have 
been incorporated into relatively few studies on the HPV vaccine, subjective norms 
represents a more common factor associated with this area of study. Perceptions of what 
important others believe about the HPV vaccine appear to greatly influence college-age 
women’s decision to get vaccinated. For instance, acceptance of the vaccine was higher 
when parents, doctors, friends, and partners approved of the vaccine (Boehner et al., 
2003; Jones & Cook, 2008; Costar, 2008). According to the literature, cues to action, 
self-efficacy, and subjective norms are all factors that can influence women’s decision to 
receive the HPV vaccine. Since very few studies have explored these factors along with 
the original HBM framework, this study augmented the model with additional 
components. 
In addition to the aforementioned areas of interest, the present study collected 
descriptive data about the women in the sample. Specifically, women’s HPV knowledge 
and sexual risk factors for HPV infection were collected to explore how these factors 
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might contribute to HPV vaccination decisions. Previous literature suggests that these 
factors have an influence on women’s intentions to receive the HPV vaccine (Allen et al., 
2009; Gerend & Magloire, 2008; Jones & Cook, 2008; Boehner et al., 2003; Costar, 
2008; Buchanan, 2008). Open-ended questions were included regarding the most salient 
benefits and drawbacks to receiving the vaccine as well as what factors led to or kept 
participants from receiving the vaccine.  Finally, the study included demographic 
information, such as subjects’ ages, ethnicities and health insurance status. 
The HPV vaccine became available in 2006, therefore studies have only recently 
begun to include women who intend to or have already received the Gardasil vaccine. 
Prior to the Gardasil vaccine, intentions to receive hypothetical HPV vaccines served as 
the outcome measure for many HPV studies. While research on hypothetical vaccines 
provides useful information about health decisions, studies on the currently available 
Gardasil vaccine are more applicable to women’s actual health behavior. Since the HPV 
vaccine has been available for just over three years, research can explore the differences 
between women who have received the HPV vaccine and those who have not. This 
remains an important area to study since the factors that influence intention to receive a 
hypothetical or real vaccine might be different than those that influence vaccination 
behavior. A recent survey of adolescent girls aged 13-18 found that 37% had received at 
least one HPV vaccine shot through 2008 (CDC, 2009). However, only 18% have 
received the full three shots. This information suggests that HPV vaccine implementation 
in this age group might be more successful for the first shot than the full vaccine series. It 
remains unknown whether this pattern also applies to college-aged women since few 
studies have explored the number of women in this age group to become vaccinated. 
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Based on gaps in the literature and important factors that still require exploration, this 
study tested the following hypotheses and research questions in HPV vaccinated and 
unvaccinated college-age women. Among those who have not received the HPV vaccine, 
intentions to receive the vaccine in the future were assessed.  
HPV Vaccination Intentions 
Research Hypotheses 
Hypothesis 1: HBM variables of perceived susceptibility, severity, benefits, 
barriers and self-efficacy will each contribute unique variance in predicting HPV 
vaccination intentions among unvaccinated women. Women who report greater 
perceived susceptibility to HPV, greater perceived severity of HPV, greater 
perceived benefits of HPV vaccination, fewer perceived barriers to HPV 
vaccination, and higher self-efficacy for receiving the HPV vaccine will report 
higher intentions to obtain the HPV vaccine.   
Several studies have found that the original HBM concepts significantly predict 
HPV vaccination intentions among college students. Research indicates that higher 
perceived susceptibility and lower perceived barriers among college-age students is 
associated with increased intention to receive the HPV vaccine (Gerend & Magloire, 
2008; Jones & Cook, 2008; Boehner, 2003). Although perceived severity has not been 
significantly associated with HPV vaccine acceptance in some studies, it was found to be 
a significant predictor of young women’s intention to receive the vaccine (Boehner et al., 
2003; Jones & Cook, 2008; Kahn et al., 2003; Kahn et al., 2008). The relationship 
between perceived benefits and intentions to receive the HPV vaccine has not been 
specifically studied in college-age women. However, higher perceived benefits have been 
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associated with higher intentions to receive the vaccine among adults and parents of 
adolescents (Davis et al., 2004; Dempsey et al., 2006; Brewer & Fazekas, 2007; Zimet, 
Mays, Winston, Kee, Dickes, Su, 2000). Thus, perceived benefits were hypothesized to 
predict HPV vaccination intentions among college-age women as well. Self-efficacy was 
included in this hypothesis since it is often included in the Health Belief Model. Among 
the few studies that have investigated college student’s self-efficacy to receive the HPV 
vaccine, results indicate that this variable significantly predicts vaccination intentions 
(Buchanan, 2008; Gerend et al., 2008; Gerend & Barley, 2008). Moreover, self-efficacy 
remained a significant predictor even after accounting for the HBM components of 
perceived susceptibility, severity, benefits and barriers (Buchanan, 2008; Gerend & 
Barley, 2008). Therefore, this construct was hypothesized to significantly predict HPV 
vaccination intentions.  
Hypothesis 2: There will be a positive correlation between HPV knowledge 
and HPV vaccination intentions for unvaccinated women 
Although a substantial amount of researched has explored the role of HPV 
knowledge in HPV vaccine acceptability, the findings remain inconsistent. Several 
studies found that HPV knowledge was unrelated to acceptance of the HPV vaccine 
among college students (Boehner et al., 2003; Gerend & Magaloire, 2008). However, 
Jones and Cook (2008) found that college women who correctly answered two or three 
knowledge questions were eight times more likely to accept the HPV vaccine. While 
findings have been mixed, differences in the level of difficulty, number of questions and 
topics covered in the HPV knowledge questionnaires could account for the variation in 
results. The studies that did not find a significant association with receiving the HPV 
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vaccine might have included less valid and reliable HPV knowledge scales. This study 
aimed to incorporate a valid and reliable HPV knowledge questionnaire that has been 
used in previous studies. Given the evidence that this construct can serve as a significant 
predictor, it was hypothesized that HPV knowledge would have a positive association 
with HPV vaccination intentions. 
Hypothesis 3: There will be a positive relationship between reported HPV 
risk factors and HPV vaccination intentions for unvaccinated women. 
Several studies have explored whether women who are at higher risk for HPV 
infection are more likely to receive the HPV vaccine. Risk for contracting HPV is 
determined by certain sexual behaviors such as the number of sexual partners and the 
frequency of condom use. Findings indicate that sexually active college women and those 
with a higher number of sexual partners had higher intentions of getting the HPV vaccine 
(Gerend & Magloire, 2008; Jones & Cook, 2008; Boehner et al., 2003; Costar, 2008; 
Buchanan, 2008). Participants who reported more than five partners were four times more 
likely to intend to receive the vaccine those with no partners (Jones & Cook, 2008). This 
suggests that women who are at greater risk for HPV infection have higher intentions of 
becoming vaccinated against HPV.  
HPV Vaccination Status  
Research Hypotheses 
Hypothesis 4: The Health Belief Model (HBM) variables of perceived 
susceptibility, severity, benefits, barriers and self-efficacy will significantly 
distinguish vaccinated women from unvaccinated women. Specifically, vaccinated 
women will report greater perceived susceptibility to HPV, greater perceived 
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severity of HPV, greater perceived benefits of HPV vaccination, fewer perceived 
barriers to HPV vaccination, and greater self-efficacy for vaccination as compared 
to unvaccinated women.  
One study by Allen et al. (2009) has explored HBM components in terms of 
vaccination status among college women. They reported that previously vaccinated 
college women had significantly lower perceived barriers than those who decided against 
the vaccine. Moreover, women who had already received the vaccine or planned to 
receive the vaccine within the next 30 days had higher perceived benefits as compared to 
participants who decided against the vaccine, were undecided about vaccination and 
those not planning to be vaccinated in the near future. Although Allen et al. (2009) did 
not find that perceived susceptibility or severity significantly differentiated vaccinated 
versus unvaccinated college women, these variables were still included in the hypothesis. 
Perceived susceptibility and severity have both been found to predict intentions to receive 
the vaccine. In addition, Allen et al. (2009) did not include self-efficacy, but this variable 
has also been found to predict vaccine intentions (Buchanan, 2008; Gerend & Barley, 
2008). Since intentions tend to predict behaviors, it would make sense that perceived 
susceptibility, perceived severity and self-efficacy would also influence whether women 
become vaccinated. Moreover Allen et al.’s (2009) study represents the only known study 
to use HBM variables to explore vaccinated versus unvaccinated college women. 
Therefore, it would be premature to eliminate variables based on the results of one study. 
Hypothesis 5: Vaccinated women will report higher self-efficacy to receive the 
vaccine as compared to unvaccinated women.  
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Although self-efficacy has only been studied in relation to intentions to receive 
the HPV vaccine, it was hypothesized that this variable would act in a similar way with 
HPV vaccination status. Higher self-efficacy has been found to predict higher HPV 
vaccination intentions (Buchanan, 2008; Gerend & Barley, 2008). Therefore since self-
efficacy is a significant predictor of vaccination intentions, it remains likely that women 
who have obtained the vaccine would report higher scores for this construct as compared 
to women who have not received the vaccine. 
Hypothesis 6: Vaccinated women will report more positive cues to action for 
receiving the HPV vaccine as compared to unvaccinated women.  
Although cues to action have only been studied in relation to intentions to receive 
the HPV vaccine, it was hypothesized that this variable would act in a similar way with 
HPV vaccination status. Since positive cues to action increase vaccination intentions, it 
remains likely that women who have obtained the HPV vaccine would report a higher 
number of positive cues to action as well. In addition, studies on the influenza vaccine 
suggest that cues to action are associated with vaccination behavior. Brewer et al. (2007) 
and Chapman and Coups (1999) discovered that cues to action significantly predicted 
which participants received the influenza vaccine. Thus, it was hypothesized that positive 
cues to action would significantly differentiate college-age women who have received the 
vaccine and those who have not. 
Hypothesis 7: Vaccinated women will report higher subjective norms than 
unvaccinated women.  
Prior studies have reported that subjective norms significantly predict HPV 
vaccination status among college students. Allen et al. (2009) found that college women 
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who planned to receive the vaccine sometime in the future and those who had already 
received the vaccine had significantly higher subjective norms than women who had 
decided against the vaccine. In addition, subjective norms remained one of the most 
significant predictors of vaccination status (Allen et al., 2009). As a result, college-age 
women who had received the HPV vaccine were hypothesized to have higher subjective 
norms than women who have not received the vaccine.  
Hypothesis 8: Vaccinated women will have higher HPV knowledge scores 
than unvaccinated women.  
Although a substantial amount of researched has explored the role of HPV 
knowledge in HPV vaccine acceptability, only one study has explored this construct in 
relation to HPV vaccination status. Allen et al. (2009) found that college women who had 
already been vaccinated had significantly higher knowledge scores than those who had 
decided against vaccination. Given the evidence that this construct can serve as a 
significant predictor, it was hypothesized that vaccinated college-age women would have 
higher HPV knowledge scores than those who have not received the vaccine. 
Hypothesis 9: Vaccinated women will report higher levels of HPV risk factors 
than unvaccinated women. 
While several studies have explored whether HPV risk factors predict HPV 
vaccination intentions, no study has used this construct to differentiate HPV vaccinated 
and unvaccinated women. However, research indicates that the presence of HPV risk 
factors, such as a high number of sexual partners, predicts higher intentions of getting the 
HPV vaccine (Gerend & Magloire, 2008; Jones & Cook, 2008; Boehner et al., 2003; 
Costar, 2008; Buchanan, 2008). Therefore, it was hypothesized that a greater number of 
56 
 
HPV risk factors would be associated with women who have received the HPV vaccine 
as opposed to those who have not been vaccinated. 
Research Questions 
Research Question 1: What is the prevalence of vaccinated women in the 
sample? 
A limited number of studies have researched HPV vaccination since the vaccine 
became licensed in the U.S. in 2006. Among the studies conducted after 2006, several 
have explored the rate of HPV vaccination among young women. Studies conducted in 
2007 found that only 12% of college-aged women had received at least one vaccine 
injection (Allen et al., 2009; Grant et al., 2009). Moreover, research suggests that a fair 
number of girls and women do not complete the three shots needed for sufficient 
protection against HPV. A national survey of vaccination coverage of adolescents found 
that while 37% had initiated the HPV vaccine series, only 18% received the three shots 
needed for full protection (CDC, 2009). Although the vaccine is administered over the 
course of six months, this time frame does not seem to fully account for the discrepancy 
between those who initiate the vaccine series and those who complete it. A national 
survey has not been conducted among college-aged women, therefore, it remains difficult 
to paint an accurate picture of HPV vaccine uptake among this population. Moreover, 
studies have not explored the prevalence of HPV vaccination past 2007 among college-
aged women. Due to the lack of research in this area, this study proposed a research 
question rather than a hypothesis about the number of vaccinated college-age women  
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Question 2: For vaccinated women, is there a significant correlation between 
the length of time since vaccination and the HBM components of perceived benefits, 
barriers, susceptibility, and severity? 
Since retrospective reporting has been found to influence the perceived 
importance of HBM components, the length of time since vaccination was deemed an 
important variable to include. Perceived benefits and barriers were found to play a more 
significant role and perceived severity was found to play a less significant role as 
compared to prospective reporting. This suggests that participants who recently received 
the vaccine might report less biased responses than those who received the vaccine 
several years ago. Therefore, if a significant relationship exists between length of time 
since vaccination and the HBM components, time since vaccination should be controlled 
for in data analyses.  
 Question 3: For vaccinated women, is there a significant correlation between 
satisfaction with receiving the HPV vaccine and the HBM components of perceived 
benefits, barriers, susceptibility, and severity? 
Satisfaction with receiving the HPV vaccine has not been measured, therefore it 
remains unknown how this factor might relate to the HBM variables. Dissatisfaction with 
vaccination might occur if the participant experiences negative side-effects or 
embarrassment from receiving the HPV vaccine. If participants’ HBM perceptions match 
their satisfaction level (ie. high satisfaction combined with high benefits, susceptibility 
and severity, and low barriers), this might indicate that their expectations about the 
vaccine were fulfilled. However, if there is a disconnect between the HBM variables and 
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satisfaction, this might suggest that participants had either a more positive or a more 
negative experience than they expected.  
Question 4: Do women who report higher risk factors for HPV report higher 
perceived susceptibility to HPV?  
Several studies have investigated whether perceived susceptibility relates to actual 
risk for contracting sexually transmitted infections (STIs). Ethier, Kershaw, Niccolai, 
Lewis, and Ickovics (2003) found that sexually experienced teenage girls perceived little 
or no chance that they would contract an STI in the following year. However, 
approximately 38% of the participants tested positive for an STI. STI history represented 
the only significant risk indicator related to perceived susceptibility. Another study found 
that females aged 16 to 18 years who always used condoms were less likely to think that 
they would get an STI than participants who never used condoms (Abel & Brunton, 
2005). In a third study, young adults had elevated perceived risk of chlamydial and 
gonococcal infection if they inconsistently or never used condoms, reported multiple 
partners in the past year, received a chlamydia or gonnorhea diagnosis in the past year, or 
reported current symptoms (Ford, Jaccard, Millstein, Bardsley, Miller, 2004). Research in 
this area indicate mixed results with some studies finding numerous STI risk factors 
related to perceived susceptibility and others finding very few. 
Only one known study has explored the relation between perceived susceptibility 
to HPV and HPV risk factors. In the study, sexually experienced college women listed 
the following reasons for perceiving themselves at risk for HPV infection: not practicing 
safe sex, having sexual experience, having multiple partners, not knowing a partner’s 
diseases, testing positive for other STDs, and having a previous history of HPV infection 
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(Ramirez et al., 1997). Interestingly, perceived susceptibility was not related to HPV 
infection. Given the mixed results from the STI literature and the lack of studies specific 
to HPV, the current study proposed a research question regarding the association between 
number of risk factors to HPV and perceived susceptibility. 
Question 5: How will women respond to the following open-ended questions: 
What do you view as the greatest benefits of getting the HPV vaccination for 
yourself? 
What do you view as the greatest drawbacks of getting the HPV vaccination for 
yourself? 
What factors keep you from getting vaccinated? 
What factors led you to get vaccinated? 
The inclusion of these open-ended questions could provide additional information 
about the most important factors that influence women’s decision to get vaccinated. 
Moreover, this represents a way to assess aspects of women’s decision-making that 
standardized measures might not capture. The Health Belief Model measures the rational 
aspects of decision-making and these questions could help determine whether rationality 
actually represents the most salient influential factor or whether non-rational aspects play 







Chapter 4  
Methods 
Design 
In order to explore the factors that influence HPV vaccination, a cross-sectional 
field design was utilized. Cross-sectional studies are highly prevalent within the HBM 
literature (Brewer et al., 2007). Although prospective studies are preferred since this type 
of design increases the likelihood that the HBM variables motivate the behavior, cross-
sectional studies are often more feasible, or may be the only feasible approach, and in any 
case can still provide useful information. For instance, researchers have been able to 
produce rigorous cross-sectional studies exploring the effect of HBM variables on 
preventative behaviors such as cervical screening uptake and MMR vaccination (Orbell, 
Crombie & Johnston, 1996; Hamilton-West, 2006). In a vaccination meta-analysis by 
Brewer et al. (2007), each study received a quality score based on the study’s 
methodological rigor. Many of the cross-sectional studies received high quality scores 
and a study by Hamilton-West (2006) that compared MMR vaccinated versus 
unvaccinated students received the highest quality rating. Therefore, cross-sectional 
studies can still possess sound methodologies and produce valuable findings.    
The current study employed a cross-sectional design in order to compare HPV 
vaccinated women with non-HPV vaccinated women. A dichotomous measure of HPV 
vaccination status was used, with women who had obtained the vaccine falling into one 
group (―Yes‖) and women who had not obtained the vaccine in the other group (―No‖).  
This outcome measure provided important information not included in the previous 
literature. The opportunity for HPV vaccination had been available for three years, so 
61 
 
women who had not yet been vaccinated were hypothesized to be different from women 
who had been vaccinated within this time period. This study attempted to determine 
which factors differentiated women who had chosen to take a preventative health action 
from those who had not.  
This study also explored HPV vaccination intentions among unvaccinated 
women. This outcome variable was measured on a Likert scale and was only included in 
the sample of women who had not received the vaccine. The predictor variables for both 
outcome measures included the HBM variables of perceived susceptibility, perceived 
severity, perceived benefits, perceived barriers, cues to action, and self efficacy. 
Knowledge of HPV, subjective norms for receiving the vaccine, and sexual risk factors 
for HPV infection also served as predictor variables. Logistic regression analyses were 
used on HPV vaccination status to determine how the different predictor variables related 
to this outcome measure. In addition, multiple linear regression analyses were conducted 
on HPV vaccination intentions. 
Participants 
The target population included college-aged women who were eligible to receive 
the HPV vaccine. The sample included 208 females between the ages of 18 and 26 since 
26 is the age limit for the vaccine. Before beginning the study, potential participants were 
informed that the study explores the perceptions of female college-age students toward 
women’s health involving a common sexually transmitted disease and its prevention. The 
participants were a convenience sample recruited from sororities and/or psychology and 
education classes from three universities in the Mid-Atlantic, one university in the 
Midwest and one community college in the West. Incentives such as class credit or the 
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possibility of winning a $40 gift certificate were offered in return for participation. Of the 
232 participants who gave informed consent to take the online study, a total of 218 
completed it, for a completion rate of 94.0%. Six women were excluded from further 
analysis since they were older than age 26 and four participants were excluded since they 
did not give their age and may have been ineligible for the study. This left a total sample 
size of 208 participants. Of these women, 150 reported receiving the vaccine and 58 
reported not receiving the vaccine. Missing values were replaced using the participants’ 
mean score for that particular scale. A total of 51 missing values were calculated for the 
current sample. Of the participants who identified their university, 160 were from 
sororities or undergraduate/graduate psychology/education classes at the University of 
Maryland. Participants from other universities were recruited through specific classes that 
were taught by faculty members acquainted with the researchers. This was an attempt to 
obtain geographical diversity as well as age-related differences in the case of the graduate 
class, although the samples from these other universities were very small. For instance, 
17 were from an undergraduate psychology class at Drake University, 14 were from a 
graduate psychology class at Towson University, 6 were from a community college 
psychology class at Mt. San Antonio College and 2 were from Columbia University. The 
rest of the participants did not identify their university. 
The mean age was 20.97 (SD=1.44) for vaccinated participants and 21.24 
(SD=1.49) for unvaccinated participants. Of the entire sample, participants represented at 
least 8 different ethnicities, although the majority of women were Caucasian (69.2%). 
Most of the sample consisted of college students (89.0%), with the greatest number in 
their fourth year of college (47.6%), however, some of the participants had graduated 
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from college (6.7%) or were in graduate school (3.9%). Comparable numbers of 
participants were single or in a relationship with 53.4% of women reporting being single 
and 43.8% of women reporting being in a committed relationship. For a more 
comprehensive picture of the participants’ demographic information, see Table 1. The 
total percentages for where participants had heard of HPV and the HPV vaccine exceed 
100% since participants could choose multiple options. 
In terms of sexual activity, 80.0% of vaccinated participants reported being 
currently sexually active as compared to 53.4% of unvaccinated participants.  Additional 
information about the participants’ sexual risk factors is presented in Table 2. If 
participants answered ―No‖ to current sexual activity, then they skipped all other 
questions about intercourse. Similarly, if participants answered ―No‖ to penis/vagina 
intercourse or to penis/anal intercourse, then they skipped all other questions related to 
these topics. Therefore, not all questions have a sample size of 208. 
Measures 
Demographics  
A demographics questionnaire based on Costar’s (2008) study was used to collect 
information about participants’ backgrounds (see Appendix A). The questionnaire 
included items on participants’ age, gender, ethnicity, current year in college, and 
romantic relationship status. Health information relevant to HPV was also collected 
including general insurance coverage, insurance coverage of the HPV vaccine, and 
frequency of gynecological check-ups over the last two years. In addition, several 
questions based on Allen et al.’s (2009) study assessed awareness of HPV and the HPV 
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vaccine, including whether participants had heard of HPV and the HPV vaccine and how 
they had heard about it.  
Sexual Risk Factors 
Since HPV is a sexually transmitted disease, this study incorporated questions 
regarding sexual risk factors for HPV from previous studies (Costar, 2008; Winer et al., 
2003; Winer et al., 2006) (see Appendix B). Participants were asked about their personal 
history with HPV, sexually transmitted diseases, abnormal Pap smears, STD tests, 
unintended pregnancies and cervical cancer. In addition, participants were asked about 
behaviors related to sexual activity, including penis/vagina and/or anal intercourse, age of 
first sexual activities, number of sexual partners, type of birth control used, and the 
frequency of condom use when in committed relationships and with new partners. 
Health Belief Model 
 Valid and reliable scales for the Health Belief Model (HBM) are largely 
unavailable for most health behaviors. Several studies have developed instruments with 
sound psychometric properties for specific health concerns, such as breast self-
examination, hypertension regimens, and children’s obesity regimens (Champion, 1984; 
Abraham & Williams, 1991; Maimen, Becker, Kirscht, Haefner, & Drachman, 1977). 
While these scales have been modified for use in different studies, it would be difficult to 
apply these scales to other health behaviors. For instance, constructs such as benefits, 
barriers and cues to action require behavior-specific measures (Strecher & Rosenstock, 
1997). Even when valid and reliable scales are available, these measures must be re-
evaluated with each data collection to determine the sample-specific psychometrics. 
Therefore, it is standard practice for researchers to create their own measures when 
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utilizing the HBM in order to make the scales specific to a particular health behavior. To 
create their own measures, researchers draw on items used in previous studies and reword 
them to fit the health behavior being investigated. 
 Recent HBM studies focusing on the HPV vaccine have drawn from the previous 
HPV literature to create questionnaires. However, these studies have not focused on 
instrument development and many did not explore the construct validity or reliability of 
these measures. One study by Allen et al. (2009) tested the face validity of their measure 
by having experts in the field review the content and conducted cognitive interviews to 
ensure item comprehension and interpretability. The items in the measure assessed 
perceived severity, perceived susceptibility, perceived benefits, and perceived barriers for 
HPV vaccination in a sample of college females. Cronbach Alphas were not reported for 
the study, therefore the scale reliabilities are unknown. Due to the lack of psychometric 
data available for current measures, this study created an HBM scale by utilizing items 
tested by Allen et al. (2009) as well as following guidelines presented by Ronis (1992) 
and Brewer et al. (2007) for framing threat perception questions. In addition, previously 
validated and reliable HBM measures for breast self-examination behavior and cervical 
screening were used as a guide for item development (Champion, 1984; Orbell, et al., 
1996).  
1. Perceived Susceptibility 
Ronis (1992) found that health behavior was more accurately predicted by 
measures of susceptibility that were made conditional on not taking action. As Brewer et 
al. (2007) asserts, unconditioned risk questions, particularly in cross-sectional analyses, 
will underestimate the relationship between risk perceptions and behavior. Participants 
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who received the vaccine will interpret unconditioned measures of susceptibility 
differently than participants who did not receive the vaccine. Therefore, six items 
conditioned on inaction were used to measure vaccinated and unvaccinated participants’ 
perceived susceptibility to HPV infection (see Appendix C). Three items measured a 
participant’s perceived absolute risk of developing HPV and HPV-related diseases if not 
vaccinated. These items included questions such as, ―What are your chances of 
contracting HPV if you didn’t have the HPV vaccine?‖ Three items were related to 
perceived relative risk of developing HPV and HPV-related diseases if not vaccinated. 
These items included questions such as, ―What are your chances of contracting HPV if 
you didn’t have the HPV vaccine compared to other college-aged women?‖ All six items 
were rated on a 10% increment scale of 0-100%. The percentages were averaged to create 
a final score ranging from 0-100% where low scores indicated low perceived 
susceptibility and high scores indicated high perceived susceptibility if not vaccinated. In 
the present study, Cronbach alpha’s for this scale were .92 for both vaccinated and 
unvaccinated participants. 
2. Perceived Severity 
 
The perceived severity measure contained six items that assessed respondents’ 
reactions to a potential diagnosis of HPV and concerns about potential consequences of 
infection (see Appendix C). The six items included statements such as, ―I would be 
embarrassed to let others know that I have HPV if I found out that I contracted the 
disease,‖ and ―If I contracted HPV, it could harm my future health‖. Participants rated 
these statements on a 7-point Likert scale where 1 means ―Strongly Disagree‖ and 7 
means ―Strongly Agree‖. The scores were summed to create a total score ranging from 6 
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to 42 where low scores indicate low perceived severity and high scores indicate high 
perceived severity. In the present study, Cronbach alpha’s for this scale were .73 for both 
vaccinated and unvaccinated participants. 
3. Perceived Benefits 
Six items were used to measure participants’ perceived benefits of receiving the 
HPV vaccine (see Appendix C). The items included statements such as, ―Getting Gardasil 
is important for my health‖ and ―Gardasil is effective in preventing an HPV infection‖. 
These items were rated on a 7-point scale where 1 means ―Strongly Disagree‖ and 7 
means ―Strongly Agree‖ and scores were summed together with total scores ranging from 
6 to 42. Low scores indicated low levels of perceived benefits and high scores indicated 
high levels of perceived benefits of receiving the HPV vaccine. The Cronbach alpha’s for 
this scale were .81 for vaccinated participants and .83 for unvaccinated participants. 
4. Perceived Barriers 
Perceived barriers were assessed by participants’ responses to three items about 
the perceived negative aspects of the vaccine (see Appendix C). The items referred to the 
stigma of receiving the vaccine and included questions such as, ―If other people knew I 
received Gardasil, I would be embarrassed.‖ These items were rated on a 7-point scale 
where 1 means ―Strongly Disagree‖ and 7 means ―Strongly Agree‖. All three items were 
summed together with total scores ranging from 3 to 21. Low scores indicated low levels 
of perceived barriers and high scores indicated high levels of perceived barriers to 
receiving the HPV vaccine. The Cronbach alpha’s for this scale were .54 for vaccinated 





 To the author’s knowledge, a validated self-efficacy scale for receiving the HPV 
vaccine does not currently exist. Self-efficacy refers to a woman’s belief in her ability to 
overcome the necessary barriers to receive the HPV vaccine. Therefore, questions 
assessing self-efficacy for receiving the HPV vaccine were included after each question 
assessing barriers (see Appendix D). The items asked ―Given your answer to the above 
question (#__), how confident are you that you could get Gardasil?‖. These questions 
were rated on a 7-point scale where 1 means ―Not Confident‖ and 7 means ―Very 
Confident‖. Since there were three barrier questions, there were three items assessing 
self-efficacy. These items were summed together to create total scores ranging from 3 to 
21. Low scores indicated low levels of self-efficacy and high scores indicated high levels 
of self-efficacy for receiving the HPV vaccine. The Cronbach alpha’s for this scale were 
.86 for vaccinated participants and .90 for unvaccinated participants. 
Cues to Action 
Cues to action refer to triggers either internally or within the environment that 
could potentially influence health behavior. These cues depend on the specific health 
concerns being investigated, therefore few validated measures of cues to action exist. As 
such, there is no known reliable or validated cues to action scale for the HPV vaccine. 
This study used 11 items that other HPV studies have employed that fit into the cues to 
action construct (Jones & Cook, 2008; Buchanan, 2008; Allen et al., 2009) (see Appendix 
E). The items asked questions such as, ―Have you ever known anyone who has had 
HPV?‖ and ―Has a health care provider ever recommended that you receive the HPV 
vaccine (Gardasil)?‖ These questions were rated on a Likert scale where ―Never‖ is 
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equivalent to 1 point,  ―1-2‖ is equivalent to 2 points, ―3-4‖ is equivalent to 3 points and 
―5+‖ is equivalent to 4 points. The question ―Have you ever known anyone who has had 
negative side effects from a vaccine?‖ was reverse coded. The items were summed to 
create a total score ranging from 11 to 44 with low scores indicating a lower number of 
positive cues to action and high scores indicating a higher number of positive cues to 
action for receiving the HPV vaccine. The Cronbach alpha’s for this scale were .66 for 
vaccinated participants and .59 for unvaccinated participants. Other researchers have had 
difficulty obtaining high alphas for cues to action scales which may be due to the 
complex nature of the construct. This construct can include many different internal and 
external triggers which make it difficult to clearly define. In addition, the low alphas in 
this study may be due to the fact that items were included from a number of different 
studies and combined into one scale. Since the purpose of this study was not measure 
development, this scale was still included despite low internal reliability.   
Subjective Norms 
Subjective norms towards HPV vaccination were measured by six items based on 
a scale used in Costar’s (2008) dissertation (See Appendix F). Scores from the measure 
produced high reliability in a sample of college women (Cronbach alpha of .87). Five of 
the items included statements such as, ―If they knew about the HPV vaccine, most people 
whose opinions I value would approve/disapprove of me getting vaccinated against 
human papillomavirus (HPV)‖ and ―If they knew about the HPV vaccine, my friends 
would approve/disapprove of me getting vaccinated against human papillomavirus 
(HPV)‖. Answers were rated on a Likert scale ranging from 1-7 where 1 means ―Strongly 
Disapprove‖ and 7 means ―Strongly Approve‖. One item included, ―If they knew about 
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the HPV vaccine, most women who are important to me would get themselves vaccinated 
against the human papillomavirus (HPV) if they were at risk‖ and was rated on a on a 
Likert 7-point scale where 1 means ―Strongly Disagree‖ and 7 means ―Strongly Agree.‖ 
The items were summed to create total scores ranging from 6 to 42 where low scores 
represented perceived negative feelings toward HPV vaccination by important others and 
high scores represented perceived positive feelings toward HPV vaccination by important 
others. The Cronbach alpha’s for this scale were .88 for vaccinated participants and .89 
for unvaccinated participants. 
HPV Knowledge 
Knowledge about HPV and the HPV vaccine were assessed with nine items from 
Allen et al.’s (2009) study (see Appendix G). There were five multiple choice questions 
including items such as, ―Which of the following health issues are related to HPV? 
(Please select all that apply.)‖ with the choices ―Cervical cancer, Heart disease, HIV, 
Genital warts or I don’t know‖.  There were also four true/false statements including 
items such as, ―HPV affects only women‖ and ―HPV can occur without symptoms‖. 
Participants received 1 point for each correct response and 0 points for any incorrect 
responses. For questions that had two correct responses, participants received .5 points 
for each correct response, with a total of 1 point if the participant gave both correct 
responses. Answers to each question were provided after participants responded. The 
items were summed to create total scores ranging from 0 to 9 where low scores indicated 







Two open-ended questions were used to assess the biggest influential factors in 
participants’ decision about getting vaccinated (see Appendix H). The first question 
asked, ―What do you view as the greatest benefits of getting the HPV vaccination for 
yourself?‖ and the second question asked ―What do you view as the greatest drawbacks 
of getting the HPV vaccination for yourself?‖ In addition, vaccinated participants were 
asked the open-ended question, ―What factors led you to get vaccinated?‖ and rated their 
level of satisfaction with their decision to receive the vaccine on a 7-point scale. 
Unvaccinated participants were asked the open-ended question, ―What factors keep you 
from getting vaccinated?‖ and rated their level of satisfaction with their decision to not 
yet receive the vaccine on a 7-point scale.  
 Outcome Variables 
HPV Vaccination Status. HPV vaccination status served as an outcome measure 
and included one multiple choice item used in Costar’s (2008) dissertation (see Appendix 
I). This item asked ―Which of the following best describes your current situation?‖ 
followed by the choices a. ―Have completed the series of 3 shots for the HPV vaccine‖, b. 
―Have started, but not completed, the series of 3 shots for the HPV vaccine‖, c. ―Have 
scheduled an appointment with my doctor to receive the HPV vaccine‖, d. ―Have not 
received the HPV vaccine or scheduled an appointment to receive the HPV vaccine‖. 
Choices a and b were coded as Group 1: Vaccinated. Choices c and d were coded as 
Group 2: Not Vaccinated. A similar item was previously used in a sample of university 
women (Costar, 2008). In addition, vaccinated participants were asked to respond to the 
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open statement ―Please indicate the approximate date of your last HPV vaccine shot‖ in 
order to assess the length of time since vaccination. Participants who indicated that they 
had not yet completed the vaccine series were asked if they planned to finish. 
HPV Vaccination Intentions. Intentions to get vaccinated against HPV were 
assessed using four items, taken from Costar’s (2008) dissertation (see Appendix J). The 
first item included the statement, ―I want to get vaccinated against the human 
papillomavirus (HPV) within the next year,‖ followed by ―I expect that I will get 
vaccinated against the human papillomavirus (HPV) within the next year,‖ ―I do not 
intend to get vaccinated against the human papillomavirus (HPV) within the next year,‖ 
and ―I plan to make an appointment for the HPV vaccine within the next year.‖ 
Responses were rated on a 7-point scale where 1 means ―Strongly Disagree‖ and 7 means 
―Strongly Agree‖. Items were summed together (the third item was reverse coded) for a 
total score ranging from 4 to 28. Low scores indicated lower intentions to be vaccinated 
while high scores indicated higher intentions to be vaccinated. Costar (2008) used this 
scale in a sample of university women and found a coefficient alpha of .94. In the present 
study, the Cronbach alpha for this scale was .88. 
Procedures 
College-age women in psychology or education classes and/or sororities at five 
different universities/colleges completed the measures through Psychdata, an online 
survey system. The website to the study survey was distributed to the participants along 
with a description of the study (see Appendix N). The study was advertised in 
conjunction with another study recruiting both men and women to explore HPV vaccine 
health messages. Therefore, the advertisement described studies exploring men and 
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women’s attitudes about sexual health. The men who participated were assigned to the 
other study along with half of the women who were not yet vaccinated. When 
participants went to the survey website, they viewed the informed consent which 
encouraged participants to complete the survey in one sitting in a private area with as few 
distractions as possible (see Appendix K). By clicking ―continue‖ after the informed 
consent, participants gave their consent to participate in the study. At the end of the 
survey, participants were asked to leave an identifying number or their email address 
which was used to give them either class credit or enter them into the raffle for the gift 
certificate (see Appendix L). The participants’ email addresses were not connected to 
their survey responses in any way and participants were assured that their information 
was kept confidential throughout the survey. 
 This study drew from previous research to create scales that measure perceived 
benefits, perceived barriers, perceived severity and perceived susceptibility, subjective 
norms, cues to action and self-efficacy. The psychometric properties of these scales were 
determined throughout the course of the study. Reliability (internal consistency) of the 
scales were calculated based on the scores of the participants in the study. Moreover, two 
experts in the field of HPV vaccination research assessed content validity by reviewing 
items from the HBM scale (Appendix C) and categorizing them according to the model 
constructs.  
Participants completed the HPV Knowledge measure first so that participants’ 
level of knowledge was unaffected by the rest of the survey. The outcome measure of 
HPV Vaccination was included next since the administration of subsequent measures 
depended on the vaccination status. The participants who indicated that they had not 
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received the HPV vaccine completed the outcome measure of HPV Vaccination 
Intentions (see Appendix F) as well as questions about Decision-Making pertaining to 
unvaccinated women. Participants who indicated that they had received the HPV vaccine 
were asked for the date of their last shot as well as questions about Decision-Making 
pertaining to vaccinated women. The individual items measuring Perceived Benefits, 
Perceived Barriers, Perceived Susceptibility and Perceived Severity were randomly 
ordered and combined into one HBM scale to avoid redundancy (see Appendix C). Self-
efficacy questions were included following each Perceived Barriers item. The HBM scale 
and predictor measures for Cues to Action, Subjective Norms and Sexual Risk Factors 
were then presented. Participants completed the demographics questionnaire at the end of 
the survey and had the opportunity to find out more information about HPV by clicking 
















The results chapter includes preliminary analyses, sample description of 
demographics and sexual risk factors, preliminary correlations, exploratory factor 
analysis for the HBM variables and analysis of the nine hypotheses and five research 
questions.    
Preliminary Analyses 
The analyses were completed using the statistical package software SPSS Version 
17. The analyzed variables were screened for missing values, and one missing value was 
found in the Knowledge Scale, five missing values were found in the Susceptibility 
Scale, three missing values were found in the Severity Scale, eight missing values were 
found in the Benefits Scale, nine missing values were found in the Barriers Scale, eight 
missing values were found for the Self-Efficacy Scale, 11 missing values were found for 
the Cues to Action Scale, five missing values were found for the Subjective Norms Scale, 
and one missing value was found for the Vaccine Intentions Scale, totaling 51 missing 
values. These missing values were replaced using the participant’s mean score for that 
particular scale. Data from the 14 participants who did not complete two or more of the 
scales was discarded leaving a total sample of 208. The normality of each variable was 
checked and the scales were assessed for internal consistency. Subjective norms, self-
efficacy, benefits and barriers displayed some skewness and/or kurtosis as indicated by 
values greater than 1. However, these variables were not transformed since the 
assumptions of linear regression analyses were met, including normality, linearity, 
independence and homoscedasticity. All other variables were close to normally 
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distributed. The open-ended questions were scored by 3 coders, who reached an 
acceptable reliability level ranging from a cohen’s kappa of .76 to .94. The coders 
reached consensus on the additional responses through discussion. 
Sample Description of Demographics and Sexual Risk Factors 
Descriptive data about the demographic and sexual risk factors of participants are 
presented in Tables 1 and 2. On some of the sexual risk questions the option of ―prefer 
not to respond‖ was offered to participants as required by the IRB. The approximate 
percentage that did not respond to various items was low and can be seen in Tables 1 and 
2. The mean age of the sample was 21.04 (SD=1.46) and all participants were 26 or under 
since this is the cutoff age at which women can receive the HPV vaccine. Since all of the 
participants were in the age range of 18-26 they were considered college-age and the 
majority of participants were undergraduates, however a small number were graduate 
students (3.9%) or college graduates (6.7%). The sample was primarily White (69.2%), 
college students (89%), approximately half of whom were in a committed relationship 
(43.8%) and half of whom were single (53.4%).  Fewer unvaccinated women reported 
that they had health insurance (89.7%) as compared to vaccinated women (97.3%). 
Moreover, only 60.3% of unvaccinated women had health insurance that covered the 
HPV vaccine, as compared to 83.3% of vaccinated women. In terms of gynecological 
appointments, vaccinated participants reported an average of 2.0 visits (SD=1.44) over 
the past two years, whereas unvaccinated participants reported an average of 1.3 visits 
(SD=1.41). In addition, more unvaccinated women (36.2%) reported that they had not 
attended a gynecological appointment in the past two years than vaccinated women 
(12.0%). Vaccinated women had significantly more (t204= -3.27, p<0.001) gynecologists 
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visits as compared to unvaccinated women. The number of visits ranged from 0-10 for 
the entire sample.  
Most of the women had heard of HPV (97.6%) and Gardasil (97.6%) before 
taking the survey. Participants reported multiple ways of hearing about HPV, the most 
common for vaccinated women were through a health care provider (53.3%), television 
or radio (41.3%) and/or a family member (38.0%), whereas the most common for 
unvaccinated women were through a health care provider (36.2%), television or radio 
(50.0%) and/or a friend (29.3%).  The most common ways that vaccinated participants 
had heard of Gardasil were through the television or radio (30.0%), a health care provider 
(25.3%) or through a family member (28.0%). The most common ways that unvaccinated 
participants had heard of Gardasil were through television or radio (46.6%) and a health 
care provider (19.0%). For vaccinated women, the mean reported satisfaction with the 
decision to receive the vaccine was 6.18 (SD=1.44) with scores ranging from 1-7, where 
1=low satisfaction and 7=high satisfaction. For unvaccinated women, the mean reported 
satisfaction with the decision to not yet receive the vaccine was 4.74 (SD=1.84) with 
scores ranging from 1-7. Therefore, vaccinated women were significantly (t83.59= -5.34, 
p<0.001) more satisfied with their decision than unvaccinated women. Twenty-two of the 
vaccinated women had started but not completed all three shots. Among these women, 
four indicated that they do not plan to complete the vaccine series, 17 indicated that they 
do and one participant did not respond. Of the women who received the vaccine, the 
average time since the participant’s last vaccination was 16.9 months (SD = 11.0) with 
length of time ranging from 1 to 44 months. More details on demographic factors can be 
seen in Table 1. 
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Most of the women reported being currently sexually active (72.6%) and among 
these women, 93.7% reported having penis/vagina intercourse in the past. Vaccinated and 
unvaccinated women had the same mean age of first intercourse (17.3) and similar age 
ranges (13-22 for vaccinated women, 14-22 for unvaccinated women). However, the 
number of sexual partners differed by vaccination status, where vaccinated women had a 
mean of 5.16 partners (SD=4.58) and a range from 1-22, whereas unvaccinated women 
had a mean of 3.72 partners (SD=3.25) and a range from 1-13. Vaccinated women had 
significantly more sexual partners than unvaccinated women (t70=-2.01, p<.05). While 
slightly more than half of the participants (59.5%) reported always using a condom with a 
new partner, far fewer (19.4%) reported always using a condom with a partner when in a 
committed relationship. A greater percentage of unvaccinated women reported always 
using a condom with a new partner and when in a committed relationship (respectively, 
78.1% and 25.0%) as compared to vaccinated women (respectively, 54.3% and 17.9%).  
Among the women who were sexually active, relatively few (18.9%) reported 
ever engaging in penis/anus intercourse. Only three (5.2%) unvaccinated women reported 
engaging in anal intercourse. For women out of the total sample who had anal 
intercourse, the age of first anal intercourse ranged from 15-21 with a mean age of 18.6 
(SD=1.71). The number of penile/anal sexual partners ranged from 1-5 with a mean of 
1.62 (SD=1.08). Information on the sexual risk factors for participants is displayed in 
Table 2.  
The means, standard deviation, and internal consistency values for the HBM 
measures for both vaccinated and unvaccinated women is presented in Table 3. The same 
information for the rest of the measures can be found in Table 4.  
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Table 1. Demographic characteristics of participants (N=208) 
 
 
 VACCINATED UNVACCINATED TOTAL SAMPLE 
Race/Ethnicity N Percentage N Percentage N Percentage 
African American/Black 7 4.7% 11 19% 18 8.7% 
Asian American/Pacific 
Islander/ 
13 8.7% 6 10.3% 19 9.1% 
Asian Indian/Pakistani 3 2.0% 4 6.9% 7 3.4% 
Middle-Easter/Arab 1 0.7% 1 1.7% 2 1.0% 
Biracial 5 3.3% 2 3.4% 7 3.4% 
Hispanic/Latino(a) 7 4.7% 2 3.4% 9 4.3% 
Native American/Native 
Alaskan 
1 0.7% 1 1.7% 2 1.0% 
White 113 75.3% 31 53.4% 144 69.2% 
 
 VACCINATED UNVACCINATED TOTAL SAMPLE 
Student Status N Percentage N Percentage N Percentage 
First Year 5 3.3% 1 1.7% 6 2.9% 
Second Year 26 17.3% 7 12.1% 33 15.9% 
Third Year 33 22.0% 11 19.0% 44 21.2% 
Fourth Year 67 44.7% 32 55.2% 99 47.6% 
Fifth Year 1 0.7% 2 3.4% 3 1.4% 
College Graduate 10 6.7% 4 6.9% 14 6.7% 
Graduate Student 7 4,7% 1 1.7% 8 3.9% 







Table 1 continued. Demographic characteristics of participants (N=208) 
 
 VACCINATED UNVACCINATED TOTAL SAMPLE 
Relationship Status N Percentage N Percentage N Percentage 
Married 4 2.7% 2 3.4% 6 2.9% 
Committed Relationship 62 41.3% 29 50% 91 43.8% 
Single 84 56.0% 27 46.6% 111 53.4% 
 
 
 VACCINATED UNVACCINATED TOTAL SAMPLE 
Health Insurance N Percentage N Percentage N Percentage 
Yes 146 97.3% 52 89.7% 198 95.2% 
No 4 2.7% 6 10.3% 10 4.8% 
 
 
 VACCINATED UNVACCINATED TOTAL SAMPLE 
Insurance for Vaccine N Percentage N Percentage N Percentage 
Yes 125 83.3% 35 60.3% 160 76.9% 
No 17 11.3% 12 20.7% 29 13.9% 
No Answer 8 5.3% 11 19.0% 19 9.1% 
 
 
 VACCINATED UNVACCINATED TOTAL SAMPLE 
Heard of HPV N Percentage N Percentage N Percentage 
Yes 147 98.0% 56 96.6% 203 97.6% 









Table 1 continued. Demographic characteristics of participants (N=208) 
 VACCINATED UNVACCINATED TOTAL SAMPLE 
Where Heard of HPV N Percentage N Percentage N Percentage 
Health care provider 80 53.3% 21 36.2% 101 48.6% 
Friend 21 14.0% 17 29.3% 38 18.3% 
Family member 57 38.0% 6 10.3% 63 30.3% 
Television or radio 62 41.3% 29 50.0% 91 43.8% 
Internet 12 8.0% 5 8.6% 17 8.2% 
Newspaper or magazine 18 12.0% 9 15.5% 27 13.0% 
At school 26 17.3% 12 20.7% 38 18.3% 
I don’t remember 13 8.7% 6 10.3% 19 9.1% 
Other 0 0.0% 1 1.7% 1 0.5% 
No Answer 3 2.0% 2 3.4% 5 2.4% 
 
 VACCINATED UNVACCINATED TOTAL SAMPLE 
Heard of Vaccine N Percentage N Percentage N Percentage 
Yes 150 100% 53 91.4% 203 97.6% 
No 0 0% 4 6.9% 4 1.9% 
I don’t know 0 0% 1 1.7% 1 0.5% 
 
 VACCINATED UNVACCINATED TOTAL SAMPLE 
Where Heard of Vaccine N Percentage N Percentage N Percentage 
Health care provider 38 25.3% 11 19.0% 49 23.6% 
Friend 8 5.3% 4 6.9% 12 5.8% 
Family member 42 28.0% 5 8.6% 47 22.6% 
Television or radio 45 30.0% 27 46.6% 72 34.6% 
Internet 0 0.0% 0 0.0% 0 0.0% 
Newspaper or magazine 4 2.7% 1 1.7% 5 2.4% 
At school 5 3.3% 1 1.7% 6 2.9% 
I don’t remember 6 4.0% 4 6.9% 10 4.8% 
Other 1 0.7% 0 0.0% 1 0.5% 
No Answer 1 0.7% 5 8.6% 6 2.9% 
82 
 
Table 2. Sexual risk factors (N=208) 
 
 VACCINATED UNVACCINATED TOTAL SAMPLE 
Sexually Active N Percentage N Percentage N Percentage 
Yes 120 80.0% 31 53.4% 151 72.6% 
No 26 17.3% 23 39.7% 49 23.6% 
Prefer not to respond 4 2.7% 4 6.9% 8 3.8% 
 
 VACCINATED UNVACCINATED TOTAL SAMPLE 
Penis-Vagina Intercourse N Percentage N Percentage N Percentage 
Yes 117 94.4% 32 91.4% 149 93.7% 
No 2 1.6% 1 2.9% 3 1.9% 
Prefer not to respond 5 4.0% 2 5.7% 7 4.4% 
 
 
 VACCINATED UNVACCINATED TOTAL SAMPLE 
Penis-Anal Intercourse N Percentage N Percentage N Percentage 
Yes 27 21.8% 3 8.6% 30 18.9% 
No 93 75.0% 31 88.6% 124 78.0% 
Prefer not to respond 4 3.2% 1 2.9% 5 3.1% 
 
 
 VACCINATED UNVACCINATED TOTAL SAMPLE 
Condom Use with New 
Partner for Penis-Vagina 



















Always 63 54.3% 25 78.1% 88 59.5% 
Usually 36 31.0% 4 12.5% 40 27.0% 
Sometimes 12 10.3% 1 3.1% 13 8.8% 





Table 2 continued. Sexual risk factors (N=208)  
 
 VACCINATED UNVACCINATED TOTAL SAMPLE 





















Always 20 17.9% 8 25.0% 28 19.4% 
Usually 30 26.8% 9 28.1% 39 27.1% 
Sometimes 27 24.1% 9 28.1% 36 25.0% 
Never 35 31.3% 6 18.8% 41 28.5% 
 
 VACCINATED UNVACCINATED TOTAL SAMPLE 
Condom Use with New 




















Always 14 51.9% 3 100% 17 56.7% 
Usually 2 7.4% 0 0% 2 6.7% 
Sometimes 4 14.8% 0 0% 4 13.3% 
Never 7 25.9% 0 0% 7 23.3% 
 
 
 VACCINATED UNVACCINATED TOTAL SAMPLE 





















Always 8 29.6% 2 66.7% 10 33.3% 
Usually 1 3.7% 0 0% 1 3.3% 
Sometimes 3 11.1% 0 0% 3 10.0% 





Table 2 continued. Sexual risk factors  (N=208) 
 
 VACCINATED UNVACCINATED TOTAL SAMPLE 
Birth Control N Percentage N Percentage N Percentage 
Condoms Only 23 15.3% 11 19.0% 34 16.3% 
Multiple Methods 
(Condoms & pills, etc.) 
35 23.3% 7 12.1% 42 20.2% 
Birth Control Pill Only 67 44.7% 13 22.4% 80 38.5% 
Depo Provera/Nuva Ring 9 6.0% 2 3.4% 11 5.3% 
Abstinence 3 2.0% 7 12.1% 10 4.8% 
Pull-Out Method 1 0.7% 0 0% 1 0.5% 
None 3 2.0% 6 10.3% 9 4.3% 
Prefer not to respond 1 0.7% 0 0% 1 0.5% 
N/A 3 2.0% 7 12.1% 10 4.8% 
No Answer 5 3.3% 5 8.6% 10 4.8% 
 
 
 VACCINATED UNVACCINATED TOTAL SAMPLE 
Unintended Pregnancy N Percentage N Percentage N Percentage 
Yes 6 4% 4 6.9% 10 4.8% 
No 144 96% 54 93.1% 198 95.2% 
 
 
 VACCINATED UNVACCINATED TOTAL SAMPLE 
Diagnosed with HPV N Percentage N Percentage N Percentage 
Yes 16 10.7% 3 5.2% 19 9.1% 
No 132 88.0% 54 93.1% 186 89.4% 







Table 2 continued. Sexual risk factors  (N=208) 
 
 VACCINATED UNVACCINATED TOTAL SAMPLE 
Abnormal Pap Smear N Percentage N Percentage N Percentage 
Yes 31 20.7% 11 19.0% 42 20.2% 
No 118 78.7% 47 81.0% 165 79.3% 
No Answer 1 0.7% 0 0% 1 0.5% 
 
 
 VACCINATED UNVACCINATED TOTAL SAMPLE 














Yes 12 8.0% 3 5.2% 15 7.2% 
No 137 91.3% 54 93.1% 191 91.8% 
No Answer 1 0.7% 1 1.7% 2 1.0% 
 
 
 VACCINATED UNVACCINATED TOTAL SAMPLE 
Tested for STDs N Percentage N Percentage N Percentage 
Yes 96 64.0% 27 46.6% 123 59.1% 
No 51 34.0% 31 53.4% 82 39.4% 
No Answer 3 2.0% 0 0% 3 1.4% 
 
 
 VACCINATED UNVACCINATED TOTAL SAMPLE 
STD Diagnosis N Percentage N Percentage N Percentage 
Yes 15 10% 3 5.2% 18 8.7% 
No 134 89.3% 55 94.8% 189 90.9% 
Prefer not to respond 1 7% 0 0% 1 0.5% 
86 
 





Scoring Mean SD Alpha 
Perceived 
Susceptibility 
0 -100% 0 -100% 10% increment scale (higher= higher 
susceptibility)  
46.52 20.87 0.92 




33.57 6.08 0.73 




35.92 5.39 0.81 
Perceived Barriers 3-21 3-15 Likert range 1-7 (higher= higher 
barriers) 
4.54 2.32 0.54 
Self-Efficacy 
 
8-56 24-56 Likert range 1-7 (higher= higher self-
efficacy) 

















15.1-40.4 Likert range 1-4 (higher=more cues to 
action) 
27.51 4.16 0.66 















Scoring Mean SD Alpha 
Perceived 
Susceptibility  
0 -100% 0 -76.7% 10% increment scale (higher= higher 
susceptibility) 
34.60 20.45 0.92 
Perceived Severity 6-42 16-42 Likert range 1-7 (higher= higher 
severity) 
32.42 6.34 0.73 




30.43 6.43 0.83 
Perceived Barriers 3-21 3-20 Likert range 1-7 (higher=higher 
barriers) 
7.03 4.11 0.72 
Self-Efficacy 
 
8-56 17-56 Likert range 1-7 (higher= higher self-
efficacy) 





























HPV Knowledge 0-9 
 
4-9 T/F and Multiple Choice 6.96 1.26 0.29 
Vaccine Intentions 4-28 4-28 Likert range 1-7 (higher=higher 
intentions to receive the vaccine) 
 





A correlation matrix of Pearson’s r correlation coefficients was created to capture 
information about the relationships among all dichotomous and interval variables, 
including the demographic variables such as age, whether participants were sexually 
active, and how often participants had seen a gynecologist in the past two years. Due to 
the large number of correlations run, a more strict alpha value (p <.01) was used to 
control for family-wise error. This information can be found in Figures 1, 2 and 3. 
Demographic and predictor variables that correlated with the four HBM variables as well 
as self-efficacy at medium to large effect (r ≥ .30) were controlled for in subsequent 
analyses (highlighted in Figures 1, 2 and 3). For vaccinated women, correlations between 
subjective norms and benefits (r =0.33, medium effect) and between subjective norms 
and self-efficacy (r= 0.31, medium effect) were significant at the p<.01 level, such that 
higher perceived benefits and higher self-efficacy were related to higher levels of 
subjective norms for vaccinated women. The correlation between subjective norms and 
benefits (r =.39, medium effect) also was significant for unvaccinated women. In 
addition, subjective norms and vaccination intentions (r= 0.36, medium effect) were 
correlated significantly as were barriers with HPV knowledge and sexual activity (r=-
.036 for both, medium effects). Cues and self-efficacy (r=0.40, medium effect) were also 
significantly correlated for unvaccinated women. When the correlations were run on the 
total sample, benefits and subjective norms (r=0.47, medium effect) as well as self-
efficacy and cues (r=0.46, medium effect) continued to have significant correlations. 
Moreover, subjective norms and cues had significant correlations with vaccination status 
(respectively r=.49 and r=.43, medium effects) and with barriers (respectively r =-.36 and 
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r =-.34, medium effects). Finally, self-efficacy correlated significantly with subjective 
norms (r=.49, medium effect) and HPV knowledge (r =.31, medium effect). 
Sexual activity, HPV knowledge, cues and subjective norms were controlled for 
in regression analyses conducted only on unvaccinated women to account for the effects 
of these variables. HPV knowledge, cues and subjective norms were controlled for in 
regression analyses that compared vaccinated and unvaccinated women. To assess the 
relationship between the multi-level nominal demographic variables of ethnicity, 
relationship status and student status (first year, second year, third year, fourth year, fifth 
year, college graduate, graduate student) with the HBM and self-efficacy predictors and 
outcome variables, one-way ANOVAs were run using an alpha of 0.01, finding no 
significant differences. Further analyses were computed to assess each of the research 
hypotheses and research questions.
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Key to Abbreviations in Figure 1: Susc (Perceived Susceptibility); Sev (Perceived Severity); Ben (Perceived Benefits); Barrier (Perceived Barriers); SE 
(Self-Efficacy to receive the vaccine); Norm (Subjective Norms); Cues (Cues to Action); Know (HPV Knowledge); Age (Current Age); Sex (Currently 
Sexually Active, 1 is yes, 0 is no); Gyn (Number of Gynecologist Visits Over the Past Two Yearst). Correlations significant at p<.01 are marked with an 
―**‖ and correlations significant at p<.05 are marked with an ―*.‖  
   Susc Sev    Ben   Barrier 
 
SE    Norm   Cues   Know  Age 
 
Sex   Gyn 
Susc 1.00    
 
    
 
 




    
 
 




    
 
 




    
 
 
SE .12 .08 .52** -.31** 
 
1.00     
 
 
Norm .04 .15 .33** -.15 
 
.31**    1.00    
 
 




.21* .06 1.00   
 
 




.21** -.09 .17* 1.00  
 
 








Sex .01 -.03 .02 -.03 
 
-.01 .03 .05 .04 .11 
 
1.00  









Figure 2. Correlations for Non-Vaccinated Women 
 
Key to Abbreviations in Figure 2: Intent (Vaccination Intentions); Susc (Perceived Susceptibility); Sev (Perceived Severity); Ben (Perceived Benefits); 
Barrier (Perceived Barriers); SE (Self-Efficacy to receive the vaccine); Norm (Subjective Norms); Cues (Cues to Action); Know (HPV Knowledge); 
Age (Current Age); Sex (Currently Sexually Active, 1 is yes, 0 is no); Gyn (Number of Gynecologist Visits Over the Past Two Yearst). Correlations 
significant at p<.01 are marked with an ―**‖ and correlations significant at p<.05 are marked with an ―*.‖  
 
     Intent   Susc Sev    Ben   Barrier 
 
SE    Norm   Cues   Know  Age 
 
Sex   Gyn 
Intent 1.00     
 
    
 
 
Susc .05 1.00 
 
   
 
    
 
 
Sev .22 .14 
 
1.00   
 
    
 
 
Ben .46** .24 
 
.29* 1.00  
 
    
 
 




    
 
 
SE .12 .23 .32* .23 -.56** 
 
1.00     
 
 
Norm .36** .13 .21 .39** -.33* 
 
.28* 1.00    
 
 
Cues -.12 .23 .04 -.01 -.33* 
 
.40** .02 1.00   
 
 
Know .07 .12 .29* .31* -.36** 
 
.24 .25 .26* 1.00  
 
 
Age .15 -.14 -.08 .28* -.04 
 




Sex .09 .19 -.03 .01 -.36** 
 
.19 .18 .16 .16 .12 
 
1.00  
Gyn .07 .09 .01 .17 -.30* 
 





Figure 3. Correlations for Total Sample 
 
Key to Abbreviations in Figure 3: Status (Vaccination Status, 1 is vaccinated, 0 is non-vaccinated); Susc (Perceived Susceptibility); Sev (Perceived 
Severity); Ben (Perceived Benefits); Barrier (Perceived Barriers); SE (Self-Efficacy to receive the vaccine); Norm (Subjective Norms); Cues (Cues to 
Action); Know (HPV Knowledge); Age (Current Age); Sex (Currently Sexually Active, 1 is yes, 0 is no); Gyn (Number of Gynecologist Visits Over the 
Past Two Yearst). Correlations significant at p<.01 are marked with an ―**‖ and correlations significant at p<.05 are marked with an ―*.‖  
     Status   Susc Sev    Ben   Barrier 
 
SE    Norm   Cues   Know  Age 
 
Sex   Gyn 
Status 1.00     
 





.25** 1.00    
 
    
 
 
Sev    .08 .09 1.00   
 





.40** .26** .32** 1.00  
 





-.36** -.09 .03 -.21** 1.00 
 
    
 
 
SE .60** .27** .19** .52** -.55** 
 
1.00     
 
 
Norm .49** .18* .19** .47** -.36** 
 
.49** 1.00    
 
 
Cues .43** .22** -.01 .25** -.34** 
 
.46** .25** 1.00   
 
 
Know .22** .01 .04 .16* -.27** 
 
.31** .13 .26** 1.00  
 
 
Age -.09 -.05 -.14* .11 -.002 
 




Sex .26** .13 -.01 .11 -.25** 
 
.21** .20** .17* .12 .09 
 
1.00  
Gyn .22** .16* -.03 .12 -.17* 
 






Exploratory Factor Analysis for the HBM Variables 
Before the hypotheses could be tested, the HBM variables needed to be derived. 
An exploratory factor analysis (EFA) with a factor-extraction method of principle-axis 
factoring and oblimin rotation was conducted on each of the HBM variables (perceived 
susceptibility, severity, benefits and barriers). EFA was used to develop psychometrically 
sound subscales since the present study did not test pre-existing subscales representing 
each HBM variable. The items for the scale were developed based on previous HPV 
measures, HBM theory, and review by two experts in the field of HPV vaccination 
research and who were familiar with the HBM. Valid and reliable HBM subscales are 
lacking within the literature, especially for HPV vaccination. Moreover, most studies that 
use the HBM as a framework fail to include all four model variables. Since the sample in 
the current study included both vaccinated and unvaccinated women, it was important to 
retain items that had adequate psychometric qualities for the entire sample as well as each 
of these two subsamples. Therefore, EFAs for each subscale were conducted on the 
whole sample as well as on the vaccinated and unvaccinated subgroups. In order to retain 
as many items as possible, a structure coefficient of .30 was used as minimum criteria 
(Kahn, 2006). This means that items were retained if they had a structure coefficient of at 
least .30 for the entire sample as well as the two subsamples. In addition, it was 
determined that items would be dropped if they had a loading of .30 or above on more 
than one factor or if there was a difference of less than .20 between the primary and the 
cross-loading factor (Fabringar, Wegener, MacCallum, & Strahan, 1999). 
EFAs with one and two factors, where each factor represents a similar dimension 




to retain. Empirical decisions of how many factors to retain were based on multiple 
criteria (Fabrigar et al., 1999; Tinsley & Tinsley, 1987). For instance, Kahn’s (2006) 
guidelines were followed which state that the number of factors to retain should be based 
on the percentage of variance among variables explained by each factor. Factors that 
explained a large percentage of variance to be deemed important were retained, and those 
that explained only a small percentage of variance were discarded (Kahn, 2006). In 
addition, this study followed Cattell’s (1966) suggestion of looking at the scree plot to 
find the point where the eigenvalues flatten out. Factors were retained if they were above 
the last substantial drop in eigenvalues. According to the literature, there should be at 
least three to five items for each factor since EFAs produce more accurate results when 
factors are overdetermined (MacCallum, Widaman, Zhang & Hong, 1999). Therefore, 
additional factors were dropped if they had less than three items. 
Given the criteria for factor retention, a one factor solution was deemed the most 
appropriate for the susceptibility subscale since it contained six items and none of the 
items loaded onto a second factor. The subscale of severity contained six items and only 
two items loaded onto the second factor. Therefore a one factor solution was retained for 
the severity subscale. While the benefits subscale contained nine items, only one item 
loaded onto a second factor for the whole sample as well as for the vaccinated and 
unvaccinated subgroups. Thus, a one factor solution was retained for the benefits 
subscale. In addition, a one factor solution was deemed the most appropriate for the 
barriers subscale since it contained eight items and only two items loaded onto a second 
factor. All of the subscales, except for barriers, met the additional criterion for retaining 




remained the only factor above the last substantial drop in eigenvalues (Appendices O-
Q). The barriers subscale explained 27.6% of the variance and appeared to have two or 
three factors above the last drop in eigenvalues (Appendix R). However, there were not 
enough items to justify including more than one factor since at least three items needed to 
be associated with each factor. This will be discussed further in the discussion chapter. 
All six items for the susceptibility and severity subscales were retained since they 
met the structure coefficient criteria of .30 or above for the entire sample as well as the 
two subsamples (Tables 5 and 6). Six out of the nine items for the benefits subscale were 
retained as well. Initially, only two of the benefits items had a structure coefficient below 
.30. However, removing these items caused a third item to have a structure coefficient 
below .30 for vaccinated participants. Therefore, all three items were removed and a total 
of six items were retained. Tables 7, 8 and 9 show this progression. Three out of the eight 
items on the barriers subscale were retained (Tables 10 and 11), all of which referred to 
the stigma of receiving the HPV vaccine (ie. embarrassment) as opposed to logistical 
concerns (ie. expense, time constraints). This may indicate that stigma is emerging as the 























What are your chances of contracting genital warts if you 
didn't get Gardasil compared to other college-aged 
women? 
.910 .891 .910 
What are your chances of developing cervical cancer if 
you didn't get Gardasil compared to other college-aged 
women? 
.867 .866 .875 
What are your chances of contracting HPV if you didn't 
get Gardasil compared to other college-aged women? 
.855 .851 .862 
What are your chances of contracting genital warts if you 
didn't get Gardasil? 
.875 .786 .858 
What are your chances of developing cervical cancer if 
you didn't get Gardasil? 
.720 .717 .722 
What are your chances of contracting HPV if you didn't 
get Gardasil? 
































If I contracted HPV, it could hinder my future 
relationships. 
.902 .813 .884 
If I contracted HPV, it could hinder my present 
relationship. 
.650 .605 .646 
If I found out I had contracted HPV, I would be 
devastated. 
.606 .520 .569 
I would be embarrassed to let others know that I have 
HPV if I found out that I contracted the disease. 
.462 .625 .504 
If I contracted HPV, it could harm my future health. .384 .481 .396 


































Getting Gardasil is important for my health. 
One of the benefits to getting Gardasil is peace of mind 
about my health. 
One of the benefits to getting Gardasil, is feeling that I've 
done everything I can do to protect myself against HPV. 
Gardasil is effective in preventing cervical cancer. 
Gardasil is effective in preventing an HPV infection. 
How likely is it that the benefits of Gardasil outweigh the 
potential side effects? 
.789 




















Gardasil is effective in preventing genital warts. .333 .432 .381 
Gardasil is effective in preventing the spread of HPV to 
partners.* 









































Getting Gardasil is important for my health. 
One of the benefits to getting Gardasil is peace of mind 
about my health. 
One of the benefits to getting Gardasil, is feeling that I've 
done everything I can do to protect myself against HPV. 
Gardasil is effective in preventing cervical cancer. 
How likely is it that the benefits of Gardasil outweigh the 
potential side effects? Gardasil is effective in preventing 
an HPV infection.  




























*Items removed from final analysis 
 












One of the benefits to getting Gardasil is peace of mind 
about my health. 
Getting Gardasil is important for my health. 
One of the benefits to getting Gardasil, is feeling that I've 
done everything I can do to protect myself against HPV. 
Gardasil is effective in preventing cervical cancer. 
How likely is it that the benefits of Gardasil outweigh the 






































If other people knew I received Gardasil, I would be 
embarrassed. 
I would worry about what my partner or future partners 
would think if I got Gardasil. 
It would be difficult for me to ask for Gardasil because it's 










Getting Gardasil would go against my beliefs.* 
In your opinion, how likely is it that Gardasil causes 
significant side effects?* 
Getting Gardasil is painful.* 













Having to get multiple doses of Gardasil is time 
consuming.* 
-.013 -.212 .088 
    



























If other people knew I received Gardasil, I would be 
embarrassed. 
I would worry about what my partner or future partners 
would think if I got Gardasil. 
It would be difficult for me to ask for Gardasil because it's 










    
 
 
The main focus was on the HBM subscales since they were theorized to represent 
distinct constructs. However, an EFA was conducted on the items in their entirety to 
explore whether they loaded onto the expected subscales (Table 12). Each item was 
examined for sufficient loading on the hypothesized factor and for cross-loadings onto 
more than one factor. If an item had a loading of .30 or above on more than one factor or 
if there was a difference less than .20 between the primary and the cross-loading factor, 
then the item was not retained  (Fabringar, Wegener, MacCallum, & Strahan, 1999). All 
six items from the susceptibility subscale loaded cleanly onto Factor 2 and all six items 
from the severity subscale loaded cleanly onto Factor 3. Seven of the nine items from the 
benefits subscale loaded solely onto Factor 1, whereas one item double-loaded onto 
Factor 4 which represents barriers and one item loaded below .30. In addition, two items 
from the barriers subscale (―In your opinion, how likely is it that Gardasil causes 




represents benefits. It could be that participants did not view these aspects of getting the 
vaccine as large barriers, especially if they gave them low ratings. Finally, three of the 
eight items from the barriers subscale loaded solely onto Factor 4. Two items loaded 
below .30 and one item double-loaded onto another factor. Overall, 76% of the items on 
the HBM scale loaded significantly and solely onto the hypothesized subscales. These 
were also the same items retained after EFAs were performed on each subscale. 
Therefore, the final subscale items did not load significantly onto any other subscale. 
Most of the other 24% of the items loaded onto the hypothesized factors, but did not meet 
psychometric guidelines in that they did not load high enough or double loaded onto 
another factor. Only two items loaded onto a different construct than hypothesized which 
is likely the result of the wording of the items. The final items used in the HBM measure 















Table 12. Structure coefficients for the HBM 
 Factor (N=208) 
 1 2 3 4 
What are your chances of contracting HPV if you didn't get Gardasil? .099 -.655 -.099 -.086 
How likely is it that the benefits of Gardasil outweigh the potential side 
effects? 
.572 -.083 .028 -.059 
I would be embarrassed to let others know that I have HPV if I found 
out that I contracted the disease. 
.212 .003 .433 .187 
Getting HPV could hinder my ability to become pregnant. -.064 .004 .438 -.016 
Gardasil is effective in preventing an HPV infection. .609 .000 .109 -.015 
What are your chances of developing cervical cancer if you didn't get 
Gardasil? 
-.038 -.738 .090 .094 
It would be difficult for me to ask for Gardasil because it's associated 
with an STD. 
-.089 -.016 .050 .551 
Gardasil is effective in preventing genital warts. .415 .010 -.011 .064 
In your opinion, how expensive is Gardasil? -.092 -.017 .102 .079 
If I contracted HPV, it could hinder my present relationship. .067 -.014 .616 -.029 
One of the benefits to getting Gardasil, is feeling that I've done 
everything I can do to protect myself against HPV. 
.493 -.159 .145 -.100 
Having to get multiple doses of Gardasil is time consuming. -.089 .175 .112 .001 
Gardasil is effective in preventing cervical cancer. .618 -.023 .116 -.077 
What are your chances of contracting genital warts if you didn't get 
Gardasil? 
-.041 -.870 -.022 .051 
Getting Gardasil is painful. -.381 -.064 .134 -.024 
Gardasil is effective in preventing some types of oral cancer. .315 .094 .044 .214 
If I contracted HPV, it could hinder my future relationships. .134 -.071 .812 .012 
In your opinion, how likely is it that Gardasil causes significant side 
effects? 
-.488 -.022 .054 .107 
What are your chances of contracting genital warts if you didn't get 
Gardasil compared to other college-aged women? 
-.076 -.915 .051 .027 
Gardasil is effective in preventing the spread of HPV to partners. .272 -.028 .031 .102 
I would worry about what my partner or future partners would think if I 
got Gardasil. 
.013 -.039 .002 .621 






Table 12 continued. Structure coefficients for the HBM: benefits, barriers, susceptibility 
and severity 
 
 Factor (N=208) 
 1 2 3 4 
What are your chances of contracting HPV if you didn't get Gardasil 
compared to other college-aged women? 
-.004 -.853 -.015 -.038 
If other people knew I received Gardasil, I would be embarrassed. .023 .039 -.162 .826 
If I contracted HPV, it could harm my future health. .006 .049 .435 -.102 
One of the benefits to getting Gardasil is peace of mind about my 
health. 
.676 -.092 .177 -.116 
What are your chances of developing cervical cancer if you didn't get 
Gardasil compared to other college-aged women? 
-.033 -.879 .087 .008 
Getting Gardasil would go against my beliefs. -.412 .042 -.045 .309 
If I found out I had contracted HPV, I would be devastated. .127 -.006 .554 .007 

















Analysis of Hypotheses and Research Questions 
HPV Vaccination Intentions 
Research Hypotheses 
Hypothesis 1: HBM variables of perceived susceptibility, severity, benefits, 
barriers and self-efficacy will each contribute unique variance in predicting HPV 
vaccination intentions among unvaccinated women. Women who report greater 
perceived susceptibility to HPV, greater perceived severity of HPV, greater 
perceived benefits of HPV vaccination, fewer perceived barriers to HPV 
vaccination, and higher self-efficacy for receiving the HPV vaccine will report 
higher intentions to obtain the HPV vaccine.   
Hierarchical regression analyses were run to assess vaccine intentions as the 
criterion variable after controlling for the variables of sexual activity, HPV knowledge, 
cues and subjective norms in the first step; susceptibility, severity, benefits, barriers and 
self-efficacy were included as the predictor variables in the second step (Table 13). The 
final multiple regression with both control and HBM variables included was statistically 
significant (R
2
 = 0.32, F5, 43 = 2.29, p < 0.05, large effect) and all nine variables 
accounted for 32% of the variance in vaccine intentions. However, the amount of 
additional variance predicted by the HBM variables of susceptibility, severity, benefits, 
barriers and self-efficacy after controlling for the variables of sexual activity, HPV 
knowledge, cues and subjective norms was not statistically significant ( 2R =0.17, F5, 
43 = 2.17, p > 0.05). In the first model, subjective norms was a significant predictor of 
vaccine intentions (t48=2.45, p<0.05, medium effect), however, in the final model, once 




final model, only benefits had a statistically significant effect on vaccine intentions 
(t43=2.13, p< 0.05, medium effect). In other words, for each additional point of perceived 
benefits, women’s intentions for receiving the vaccine increased by 0.32 points, 
controlling for susceptibility, severity, barriers, self-efficacy, norms, cues, HPV 
knowledge and sexual activity. None of the control variables predicted unique variance 
after the HBM variables were included in the model. 
Table 13:  Summary of hierarchical regression predicting vaccine intentions 
Predictors  R   2R        df       F          *         p          Semi-
partial r
2 
Step 1:  .39 .15     48      2.17                 .09 
 Sexual Activity          1.28         .49          .01 
 Cues            -.23          .30 .02 
 Subjective Norms            .26          .02 .11 
 HPV Knowledge          -.002        .99 .000 
 
Step 2:   .57 .17     43     2.17           .08 
 Sexual Activity          2.63         .16 .03 
 Cues           -.11         .64 .004 
 Subjective Norms            .21         .07 .05 
 HPV Knowledge           -.20         .80 .001 
 Susceptibility           -.03         .49 .01 
 Severity               .10         .48 .01 
 Benefits             .32         .04 .07 
 Barriers             .47         .11         .04      








Hypothesis 2: There will be a positive correlation between HPV knowledge 
and HPV vaccination intentions for unvaccinated women 
The correlation between HPV knowledge and HPV vaccination intentions for 
unvaccinated women was not significant (r= 0.07, p>0.05). 
Hypothesis 3: There will be a positive relationship between reported HPV 
risk factors and HPV vaccination intentions for unvaccinated women. 
Two t-tests for independent groups were conducted using sexually active (yes or 
no) and abnormal pap smear (yes or no) as the status variables and vaccination intentions 
as the outcome variable. Neither sexual activity (t52=-.64, p>.05) nor the occurrence of an 
abnormal pap smear (t56=-.40, p>.05) was significant. A Pearson correlation was 
conducted between vaccination intentions and number of sexual partners (r=.13, p>.05) 
as well as between vaccination intentions and age of first intercourse (r=-.10, p>.05). A 
Spearman correlation was conducted between vaccination intentions and frequency of 
condom use with a new partner (ρ =.09, p>.05) and in a committed relationship (ρ=.08, 
p>.05). None of these correlations were significant. 
HPV Vaccination Status  
Research Hypotheses 
Hypothesis 4: The Health Belief Model (HBM) variables of perceived 
susceptibility, severity, benefits, barriers and self-efficacy will significantly 
distinguish vaccinated women from unvaccinated women. Specifically, vaccinated 
women will report greater perceived susceptibility to HPV, greater perceived 




barriers to HPV vaccination, and greater self-efficacy for vaccination as compared 
to unvaccinated women.  
A logistic hierarchical regression analysis was run with HPV vaccination status as 
the dichotomous outcome variable after controlling for HPV knowledge, cues and 
subjective norms in the first step; perceived susceptibility, severity, benefits, barriers and 
self-efficacy were included the predictor variables in the second step (Table 14). The 
final logistic regression with both control and HBM variables included was statistically 
significant (χ
2
8=100.31, p<.001, large effect). The addition of the HBM variables of 
susceptibility, severity, benefits, barriers and self-efficacy after controlling for the 
variables of sexual activity, HPV knowledge, cues and subjective norms was also 
statistically significant ( χ
2
5=19.2, p < 0.01, medium effect). After controlling for HPV 
knowledge, cues and subjective norms, self-efficacy (Wald=9.05, p< 0.01) was the only 
significant HBM variable. This means that for a one point increase in the self-efficacy 
score, we expect the odds of being in the vaccinated group to become 1.118 times what 
they were (11.8% increase in odds), holding all else constant. Cues (Wald=7.98, p< 0.01) 
and subjective norms (Wald=10.94, p< 0.001) also remained significant after all of the 
variables were entered into the model. Therefore, a one point increase in the cues and 
subjective norms scores would increase the odds of being in the vaccinated group by 
19.3% and 10.0% respectively. The Nagelkerke R
2
, which is an approximation of the 
percent of variance explained, was 0.47 for the model with just the control variables and 






Table 14:  Summary of hierarchical logistical regression predicting vaccine status 
Predictors  R
2
*   χ
2
       df  Wald     Exp(B)         p          
 
Step 1:  .47         81.12        3            .000      
 Cues       22.05        1.31 .000  
 Subjective Norms        30.30        1.15 .000  
 HPV Knowledge         1.31        1.20 .25 
 
Step 2:  .56 100.31        8        .000 
 Cues         7.98         1.19 .005 
 Subjective Norms       10.94         1.10 .001 
            HPV Knowledge           .38         1.12 .54 
 Susceptibility           .89         1.01 .34  
 Severity            1.45           .96 .23 
 Benefits            .89         1.04 .35  
 Barriers            .19         1.04 .66        
   
 Self-Efficacy          9.05         1.12 .003 
 
*Nagelkerke R Square 
Hypothesis 5: Vaccinated women will report higher self-efficacy to receive the 
vaccine as compared to unvaccinated women.  
A two sample t-test for independent groups was conducted using vaccination 
status as the status variable and self-efficacy as the outcome variable. The Levene’s Test 
for equality of variances was significant (F=28.61, p<.001), therefore equal variances 
were not assumed. Vaccinated women reported significantly higher vaccination self-
efficacy as compared to unvaccinated women (t72= -8.48, p<0.001, large effect). 
Hypothesis 6: Vaccinated women will report more positive cues to action for 
receiving the HPV vaccine as compared to unvaccinated women.  
A two sample t-test for independent groups was conducted using vaccination 




variable. Vaccinated women reported significantly higher cues to action as compared to 
unvaccinated women (t205= -6.74, p<0.001, large effect). 
Hypothesis 7: Vaccinated women will report higher subjective norms than 
unvaccinated women.  
A two sample t-test for independent groups was conducted using vaccination 
status as the status variable and subjective norms as the outcome variable. The Levene’s 
Test for equality of variances was significant (F=6.82, p<.05), therefore equal variances 
were not assumed. Vaccinated women reported significantly higher subjective norms for 
receiving the vaccine as compared to unvaccinated women (t86= -7.16, p<0.001, large 
effect). 
Hypothesis 8: Vaccinated women will have higher HPV knowledge scores 
than unvaccinated women.  
A two sample t-test for independent groups was conducted using vaccination 
status as the status variable and HPV knowledge as the outcome variable. Vaccinated 
women had significantly higher levels of HPV knowledge than unvaccinated women 
(t206= -3.28, p<0.05, small-medium effect). 
Hypothesis 9: Vaccinated women will report higher levels of HPV risk factors 
than unvaccinated women. 
Four chi-square analyses were conducted between vaccination status and the four 
HPV risk factors of sexually active (yes or no), frequency of condom use with new 
partners and in a committed relationship (always, often, sometimes, never), and abnormal 
pap smear (yes or no).  Significantly more vaccinated women reported being sexually 
active (χ
2




difference in terms of condom use with new partners (χ
2
=7.27, p>.05), condom use in a 
committed relationship (χ
2
=2.20, p>.05), and abnormal pap smears (χ
2
=0.09, p>.05). For 
condom use, both groups of women were also compared on the dimensions of always 
using a condom and significantly more unvaccinated women reported always using a 
condom with a new partner (χ
2
=5.90, p<.05) as compared to vaccinated women. There 
was no significant difference between the groups for always using a condom in a 
committed relationship (χ
2
=0.81, p>.05). Additionally, two t-tests with independent 
groups were conducted with vaccination status as the status variable and number of 
sexual partners and age of first intercourse as the outcome variables. Vaccinated women 
had a significantly higher number of sexual partners (t70=-2.01, p<.05, small effect) as 
compared to unvaccinated women but there was no significant difference in age of first 
intercourse (t145=.022, p>.05). 
Research Questions 
Research Question 1: What is the prevalence of vaccinated women in the 
sample? 
In this sample, 150 women out of 208 had received at least one of the HPV 
vaccine shots, which results in a prevalence rate of 72%. However, recruitment in this 
study was combined with another HPV study and unvaccinated participants were 
randomly assigned to either this study or the other HPV study. Therefore, 58 
unvaccinated women participated in this study and 89 unvaccinated women participated 
in the other HPV study, providing a total of 147. Therefore, the prevalence of vaccinated 




but not completed the series which results in 43.1% of the sample who had completed the 
full vaccination series and 7.4% started, but had not completed the series. 
Question 2: For vaccinated women, is there a significant correlation between 
the length of time since vaccination and the HBM components of perceived benefits, 
barriers, susceptibility, and severity? 
The correlation between length of time since vaccination and the four HBM 
variables was not significant (benefits: r= -0.08, p>0.05; barriers: r= -0.10, p>0.05; 
susceptibility: r=          -0.03, p>0.05; severity: r= 0.03, p>0.05). 
 Question 3: For vaccinated women, is there a significant correlation between 
satisfaction with receiving the HPV vaccine and the HBM components of perceived 
benefits, barriers, susceptibility, and severity? 
The correlation was significant between the variables of satisfaction with 
receiving the HPV vaccine and perceived severity (r= 0.26, p<0.001, small effect) as well 
as between satisfaction and perceived benefits (r= 0.65, p<0.001, large effect). However, 
the correlation was not significant between the variables of satisfaction and perceived 
susceptibility (r= 0.09, p>0.05) or between satisfaction and perceived barriers (r= -0.15, 
p>0.05). 
Question 4: Do women who report higher risk factors for HPV report higher 
perceived susceptibility to HPV?  
Two t-tests for independent groups were conducted using sexually active (yes or 
no) and abnormal pap smear (yes or no) as the status variables and susceptibility as the 
outcome variable. Women who had an abnormal pap smear reported significantly higher 




abnormal pap. However, there was no significant difference for sexual activity (t198=-
1.80, p>.05). A Pearson correlation was conducted between susceptibility and number of 
sexual partners (r=.18, p<.05, small effect) as well as between susceptibility and age of 
first intercourse (r=-.10, p>.05). A Spearman correlation was conducted between 
susceptibility and frequency of condom use with a new partner (ρ=.06, p>.05) and in a 
committed relationship (ρ=.02, p>.05). The only significant correlation was between 
perceived susceptibility and number of sexual partners, meaning that the greater the 
number of sexual partners, the greater the perceived susceptibility to HPV.  
Analysis of Open-Ended Questions 
Question 5: How will women respond to the following open-ended questions: 
What do you view as the greatest benefits of HPV vaccination? 
What do you view as the greatest drawbacks of HPV vaccination?  
A team of two raters first reviewed the responses to these questions to generate 
common themes or categories. One rater was a 60-year-old white, female faculty member 
and the other rater was a 26 year-old white, female third-year doctoral student. The raters 
coded a subsample of the responses to see if these categories needed refinement. After 
further refinement of the categories, they rated the items to see if any other changes 
needed to be made in the categories. Then a team of three raters coded each response into 
the identified categories and could assign multiple categories to a response if deemed 
necessary. These raters included the 26-year-old female described above, a 27-year-old 
white, female third-year doctoral student and a 32-year-old white, female fourth-year 
doctoral student. Inter-rater reliability was determined by calculating kappas for each pair 




on the individual categories. For instance, if rater A assigned categories 1 and 2 to a 
response and rater B assigned only category 1, it would be marked as agreement for 
category 1 and disagreement for category 2. 
Responses to the open-ended question inquiring as to the benefits of HPV 
vaccination fit into the categories listed in Table 15. In addition, chi-squares were 
conducted to see if a significant difference existed between vaccinated and unvaccinated 
women for each category. For the chi-squares, a contingency table was created with four 
cells representing the observed number of vaccinated participants who had and had not 
described a category and the number of unvaccinated participants who had and had not 
described the category. The chi-square test involved comparing these observed values 
with the expected values. The majority of responses for both vaccinated and unvaccinated 
participants described the benefits of prevention (e.g., reduced risk of contracting HPV, 
gential warts or cervical cancer). There was no significant difference between these two 
groups of women for this category. However, a significantly greater proportion of 
vaccinated women described reducing worry or anxiety (e.g., peace of mind, feeling safe) 
as a benefit of receiving the vaccine as compared to unvaccinated women (χ
2
=3.93, 
p<.05). Although very few respondents indicated that they had no need or interest in the 
vaccine, a significantly greater proportion of unvaccinated women cited this response as 
compared to vaccinated women (χ
2
=7.57, p<.01). Almost 20% (18.6%) of responses cited 
more than one category that was considered the best aspect of receiving the vaccine. 
Among the three coders, cohen’s kappa values ranged from .76 to .82, with an average 




Responses to the open-ended question inquiring as to the drawbacks of HPV 
vaccination fit into the categories listed in Table 16. The most common response from 
vaccinated women was that there was no drawback to getting the vaccine. On the other 
hand, the majority of unvaccinated women cited concerns about the efficacy and safety of 
the vaccine (e.g., unknown side-effects), as the biggest drawback to getting vaccinated. 
Although vaccinated participants also described concerns about efficacy of the vaccine, 
there was a greater proportion of unvaccinated participants who responded with this 
drawback. Both groups reported logistical concerns about getting the vaccine (e.g., cost, 
time-consuming) and having to get a shot (e.g., pain of shot) as drawbacks to vaccination. 
More unvaccinated women reported stigma and embarrassment, not perceiving self to be 
at risk, or no need or interest in the vaccine as drawbacks as compared to vaccinated 
women. Slightly over a quarter (28.5%) of responses cited more than one category that 
was considered the worst aspect of receiving the vaccine. Among the three coders, 
cohen’s kappa values ranged from .91 to .93, with an average cohen’s kappa value of .92. 
Chi-squares were conducted to see if a significant difference existed between 
vaccinated and unvaccinated women for each category. A significantly greater proportion 
of unvaccinated women reported concerns about safety (χ
2
=13.83, p<.001), not 
perceiving themselves to be at risk (χ
2
=19.29, p<.001), concern about stigma (χ
2
=4.81, 
p<.05), and no need or interest in the vaccine (χ
2
=13.63, p<.001) as compared to 
vaccinated women. Conversely, a significantly greater proportion of vaccinated women 
reported concerns about having to get a shot (χ
2
=4.05, p<.05) and no perceived 
drawbacks to vaccination (χ
2




was no significant difference between vaccinated and unvaccinated women reporting 






































Categories Count % Count % Count % χ
2
 df p 
Prevention 108 76.6% 38 73.1% 146 75.6% 0.26 1 >.05 
Reduced worry 60 42.6% 14 26.9% 74 38.3% 3.93 1 <.05 
No need or interest 3 2.1% 6 11.5% 9   4.7% 7.57 1 <.01 














   
Categories Count % Count % Count % χ
2
 df p 
Concerns about safety 35 25.4% 28 53.8% 63 33.2% 13.83 1 <.001 
No drawbacks 55 39.9% 4   7.7% 59 31.1% 18.25 1 <.001 
Logistical concerns 41 29.7% 14 26.9% 55 28.9% 0.14 1 >.05 
Having to get a shot 41 29.7% 8 15.4% 49 25.8% 4.05 1 <.05 
Do not perceive self to 
be at risk 
0   0.0% 7 13.5% 7   3.7% 19.29 1 <.001 
Stigma  2   1.4% 4   7.7% 6   3.2% 4.81 1 <.05 
No need or interest 0   0.0% 5   9.6% 5   2.6% 13.63 1 <.001 






What factors led you to get vaccinated? 
What factors keep you from getting vaccinated? 
These final two open-ended questions were analyzed through the same procedure 
as the benefits and drawbacks of vaccination open-ended questions. Only vaccinated 
participants responded to the question about what factors led them to get vaccinated. 
Responses to this open-ended question fit into the categories listed in Table 17. 
Responses indicated that the influence of a doctor or medical professional, the desire to 
be protected and the influence of their mother were the most common factors that led 
participants to receive the vaccine. Less common responses included perceiving 
themselves to be at risk, being influenced by a friend or sibling, being influenced by 
advertisements or the media, being influenced by their father, and expressing little or no 
downsides. A high number (81.4%) of responses cited more than one category as a factor 
that led participants to get the vaccine. Among the three coders, cohen’s kappa values 
ranged from .86 to .89 with an average cohen’s kappa value of .88. 
 
Table 17. Responses to the factors that led to HPV vaccination 
 
 Vaccinated (N=140) 
Categories Count Percentage 
Influenced by doctor 68 48.6% 
Wanting to protect self 50 35.7% 
Influenced by mother  47 33.6% 
Perceive self to be at risk  22 15.7% 
Influenced by friend or sibling 21 15.0% 
Little or no downsides 17 12.1% 
Influenced by advertisements or media 16 11.4% 
Influenced by father  13   9.3% 
 





Only unvaccinated participants responded to the question about which factors 
kept them from getting vaccinated. Responses to this open-ended question fit into the 
categories listed in Table 18. An equal number of responses described concerns about the 
efficacy and safety of the vaccine and not perceiving themselves to be at risk as the 
biggest factors keeping participants from getting the vaccine. Almost a quarter of 
responses reported logistical concerns about getting the vaccine. Less common responses 
included having no need or interest in the vaccine, thinking that the vaccine won’t help 
non-virgins and concerns about having to get a shot. Only one response cited stigma and 
embarrassment as a factor keeping the participant from becoming vaccinated. Slightly 
less than half (41.4%) of responses cited more than one category as a factor that 
contributed to participants not getting the vaccine. Among the three coders, cohen’s 
kappa values ranged from .81 to .94 with an average cohen’s kappa value of .87. 
 
Table 18. Responses to the factors that keep participants from getting the HPV 
vaccine 
 Unvaccinated (N=53) 
Categories Count Percentage 
Concerns about safety of vaccine 22 41.5% 
Do not perceive self to be at risk  22 41.5% 
Logistical concerns 13 24.5% 
No need or interest in vaccine 6 11.3% 
Not effective for non-virgins 6 11.3% 
Having to get a shot  5   9.4% 
Stigma and embarrassment 1   1.9% 
 










 This chapter presents a summary and comparative description of women who had, 
and who had not, received a vaccine to prevent HPV. These two samples did not take 
exactly the same measures. For instance, unvaccinated women completed the HPV 
vaccination intentions measure, but vaccinated women did not.  However, both samples 
completed the HBM measures as well as the self-efficacy, subjective norms, cues to 
action and HPV knowledge measures. Some hypotheses were specific for only 
unvaccinated women, only vaccinated women or for comparing the two samples. Very 
few studies have used the HBM to understand decision-making around the HPV vaccine, 
especially for college-aged women. Therefore, the current study fills a gap in the 
literature. A discussion of the results of the hypotheses and research questions are 
provided, beginning with unvaccinated women only, then comparing unvaccinated and 
vaccinated women, looking at vaccinated women only and ending with the open-ended 
questions. Then, a discussion of the study’s limitations and suggested implications for 
future research and clinical practice are included. However, before examining the 
hypotheses or future implications, some description of the two groups of women 
comprising the sample is necessary. 
Overview of sample 
 In this sample, approximately half (50.5%) of the participants had received at 
least one of the HPV vaccine shots. This is higher than the 2008 national percentage of 
vaccinated adolescents (37%) and percentages of vaccinated college women (12%) from 




national survey of vaccination coverage among adolescents found regional differences in 
the percentage of females who had received the HPV vaccine (CDC, 2009). However, 
according to the survey, the main states represented in the present study had vaccination 
coverage close to the national average (Maryland=41% and D.C.=39%). Therefore, 
regional differences may not account for the higher levels of vaccination uptake in this 
study. Instead, it appears that HPV vaccination has increased the longer it has been 
available and that rates are fairly high among students who elected to participate in the 
current study.  
Since the vaccine has only been available since 2006, the women in this study 
were not able to get vaccinated during the recommended age range of 11-12. Therefore, 
the women in this sample, who were in their late teens and early 20’s, may have been 
especially motivated to receive the vaccine before they turned 26 and were no longer 
eligible. Moreover, women at this age are more likely to link the vaccine with becoming 
sexually active as compared to 11-12 year old girls. In the total sample, 22 participants 
(7.4%) had started but not completed the series and among these women, 17 reported that 
they planned to become fully vaccinated. Therefore, the majority of women in this study 
who started the vaccine plan to complete it. This differs from national samples which 
report that more adolescents initiate the vaccine than complete the series. These findings 
suggest that college-age women may be more committed to completing the vaccine series 
than adolescents. While the prevalence of vaccinated women provides important 
information, the hypotheses and research questions related to unvaccinated women can 





Findings about Unvaccinated Women 
Relationship of HBM to HPV vaccination intentions in unvaccinated women. 
One purpose of this study was to explore which HBM variables predict HPV vaccination 
intentions among participants who had not yet received the HPV vaccine. Vaccine 
intentions were defined as the extent that women intended to get the vaccine (i.e. I expect 
that I will get vaccinated against HPV within the next year) and ranged from low 
intentions to high intentions. Since the vaccine has been available for several years, it is 
important to determine which factors may influence women in their decision to receive or 
to not receive the vaccine. The variables of sexual activity, HPV knowledge, cues to 
action and subjective norms were controlled for before examining the HBM variables. 
When these variables were included in the analysis prior to the HBM variables, 
subjective norms was the only factor that predicted vaccine intentions. However, once the 
HBM variables were included, subjective norms was no longer significant. Cues to 
action, sexual activity and HPV knowledge were not significant predictors of vaccine 
intentions at any step in the analysis. Once the HBM variables were included, the 
findings showed that perceived benefits of receiving the vaccine significantly predicted 
HPV vaccine intentions. Perceived benefits remained a significant predictor of vaccine 
intentions even after controlling for the other HBM variables (barriers, susceptibility, 
severity and self-efficacy). Thus, perhaps the best determinant of vaccine intentions is 
how effective and beneficial women perceive the vaccine to be in protecting them against 
HPV and its consequences. This finding is supported by the literature which found an 
association between higher perceived vaccine effectiveness and greater HPV vaccine 




perceived benefits by including not only vaccine effectiveness, but also peace of mind 
about health and the feeling of doing everything possible to protect the self against HPV.  
In contrast to what was hypothesized based on the previous literature, the rest of 
the HBM variables, including perceived susceptibility, severity, barriers and self-
efficacy, did not significantly predict HPV vaccination intentions. The discrepancy in 
these findings may be due to several reasons. First, most previous studies on HPV 
vaccine intentions did not control for other important variables, like sexual activity, HPV 
knowledge, cues and subjective norms. Second, many previous studies on HPV vaccine 
intentions as well as other health decisions did not include all of the HBM variables in the 
same model (Boehner et al., 2003; Ramirez et al., 1997; Yacobi et al., 1999). Therefore, 
the analyses conducted in this study may represent more rigorous testing of the HBM 
model since confounding factors such as, sexual activity, HPV knowledge, cues to action 
and subjective norms, were controlled for and the entire HBM model was included. The 
HBM variables may not be as independent as originally thought and this overlap could 
have affected the results. For instance, perceived severity was significantly correlated 
with perceived benefits and self-efficacy, and perceived barriers was also significantly 
correlated with self-efficacy although these were small to moderate correlations.  Finally, 
the HPV vaccine was not yet available at the time that many of the studies about HPV 
vaccine acceptance were conducted. The discrepancy in results may reflect the difference 
in the actual availability of the HPV vaccine. Different factors may become more salient 
when a vaccine has been available for several years in contrast to when a vaccine is 




Relationship between HPV knowledge and vaccination intentions in 
unvaccinated women. The relationship between HPV knowledge and HPV vaccination 
intentions was not significant among participants who had not received the vaccine. It is 
possible that since the vaccine has been available for three years and there have been 
many advertisements in the media for Gardasil, that most participants already had high 
levels of knowledge about HPV and the vaccine. The majority of unvaccinated women 
had heard of HPV (96.6%) and Gardasil (91.4%) and the average knowledge score for 
unvaccinated women was 6.96 (SD=1.26) out of a sample range of 4 to 9. However, this 
is still lower than the average knowledge score of 7.56 (SD=1.15) for vaccinated women. 
The literature suggests that awareness of HPV has increased over the past decade 
(Gerend & Magaloire, 2008; Baer et al., 2000; Yacobi et al., 1999). Moreover, HPV 
knowledge has not been a reliable predictor of HPV vaccine acceptance in previous 
studies (Boehner et al., 2003; Gerend & Magaloire, 2008; Jones & Cook, 2008).  
Relationship between HPV risk factors and vaccination intentions in 
unvaccinated women. Contrary to the literature, none of the HPV risk factors which 
included sexual activity, occurrence of an abnormal pap smear, number of sexual 
partners, age of first intercourse and frequency of condom use with a new partner as well 
as in a committed relationship, predicted HPV vaccine intentions. Since the vaccine has 
been available for several years, the women with the most HPV risk factors may have 
already been vaccinated. Therefore, women who have not yet been vaccinated may not be 





In summary, perceived benefits appears to be an important factor that influences 
unvaccinated women to get the vaccine. However, HPV knowledge and HPV risk factors 
were not salient in predicting vaccination intentions. In order to further understand why 
some women get the vaccine and others do not, the next section explores which factors 
differentiate vaccinated from unvaccinated women.   
Findings Comparing Vaccinated and Unvaccinated Women 
HBM for vaccinated versus unvaccinated women. Another purpose of this 
study was to explore which HBM variables differentiated vaccinated from unvaccinated 
women. The majority of studies about the HPV vaccine have not included women who 
have been vaccinated (Gerend & Magloire, 2008; Jones & Cook, 2008; Kahn et al., 
2003). Including vaccinated women is important since it increases the understanding of 
which factors positively influence vaccination and which factors serve as barriers. Since 
this study aimed to explore vaccination behavior, women who had already received the 
vaccine were asked to think back to when they were contemplating getting the vaccine 
and answer the questions according to their thoughts and perceptions at that time. 
Unvaccinated women were asked about their current thoughts and perceptions about the 
vaccine.  
The variables of HPV knowledge, cues to action and subjective norms were 
controlled for before examining the HBM variables. The findings from these variables 
are discussed in the next section. It was hypothesized that all of the HBM model variables 
would differentiate vaccinated and unvaccinated women but only self-efficacy was found 
to be a significant predictor. This finding partially supports the stated hypothesis and 




efficacy remained significant (Wald=9.05, p<.01) and accounted for unique variance 
even after controlling for the other HBM variables (benefits, barriers, susceptibility and 
severity). Therefore, women who received the HPV vaccine reported higher self-efficacy 
about overcoming the barriers for vaccination as compared to unvaccinated women.  
However, in contrast to what was hypothesized based on the previous literature, 
the HBM variables of perceived susceptibility, severity, barriers and benefits did not 
significantly predict HPV vaccination status. Only one other known study has used the 
HBM variables to explore vaccinated versus unvaccinated women and their results 
partially support the present findings (Allen et al., 2009). Allen et al. (2009) found that 
perceived benefits and barriers significantly differentiated these two groups of women, 
but perceived susceptibility and severity did not. Perceived susceptibility may not be a 
salient variable if the women who received the HPV vaccine did so as a preventative 
measure before they felt susceptible to HPV. Moreover, if women do not feel susceptible 
to HPV, then even if the perceived severity of the HPV is high, this factor may not 
influence their decision to get the vaccine. In the present study, vaccinated and 
unvaccinated women had very similar levels of perceived severity with mean scores of 
33.57 and 32.42 respectively in a possible range from 6 to 42. Both groups had relatively 
high levels of perceived severity which suggests that there were other factors besides 
perceived severity that caused some women to get the HPV vaccine and others to refrain.  
The finding that perceived barriers was not a significant predictor was surprising 
given that fewer unvaccinated women reported having health insurance (89.7%) and 
having health insurance that covered the HPV vaccine (60.3%) as compared to 




not have been significant in the present study since other important variables were 
controlled for, like HPV knowledge, cues to action and subjective norms. Allen et al. 
(2009) included subjective norms in their analysis, but did not include cues to action or 
self-efficacy. Evidence of possible overlap between the HPM variables and other 
variables are reflected in low to medium significant correlations between all of the HBM 
variables and subjective norms. In addition, cues to action was significantly correlated 
with all of the HBM variables except for perceived severity. Thus, controlling for cues to 
action and subjective norms may have removed some of the predictive power of the 
HBM variables. 
Cues to action, subjective norms and HPV knowledge for vaccinated versus 
unvaccinated women. Cues to action, subjective norms and HPV knowledge were all 
found to significantly differentiate vaccinated from unvaccinated women. Cues to action 
(Wald=7.98, p<.01) and subjective norms (Wald=10.94, p<.001) predicted unique 
variance even after controlling for the HBM variables. Therefore, women who received 
the HPV vaccine reported a greater number of cues from the environment about receiving 
the vaccine (e.g. Have you ever seen an ad on T.V. about the HPV vaccine (Gardasil)?) 
and reported that more people (e.g. friends, parents, partners) in their lives would support 
their decision to become vaccinated as compared to unvaccinated women. These findings 
are also supported by the literature. Previous research has explored cues to action in 
relation to HPV vaccination intentions, but not in terms of differentiating vaccination 
status. One previous study found that higher cues to action, such as knowing a close 
friend or relative with HPV, predicted greater HPV vaccination intentions (Jones & 




college women who planned to receive the vaccine sometime in the future and those who 
had already received the vaccine reported significantly higher subjective norms than 
women who had decided against the vaccine (Allen et al., 2009).  
In the present study, vaccinated women also had significantly higher levels of 
HPV knowledge than unvaccinated women. This supports similar findings by Allen et al. 
(2009) and suggests that HPV is more salient for vaccinated women or that vaccinated 
women tend to be more informed than unvaccinated women. However, HPV knowledge 
did not significantly predict vaccination status when controlling for subjective norms and 
cues to action. Thus, although the two groups of women had different levels of HPV 
knowledge, this may not have been the most salient factor in influencing vaccinated 
women to receive the vaccine. Moreover, HPV knowledge and cues to action were 
moderately significantly correlated which may have reduced the predictive power of 
HPV knowledge. 
HPV risk factors for vaccinated versus unvaccinated women. Certain sexual 
factors differentiated the vaccinated from unvaccinated women. For instance, 
significantly more vaccinated women reported being sexually active and having more 
sexual partners than unvaccinated women. These findings are consistent with the sexual 
risk factors that predicted vaccine intentions in previous studies (Gerend & Magloire, 
2008; Jones & Cook, 2008; Boehner et al., 2003; Costar, 2008; Buchanan, 2008). The 
frequency of condom use with a new partner or in a committed relationship did not 
significantly differ between the two groups. However when looking only at the 
proportion of women who always use a condom, significantly more unvaccinated women 




In fact, the number of vaccinated women who always use condoms in a new relationship 
(54.3%) was surprisingly low. Other sexual risk factors did not differentiate the two 
groups, such as the occurrence of an abnormal pap smear and the mean age of first 
intercourse. Interestingly more vaccinated participants (10.7%) reported being diagnosed 
with HPV as compared to unvaccinated women (5.2%), even though the occurrence of an 
abnormal pap smear was the same for both groups (vaccinated = 20.7%, unvaccinated = 
19.0%). Since an abnormal pap smear generally implies the presence of HPV, this finding 
suggests that more vaccinated women knew or were told they had HPV as compared to 
unvaccinated women. In conclusion, vaccinated women appear to have more risky sexual 
behaviors in some areas, but not in others.  
It is difficult to determine the implications that these findings may hold for 
receiving the HPV vaccine. On one hand, the decision to get the HPV vaccine could be 
seen as a positive health behavior that protects women from a harmful STD. Women who 
were aware that they were more at risk for contracting HPV due to their sexual behaviors 
may have been more engaged in health protective behavior by accurately assessing their 
risk and taking action to minimize that risk.  Evidence from this study suggests that 
women with greater sexual risk behaviors reported higher perceived susceptibility for 
HPV. For instance, participants with an abnormal pap smear and more sexual partners 
reported higher perceived susceptibility. It is possible that getting the vaccine was a 
health-protective action based on their assessment of their risk or it may have been an 
action that gave them a false sense of protection. Vaccinated and unvaccinated women 
differed on sexual risk factors in some important ways, however, since the current study 




behaviors of participants. It seems that the number of sexual partners, current sexual 
activity and condom use will be important factors to explore in future studies on HPV 
vaccination.  
In summary, self-efficacy, subjective norms, cues to actions, HPV knowledge and 
certain HPV risk factors differentiated vaccinated from unvaccinated women. The next 
section further describes the vaccinated sample and explores how satisfaction with 
receiving the vaccine and the length of time since vaccination may be related to the HBM 
variables. 
Findings about Vaccinated Women 
Retrospective recall and time since vaccination for women who received the 
vaccine. The third purpose of the study was to examine vaccinated women since most 
research has only looked at unvaccinated women. Including women who have received 
the vaccine remains a relatively unexplored area and can help illuminate the reasons 
behind getting vaccinated. Vaccinated women were asked to think back to when they 
were contemplating getting the vaccine and answer the questions according to their 
thoughts and perceptions at that time. Since this involved retrospective recall, the amount 
of time that had passed since receiving the vaccine may have influenced their responses. 
Previous studies have found that retrospective reporting influences the perceived 
importance of HBM variables, where benefits and barriers are viewed as more salient and 
severity as less salient, as compared to prospective reporting (Harrison et al., 1992; 
Brewer et al., 2007). Therefore, the amount of time since getting the vaccine was 
explored to see if it correlated with women’s responses on the HBM variables (benefits, 




vaccination did not correlate with benefits, barriers, susceptibility or severity. This 
suggests that women who had received the vaccine three years ago did not respond in a 
systematically different way than women who had received the vaccine several months 
ago.  
Relevance of the HBM variables for satisfaction with receiving the HPV 
vaccine among vaccinated women. Participants were generally satisfied with their 
decision to receive the vaccine, as indicated by the mean satisfaction level of 6.18 
(SD=1.44) where scores ranged from 1 (low satisfaction) to 7 (high satisfaction). The 
relationship between satisfaction with receiving the HPV vaccine and the HBM variables 
was explored. Results indicate that there was a significant positive correlation between 
satisfaction with receiving the HPV vaccine and the HBM variables of severity and 
benefits. Participants who perceived more benefits from getting the vaccine and more 
severe consequences from HPV were more satisfied with their decision. Therefore, to a 
certain extent, participants’ expectations about the vaccine were fulfilled. However, 
perceived barriers and susceptibility were not significantly correlated with satisfaction. 
This indicates that women’s perception of the barriers to getting vaccinated and their 
susceptibility to HPV did not influence their satisfaction with their decision. Since 
vaccinated women were able to get the vaccine, perhaps they did not view the barriers as 
major obstacles or perhaps they viewed the vaccine as worth the sacrifice. This may 
explain why barriers did not influence their level of satisfaction. In addition, 
susceptibility may not have influenced women’s satisfaction with getting the vaccine 
since vaccination would protect them from future susceptibility even if they did not 




In summary, vaccinated women who reported higher levels of satisfaction with 
their decision to receive the HPV vaccine also reported higher perceived benefits of the 
vaccine and higher perceived severity of HPV. There was no relationship between the 
HBM variables and length of time since vaccination. The next section describes 
vaccinated and unvaccinated participants responses to open-ended questions about their 
decision to receive or not receive the vaccine.  
Open-Ended Questions 
Benefits and drawbacks of HPV vaccination. Another purpose of this study was 
to explore the factors that negatively and positively influence the decision to receive or 
not receive the HPV vaccine. Open-ended questions provided an opportunity to identify 
influential factors that might not be addressed by the Health Belief Model. Participants 
were asked, ―What do you view as the greatest benefits of HPV vaccination?‖ Women 
described decreased anxiety and worry as well as prevention of HPV, genital warts and 
cervical cancer as the benefits of the vaccine. Prevention of HPV and its clinical sequelae 
was cited in the majority of responses for both vaccinated (76.6%) and unvaccinated 
(73.1%) participants. Women who gave this response thought that the greatest benefit of 
the vaccine was its role keeping them ―safe from getting cervical cancer,‖ giving them 
―protection against HPV,‖ and ―not getting genital warts.‖  Women also described how 
the vaccine improves sexual health and prevents the spread of HPV to partners. 
Responses included ―improvement of health‖ and ―protecting myself from the possibility 
of contracting and then spreading it.‖  
Decreased anxiety and worry was the next most common response for both 




participants (42.6%) who cited this response as compared to unvaccinated (38.3%). The 
vaccine provided women with peace of mind and a sense of comfort about their health. 
As one participant stated, the biggest benefit of the vaccine was ―peace of mind. 
Knowing that I've done something else (besides abstinence) to help prevent HPV and 
cervical cancer. So if I do get it I won’t have to feel like I didn’t do everything I could to 
prevent it.‖ In addition, women described feeling more in control of their health and not 
having to worry about contracting HPV as a result of the vaccine. One response included, 
―Not having to think about getting checked so often for cervical cancer.‖ 
Finally a small number of vaccinated women (2.1%) and significantly more 
unvaccinated participants (11.5%) stated no need or interest in the vaccine. One 
participant wrote: 
I do not view any health benefits. I feel that people should practice safe sex and 
not be coerced into getting the Gardisil vaccine by their GYN. The vaccine has 
not been around long enough to see the long term health side effects. 
Another participant described, ―I do not see any benefits unless I decide to completely 
change my lifestyle and become sexually active with people whose health I don't know 
about.‖ One of the women who had received the vaccine responded, ―I don't really think 
there were any benefits for me because even after I had all the vaccines I still had an 
abnormal pap smear result whereas before getting the vaccines I had never had an 
abnormal result before.‖ 
Responses to these open-ended questions are similar to those found in the 
qualitative portion of Costar’s (2008) study about primary reasons women would get the 




study cited the benefits of prevention as the main reason to get vaccinated. The benefits 
of reducing worry were also evident in Costar’s (2008) study, as well as a small number 
of participants (5.2%) who had no wish to be vaccinated. In short, receiving the HPV 
vaccine has two main benefits – protection from HPV and reducing worry - that women 
should consider. 
In order to determine drawbacks to vaccination, participants were asked, ―What 
do you view as the greatest drawbacks of HPV vaccination?‖ In response participants 
described logistical concerns, stigma and embarrassment, not perceiving themselves at 
risk, perceiving no need, lack of interest or lack of knowledge about the vaccine, 
concerns about the efficacy and safety of the vaccine, and concerns about having to get a 
shot. Finally, some of the participants did not see any drawbacks to getting the vaccine. 
The most common drawback for unvaccinated women was their concern about 
the efficacy and safety of the vaccine. Significantly more unvaccinated (53.8%) cited this 
concern as compared to vaccinated women (25.4%). Responses described worries that the 
vaccine had unknown side effects and had not been thoroughly tested or around long 
enough to be safe. As one participant responded the biggest drawback about the vaccine 
was, ―the uncertainty about long term symptoms/consequences. The vaccination is 
relatively young.  I don't want to sign up for something that may turn out to be a bad 
thing in a few years.‖ Some thought that the vaccine ―may not be completely effective‖ 
or would not be effective for non-virgins. As one participant wrote, ―I heard it doesn't 
work once you've started having sex already.‖ Several participants stated that receiving 




beliefs. I also believe that since it's still a fairly new vaccine, it could cause serious 
damage/side effects down the line that we can't yet predict.‖                 
A similar percentage of vaccinated (29.7%) and unvaccinated (26.9%) 
participants reported logistical concerns as a drawback to getting the vaccine. Responses 
indicated that they felt the vaccine was ―expensive‖ and that receiving three shots was 
―time consuming.‖ One participant wrote, ―It is difficult to plan out the three shots in the 
appropriate time span.‖   Out of the total sample, 10.6% of the participants had not 
received all three vaccines even though they were motivated to begin the vaccination. In 
addition, other women stated that they would not have been able to afford the vaccine 
without insurance. As one participant responded, ―If my insurance hadn’t approved it, I 
wouldn’t have gotten it because I know it’s pretty expensive.‖ 
Participants also described concerns about having to get a shot as a drawback to 
getting vaccinated. This seemed to be more of a concern for vaccinated participants since 
significantly more of them (29.7%) cited this response than unvaccinated participants 
(15.4%). Vaccinated participants described how receiving the shot was ―painful‖ and 
complained of minor side effects from the vaccine, such as ―soreness for a few days after 
receiving the shot‖ and vomiting after vaccination. Unvaccinated participants responded 
that receiving a shot would be painful and talked about having a fear of needles (―I hate 
needles‖). 
Only unvaccinated participants described not perceiving themselves at risk for 
HPV (13.5%) or having no need or interest in getting the vaccine (9.6%).One reason 
seemed to pertain to women being in a monogamous relationship. Responses included, 




my husband has HPV since he is my only partner.‖  Other reasons for having no need for 
the vaccine involved not being sexually active. One participant stated, ―Why do it now 
when I don't need it since I'm not having sex, until I am going to have sex it would just be 
a waste of time, especially seeing as how I'm nowhere near close to having sex.‖  
Although very few vaccinated and unvaccinated participants described stigma and 
embarrassment as a drawback to getting the vaccine, significantly more unvaccinated 
participants (7.7%) cited this concern as compared to vaccinated women (1.4%). 
Unvaccinated women who endorsed this response wrote, ―I’d have to tell my parents‖ 
and described the drawback of ―having everyone around me thinking I'm at risk because 
I'm either sexually active or plan to be, when I'm not.‖ Vaccinated participants reported 
―possible social stigma‖ around getting the vaccine. 
The most common response from vaccinated participants was that there were no 
drawbacks to getting the vaccine. Significantly more vaccinated women (39.9%) 
endorsed this response as compared to unvaccinated women (7.7%). One participant 
wrote, ―No drawbacks. It’s worth it.‖ Ten percent of women at first stated that there were 
no drawbacks, but then went on to describe a downside of the vaccine. The most common 
downside in this case was the pain associated with receiving a shot. 
Responses to these open-ended questions are also similar to those found in the 
qualitative portion of Costar’s (2008) study about primary reasons women would not get 
the HPV vaccine. Costar (2008) found similar themes of participants not perceiving 
themselves at risk and having no desire to get the vaccine. Moreover, some participants in 
Costar’s (2008) study indicated that there was no reason not to get vaccinated, much like 




categories were slightly different, but may still relate to the categories in this study. For 
instance, Costar (2008) found responses that described increased anxiety which may 
relate to concerns about the efficacy and safety of the vaccine and concerns about getting 
a shot that were described in this study. Participants in Costar’s (2008) study also 
described how the benefits of vaccination do not outweigh the costs which may relate to 
the participants who reported logistical concerns in this study. 
What factors led you to get vaccinated? Only vaccinated women answered this 
open-ended question with the aim of discovering which factors most influenced their 
decision to get the vaccine. There has been speculation about how to market the vaccine 
to women and the responses to this question could help clarify which areas to target. 
Findings indicate that the majority of participants (79.3%) were influenced to get the 
vaccine by other people. Specifically, doctors or medical professionals (48.6%) and 
mothers (33.6%) were the people most commonly cited who influenced participants to 
get vaccinated. Participants also described how siblings or friends (15.0%) and fathers 
(9.3%) influenced them. This supports the finding that subjective norms, plays an 
important role in differentiating vaccinated from unvaccinated women. Subjective norms 
refer to how important people, such as parents, friends, doctors, siblings and significant 
others, view a certain health behavior. Therefore, having people accept and encourage 
health behaviors, such as getting the HPV vaccine, is perhaps the biggest factor that 
influences women to get vaccinated. Doctors and medical professionals appear to have a 
particularly strong influence (48.6%) and a proactive approach by the medical 
community to encourage HPV vaccination could be paramount in the dissemination of 




had insurance that covered the HPV vaccine (83.3%) as compared to unvaccinated 
women (89.7% and 60.3%, respectively). Therefore, doctors perhaps had more access to 
women with health insurance. Perhaps not surprisingly, mothers had more of an impact 
than fathers on participant’s decision to get vaccinated. Women may be more 
comfortable talking to their mothers about HPV or their mothers may be in charge of the 
family’s health more so than their fathers. In addition, mothers may themselves have 
worried about abnormal pap smears based on their past experience or knowing someone 
else who had one. Interestingly, friends and siblings (15.0%) did not play as large a role 
as expected in influencing participants to get the vaccine. Participants may be hesitant to 
discuss the vaccine with their friends since HPV is associated with sexual behaviors or 
mothers and physicians may have had the first opportunity to influence women.  In 
addition, many of the women may have been on their parents’ health insurance and thus 
looked to their family rather than friends for support in getting the vaccine.  
 Vaccinated participants also cited other factors that led them to get vaccinated, 
including the desire to protect themselves from HPV, genital warts, or cervical cancer 
(35.7%), perceiving themselves to be at risk for HPV (15.7%), being influenced by 
advertisements or the media (11.4%), and describing little or no downsides to receiving 
the vaccine (12.1%). Some of the women who reported a desire to protect themselves 
stated wanting to ―protect my sexual health in the long-run‖ and ―prevent the spread of a 
common disease.‖ Protection appeared to be a common factor that influences participants 
to get the vaccine and is theoretically related to the HBM variable of perceived benefits, 
which includes the vaccine’s effectiveness in preventing HPV, genital warts and cervical 




activity, but also having had an abnormal pap smear or having a family history of cancer. 
This category is related to the HBM variable of perceived susceptibility. The relatively 
low number of women who reported perceived risk as a reason for getting the vaccine 
may explain why perceived susceptibility did not differentiate vaccinated from 
unvaccinated women. Given the large amounts of Gardasil advertisements, it is surprising 
that so few women cited the media as a factor that led them to get the vaccine. Of the 
women who wrote about the media, commercials were the most common type of 
advertisements cited in participants’ responses and these commercials may have 
reinforced the importance of the vaccine as well as normalized the need to get vaccinated. 
 In summary, support and encouragement by other people, especially doctors and 
mothers, was the biggest factor that influenced participants to get the HPV vaccine. The 
desire for protection against HPV and its clinical sequelae also seemed to motivate 
women to get vaccinated. This information can be utilized to promote the vaccine to 
women and reach those in their late teens and early twenties before they are no longer 
eligible for HPV vaccination.  
What factors keep you from getting vaccinated? Only unvaccinated women 
answered this open-ended question with the aim of discovering which factors were 
hindering them from seeking the vaccine. Most of the reasons why unvaccinated women 
had not yet received the vaccine were the same as the drawbacks described by the whole 
sample. Almost half of the responses indicated that participants did not perceive 
themselves at risk for HPV (41.5%) and/or were concerned about the efficacy and safety 
of the vaccine (41.5%). All of the women who did not perceive themselves at risk 




The perception that women should not get the HPV vaccine until they are sexually active 
is problematic since the purpose of the vaccine is to prevent HPV before individuals are 
exposed. In fact, the vaccine has been recommended for 11 to 12 year old girls in order to 
protect them before they become sexually active. The participants who endorsed this 
response seemed to be making a decision about their current level of risk rather than 
considering how their circumstances might change, such as becoming sexually active or 
having a new sexual partner in the future. The participants who reported concerns about 
the efficacy and safety of the vaccine wrote that it was ―too young to be entirely trusted‖ 
and worried about ―unknown, long-term consequences.‖ These participants seemed to 
think that the vaccine was potentially dangerous and not worth the risk. Therefore, 
women’s perceptions of their current risk and of the vaccine appeared to be the biggest 
factors keeping them from getting vaccinated. 
Almost a quarter (24.5%) of the responses also described logistical concerns, 
most (84.6%) of which mentioned the cost of the vaccine and/or that their insurance did 
not cover it. This suggests that more women would become vaccinated if the shots were 
more affordable, either through better insurance coverage or through a lower overall cost 
for the vaccine. 
Equal numbers of participants cited no need or interest in the vaccine (11.3%) and 
thinking that the vaccine won’t help non-virgins (11.3%). Some women who felt no need 
to get the vaccine reported ―inadequate knowledge of what HPV is‖ or stated, ―I do not 
get vaccinations.‖ Others stated that the vaccine was no longer effective since they were 
already sexually active or that getting the vaccine was pointless since they had already 




included concerns about getting a shot (9.4%) and worries about stigma and 
embarrassment (1.9%). Some participants stated that they had a fear of needles or a 
phobia to receiving vaccines. Only one participant cited stigma and embarrassment by 
stating that she was worried about her ―parents finding out.‖ 
 In conclusion, the most common factors that kept participants from getting 
vaccinated were their concerns about the vaccine’s efficacy and safety, and their 
perception of not being at risk for HPV. However, logistical concerns, such as the cost of 
the vaccine, were also indicated as hindering women from receiving the vaccine. 
Although the large majority of unvaccinated participants had heard of HPV (96.6%) and 
the HPV vaccine (91.4%) before the study, it is clear that myths about both still abound, 
including the idea that the vaccine is no longer effective for non-virgins. Efforts to dispel 
misinformation about the vaccine and educating women about their susceptibility to HPV 
represent important steps in promoting the HPV vaccine. 
Overall Summary of Findings 
 The Health Belief Model (benefits, barriers, susceptibility and severity) and other 
social cognitive variables (subjective norms, cues to action, self-efficacy, HPV 
knowledge and sexual risk factors) were originally presented in this study to help predict 
which factors would influence women to receive the HPV vaccine. Two groups of 
women, HPV vaccinated and unvaccinated, were examined both separately and then in 
comparison to each other.  For unvaccinated women, only perceived benefits accounted 
for unique variance in predicting their intentions to get the HPV vaccine. This suggests 
that women who view the HPV vaccine as more effective and beneficial in protecting 




However, unvaccinated women qualitatively reported concerns about the vaccine’s 
efficacy and safety as factors that keep them from getting the vaccine. In addition, many 
of the women qualitatively reported that they did not perceive themselves to be at risk for 
HPV because they were either in a monogamous relationship or were not sexually active. 
The results indicate that more unvaccinated women (53.4%) reported being married or in 
a monogamous relationship than vaccinated women (44.0%). In addition, more 
unvaccinated women (39.7%) reported NOT being currently sexually active as compared 
to vaccinated women (17.3%). Therefore unvaccinated women seemed to consider their 
sexual situation with an apparent emphasis on the here and now or near future rather than 
in the long-term. These factors may account for why these participants had not yet 
received the HPV vaccine. However certain aspects may eventually persuade 
unvaccinated women to get the vaccine, such as additional evidence regarding the safety 
and efficacy of the vaccine,  changes in women’s sexual status (i.e. becoming sexually 
active or ending a current relationship), or consideration of the beneficial aspects of the 
vaccine. 
For vaccinated women, the majority were generally satisfied with their decision to 
receive the vaccine. Interestingly, participants qualitatively reported that the biggest 
factor which led them to get the vaccine was support and encouragement by other people, 
especially their doctors and mothers. This suggests that social support may be an 
important factor in helping unvaccinated women decide to receive the vaccine. In 
addition, participants qualitatively reported that the desire for protection against HPV, 




Finally, vaccinated women were compared to unvaccinated women on a number 
of factors, including the Health Belief Model variables. Surprisingly, none of the four 
main components of the HBM (perceived benefits, barriers, susceptibility and severity) 
differentiated vaccinated from unvaccinated women. Instead, other variables such as self-
efficacy for receiving the vaccine, cues to action and subjective norms all accounted for 
unique variance in predicting vaccination status. Vaccinated women also had 
significantly higher knowledge about HPV and the vaccine as compared to unvaccinated 
women, but this finding disappeared when cues to action and subjective norms were 
taken into consideration. This suggests that women’s decision to get the vaccine involves 
a complex interplay of factors that are not necessarily captured by a rational, cost-benefit 
model like the HBM. Vaccinated women reported higher self-efficacy for receiving the 
vaccine (although this is based on retrospective recall), more positive cues for receiving 
the vaccine and more approval from their social network for receiving the vaccine as 
compared to unvaccinated women. Thus external factors seem to play a key role in 
influencing HPV vaccination behavior. When a woman’s environment supports HPV 
vaccination, through encouragement by others and reminders of the vaccine in daily life, 
this may lead to increased knowledge about HPV as well as increased confidence in 
receiving the vaccine. Moreover, women who have support from their environment may 
find it easier to overcome any barriers associated with vaccination. External factors may 
be particularly salient with this health behavior since HPV vaccination has had a large 
amount of media coverage and controversy associated with it. In addition, since the 
vaccine is associated with sexual behaviors and has been marketed to young girls, parents 




was older than the target population for the vaccine, parents of these participants may still 
have been more aware and instrumental in their decision due to the media coverage. 
Finally, doctors may have been instrumental in promoting the vaccine since they may 
benefit financially from giving vaccinations and they may also realize that the HPV 
vaccine has the potential to completely eliminate cervical cancer. The HBM variables 
(benefits, barriers, susceptibility and severity) did account for significant variance, but 
not for unique variance when considering them along with the other variables (self-
efficacy, cues to action and subjective norms). Therefore, women may still consider the 
benefits and barriers of HPV vaccination as well as the severity of HPV and their 
susceptibility to it. However, the more external variables of subjective norms, self-
efficacy and cues to actions appear to be more important in influencing women’s decision 
to receive or not receive the vaccine. 
Vaccinated women also reported more HPV risk factors such as being sexually 
active and having more sexual partners than unvaccinated women. In addition, 
unvaccinated women reported always using condoms with new partners as compared to 
vaccinated women.  It is possible that women were aware of their risk for contracting 
HPV or made an accurate risk assessment based on their sexual behaviors which 
prompted them to get the vaccine. Women who perceived themselves to be at risk for 
HPV may have been more influenced by cues to action, such as advertisements, and more 
persuaded by their doctor. On the other hand, receiving the vaccine may have been an 
action that gave women a false sense of protection. In general, parents have cited 




cannot be drawn from this study since it is not longitudinal and the role that the vaccine 
plays in sexual behaviors is still unknown. 
In summary, the Health Belief Model can be useful for determining women’s 
intentions to get the HPV vaccine. In particular, the perceived benefits of receiving the 
HPV vaccine seems to play an important role. Yet many unvaccinated women viewed the 
vaccine as having benefits but not for them at the moment. When considering actual 
vaccination behavior, such as comparing vaccinated versus unvaccinated women, factors 
that go above and beyond the four main components of the Health Belief Model, such as 
self-efficacy, subjective norms, cues to action and HPV knowledge become salient. 
Additionally, this study contributes to HPV vaccination research by qualitatively 
exploring factors that keep women from and lead women to getting the vaccine. 
Limitations 
This study has several limitations. The primary limitation includes the cross-
sectional design of the study. In order to fully test the health belief model, a longitudinal 
design is required since the goal is to predict future behavior. While longitudinal research 
is important and necessary, it was beyond the scope of this study. Instead, unvaccinated 
reported on their current perceptions of the vaccine, whereas vaccinated women were 
asked to retrospectively report on their thoughts and perceptions when they were 
contemplating getting the vaccine. Since retrospective recall was involved, the amount of 
time that had passed since vaccination may have influenced their responses. Participants 
reported an average of 16.9 months (SD = 11.0) since vaccination with a range of 1 to 44 
months. Therefore, participants had to remember what their perceptions of the vaccine 




reported more benefits and fewer barriers than they actually perceived at the time. In 
order to test for this, the amount of time since vaccination was compared to the HBM 
variables and no significant correlations were found. However, participants may still be 
more biased in their accounts of their perceptions than unvaccinated women.  
Another limitation of the study includes the lack of standardization for the health 
belief model measures. These measures aren’t standardized since the scale items depend 
on the behavior and the population of interest. Although some valid and reliable HBM 
measures exist, they do not relate specifically to the HPV vaccine. In order to resolve this 
limitation, several steps were taken. First, experts were consulted to ensure the 
construction of conceptually and methodologically sound measures. Second, an 
exploratory factor analysis with oblimin rotation was conducted to see if items loaded 
onto the hypothesized HBM variable. Each item was examined for sufficient loading (.30 
or higher) on the hypothesized factor and for cross-loadings on more than one factor.  
The number of factors to retain for each HBM variable was also explored. However, 
there were not enough items in the barriers scale to thoroughly explore the possibility of 
multiple factors. Third, Cronbach alphas were calculated and found to be above 0.72 for 
all scales except for perceived barriers which was 0.54 for vaccinated women. Although 
data from both vaccinated and unvaccinated participants loaded in a similar manner onto 
the factors, there were some minor differences between the two groups which made it 
difficult to decide which items to eliminate in designing the final measure. In addition, 
unvaccinated women were answering items based on how they currently felt, whereas 
vaccinated women were retrospectively reporting about how they felt at the time of 




 Finally, this study is limited by the fact that the participants are enrolled in higher 
education settings and therefore may not be representative of all women in the 18-26 age 
group. For instance, college women are likely to have greater access to health 
information and services compared with those who are not in school (Allen et al., 2009). 
This has implications for external validity since it restricts the generalizability of the 
results. In addition, there may be a sampling bias since participants were primarily 
recruited from sororities and psychology or education classes. Therefore, the 
generalizability of this study to college-age women in general is restricted. In order to 
increase the heterogeneity of the sample, participants were recruited as much as possible 
from universities in different regions of the country. 
Implications for Research and Practice 
This study was conducted with the aim of understanding the role of the Health 
Belief Model in college-age women’s vaccination behavior for the human papillomavirus 
vaccine. The current study was one of only a few studies to include all of the components 
of the HBM such as perceived benefits, barriers, susceptibility and severity as well as 
self-efficacy and cues to action. Other social cognitive variables were of interest in 
predicting vaccination behavior, including subjective norms, HPV knowledge, and HPV 
sexual risk factors. This was also one of the few studies to look at both vaccinated and 
unvaccinated women and based on this, future studies might consider conducting 
longitudinal studies that explore which factors predict vaccination behavior rather than 
just vaccination intentions.  
Getting the HPV vaccine is a positive health-protective behavior for most young 




cancers have been identified in order of importance, so the HPV vaccine will soon protect 
against all of these strains. Given the importance of HPV vaccination, future studies 
should employ a longitudinal design to study which variables predict vaccination uptake. 
The present study explored vaccination behavior retrospectively by having vaccinated 
women think back to when they were contemplating getting the vaccine, whereas 
unvaccinated women answered questions based on their current thoughts and perceptions 
around the vaccine. This retrospective reporting may have introduced some bias, whereas 
a longitudinal study would measure current perceptions for all participants. In addition, 
the current study explored unvaccinated participants intentions to receive the HPV 
vaccine in the future. Although intentions may be correlated with behavior, it is still 
unknown what would actually lead unvaccinated women to participate in vaccination 
uptake. A longitudinal study would allow for full testing of the factors that predict HPV 
vaccination behavior. It would be important to study which variables predict vaccination 
uptake in order to determine the factors that should be emphasized in promotion of the 
vaccine.  
Future research should explore how to increase both social and informational 
environmental support for receiving the vaccine as well as increase the self-efficacy of 
unvaccinated women to overcome barriers for vaccination. Although each individual 
woman should assess her situation and decide for herself whether or not to get the HPV 
vaccine, environmental support can make it easier for women to become vaccinated. Our 
results indicate that self-efficacy represents an important variable in differentiating 
vaccinated from unvaccinated women. Specifically, self-efficacy in this study referred to 




vaccinated women had higher self-efficacy regarding pushing past perceived barriers as 
compared to unvaccinated women. Vaccinated women also reported higher subjective 
norms (e.g. parents, friends, doctor approved of the vaccine.) and cues to action (e.g. 
knowing someone who received the vaccine, seeing an ad on TV about the vaccine) as 
compared to unvaccinated women, suggesting that their environment was more 
instrumental to receiving the vaccine. In addition, a link may exist between self-efficacy 
and environmental support and future research should explore this connection in order to 
determine how these factors interact to promote vaccination.  
The scales used to measure the HBM variables in this study were created by the 
researcher and require further validation. While the measures were used in both the 
vaccinated and unvaccinated samples, further testing would provide additional validation 
that these measures are appropriate for both samples. Future research should also test 
these measures in populations other than college-age women. In the current study, there 
were not enough items in the barriers scale to thoroughly explore the possibility of 
multiple factors. Therefore, additional items should be added to the scales in order to 
determine whether subscales exist within the HBM variables.  
In future studies, HPV sexual risk factors, such as number of sexual partners, 
current sexual activity and condom use, will be important factors to explore in relation to 
HPV vaccination. The current study found that more vaccinated women reported being 
sexually active, having more sexual partners and using condoms less frequently than 
unvaccinated women. Future research should attempt to determine the implications that 
these findings may hold for receiving the HPV vaccine. For instance, did vaccinated 




vaccination or did the vaccine give these women a false sense of security and lead to 
increased sexual behaviors? These would be important questions to answer, particularly 
in light of parents’ concerns that the vaccine promotes promiscuity. The vaccine is 
targeted for young girls (age 11-12) in order to protect them from HPV before they 
become sexually active since they may not know whether their future partners have HPV. 
Many girls and women never really know their lifetime potential risk of exposure since 
their partners may not even be aware if they have HPV or not. Unvaccinated women 
reported that they did not perceive themselves to be at risk for HPV due to not being 
currently sexually active or being in a monogamous relationship. Therefore, women seem 
to base their vaccination decisions on their current level or risk rather than on their 
potential risk level in the future (if they become sexually active or if they have new 
sexual partners). Further research should explore women’s perception of risk for HPV 
and how this influences their decision to become vaccinated.   
This study was conducted at a time where college-aged women could not have 
received the vaccine during the target age range of 11-12 years since it was not yet 
available. Therefore, these women made the decision whether or not to become 
vaccinated and were also influenced by significant others (parents, doctors and friends). 
In the future, females will likely get the vaccine as a routine childhood vaccination and 
will not need to make the decision about getting it in young adulthood. This study 
represents a point in time that will not really exist in the future. However, the results from 
this study can provide important information for studying health protective actions in 
general beyond the HPV vaccine. For instance, this study suggests that factors beyond the 




efficacy, cues to action and subjective norms play an important role in influencing 
vaccination behavior. Since HPV vaccination represents a behavior that protects against 
sexual risk, these findings may apply to other sexual protection behaviors, such as 
condom use. Future studies should incorporate variables beyond the traditional HBM 
factors in exploring protective sexual behaviors. 
In terms of practice, health professionals appear to hold great influence over 
college-age women’s decision to receive the vaccine. In this study, the majority of 
vaccinated women reported that doctors or medical professionals influenced them to get 
the vaccine. This suggests that health professionals can play a large role in increasing 
women’s awareness of the vaccine and promoting its uptake. Many participants also 
indicated that their mothers influenced them to receive the vaccine. Thus, health 
professionals should not only educate college-age women about the vaccine, but also 
inform families and parents about the benefits of HPV vaccination. Education about HPV 
and the vaccine appears to be an important factor since vaccinated participants had higher 
HPV knowledge than unvaccinated participants. This suggests that being informed about 
HPV and the vaccine can help women realize the importance of getting vaccinated and 
may dispel misconceptions they have about the vaccine. The study’s open-ended 
questions revealed that unvaccinated women still hold misconceptions about the vaccine, 
such as believing that the vaccine is ineffective for non-virgins. Moreover, unvaccinated 
participants cited these misconceptions as reasons not to get the vaccine. Therefore, 
health professionals are well positioned to educate women and their families about HPV 




There has also been speculation about how to market the vaccine and this study 
helps clarify which areas to target for college-aged women. Specifically, unvaccinated 
participants had higher intentions to receive the vaccine when they perceived greater 
benefits to receiving the vaccine. Moreover, the open-ended questions revealed that the 
majority of participants thought the greatest benefit of vaccination was prevention of 
HPV and its clinical sequelae. Therefore, health messages should focus on the benefits of 
HPV vaccination and especially emphasize the efficacy of the vaccine in protecting 
against genital warts and cervical cancer. In addition, many unvaccinated participants 
held concerns about the safety of the vaccine or did not perceive themselves to be at risk 
for HPV. In order to address these concerns, health messages should include information 
about research on the vaccine and include the factors that place women at risk for 
contracting HPV, such as skin-to-skin contact. Moreover, the HPV vaccine has recently 
been approved for males and can potentially protect them against HPV-related cancers 
such as oral, penile and anal. This makes getting the vaccine something that not only 
protects women but protects their partners – male or female. Health messages should 
consider emphasizing how the vaccine can prevent the spread of HPV to partners since 
this might help them understand that the implications of vaccination goes beyond their 
own health.  
Finally, given the negative psychological and physical effects of being diagnosed 
with HPV, counseling psychologists should advocate for making the HPV vaccine more 
available and affordable to college-aged women. Many unvaccinated participants 
expressed concerns about not being able to afford the vaccine since they did not have 




reported that they were only able to get the vaccine because their parents agreed to pay 
for it. Given the ability of this vaccine to prevent painful genital warts and cervical 
cancer, it is important to make it available to all women who would benefit from it. It 
seems that clinics on campuses and in communities could make the barriers of cost and 
inconvenience less problematic.  
In summary, this study demonstrated a significant relationship between the HBM 
variable of perceived benefits and HPV vaccination intentions among women who had 
not yet received the vaccine. In addition, self-efficacy, subjective norms and cues to 
action were found to significantly differentiate vaccinated from unvaccinated women. 
Future research and a longitudinal study are needed to better identify the factors that lead 
to HPV vaccination behavior. This information can then be used to better inform 
interventions and health messages about the HPV vaccine which can lead to increased 
vaccination uptake. The current study highlighted the need to move beyond the 
traditional Health Belief Model when understanding the decision to receive the HPV 
vaccine. For instance, variables that were not a part of the traditional HBM, including 
cues to action, subjective norms and self-efficacy, were significant predictors of 
vaccination status. The use of open-ended questions allowed participants to describe 
positive and negative aspects of vaccination as well as the factors that led them to or kept 
them from getting the vaccine in their own words, such as by noting that:  
Two of my close friends have the strands of HPV that cause cervical cancer and 
genital warts. I also contracted a strand of HPV right after the first shot that has 




wanted to make sure that I was protected against the most dangerous kinds, since 
the majority of HPV is symptomless and does not have long term effects.  
In short, this study helped contribute to a greater awareness of the multifaceted 
dimensions of deciding whether or not to receive the human papillomavirus vaccine, 
including external variables such as subjective norms and cues to action that can help 



























2. Gender: female  male   
 
3. Ethnicity/Race:   
 
African-American/Black  Asian-American/Pacific Islander 
Latina/Hispanic   White/European Descent             
Middle-Eastern/Arab  Asian Indian/ Pakistani 
Biracial/Multiracial   Native American/Native Alaskan             
Other (please specify): _____________ 
 
 
4. Current relationship status:  
 
Single   Married  Divorced    Widowed   
Committed Relationship (6 months or longer)       Other  
 
5. Current year of undergraduate study: 
 
6. Do you currently have health insurance, either on your own or under the insurance 
plan of another person?   
YES  NO 
 
7. Does your health insurance cover the HPV vaccine? (if not applicable, skip this 
question) 
 YES  NO 
 
8. How many times over the past two years have you visited a gynecologist for a 
regular examination (including a Pap smear test)? 
 
9. Before taking this survey, had you ever heard of HPV (human papillomavirus)?  
YES  NO 
 
10. If yes, how did you first hear about HPV?  
a. Health care provider 
b. A friend  
c. A family member  
d. Television or radio 
e. Internet 




g. At school 
h. Other (specify): __________________ 
i. I don’t remember 
 
11. Before taking this survey, had you ever heard of the HPV vaccine called 
Gardasil? 
a. Yes 
b. No  
c. I don’t know  
 
12. If yes, how did you first hear about the HPV vaccine?  
a. Health care provider 
b. A friend  
c. A family member  
d. Television or radio 
e. Internet 
f. Newspaper or magazine 
g. At school 
h. Other (specify): __________________ 































Sexual Risk Factors 
 
In order to further our knowledge of reactions to a vaccine for a sexually transmitted disease, it is 
important that we ask questions pertaining to the health habits and sexual histories of the 
participants taking the questionnaire. Therefore, although some of the following information may 
be personal in nature, we ask that you answer as truthfully as possible. 
 
1. Are you currently sexually active (defined, for the purpose of this study, as engaging in 
penis/vagina or penis/anus intercourse)?  YES  NO 
 
2. Have you ever engaged in penis/vagina intercourse?    YES  NO 
(If you have never been sexually active, please skip to question #14) 
 
3. Have you ever engaged in anal (penis/anus) intercourse?  YES  NO 
 
4. At what age did you first engage in penis/vagina intercourse? 
 
5. With how many partners have you engaged in penis/vagina intercourse? 
 
6. At what age did you first engage in penis/anus intercourse? (if not applicable, skip this 
question) 
 
7. With how many partners have you engaged in penis/anus intercourse? (if not applicable, 
skip this question) 
 
8. How often do you use a condom when you have penis/vagina intercourse with a new 
partner?     
ALWAYS     USUALLY     SOMETIMES    NEVER 
 
9. How often do you use a condom when you have penis/anal intercourse with a new 
partner? (if not applicable, skip this question)    
ALWAYS     USUALLY     SOMETIMES    NEVER 
 
10. How often do you use a condom when you have penis/vagina intercourse with a partner 
with whom you are in a committed relationship (6 months or longer)?     
ALWAYS     USUALLY     SOMETIMES    NEVER 
 
11. How often do you use a condom when you have penis/anal intercourse with a partner 
with whom you are in a committed relationship (6 months or longer)? (if not applicable, 
skip this question)    
ALWAYS     USUALLY     SOMETIMES    NEVER 
 
12. What is your usual method of birth control? 
 
13. Have you ever had an unintended pregnancy? YES NO 
 





15. Have you ever had an abnormal Pap smear test (e.g. atypical cervical cells)? YES   NO 
 
16. Have you ever been diagnosed with a sexually transmitted disease?   YES   NO 
If yes, please indicate which disease(s): 
 
17. Have you ever been tested for a sexually transmitted disease?   YES NO 
 
18. Have you ever been diagnosed with atypical or precancerous cervical cells or cervical 









































The human papillomavirus (HPV) is a sexually transmitted disease. A vaccine 
called Gardasil that protects against four types of human papillomavirus (HPV) was 
approved by the Food and Drug Administration (FDA) in June 2006 has since been 
available to the public. The HPV vaccine will be referred to as Gardasil in the following 
items. 
Please answer the following questions regarding your thoughts about HPV and 
Gardasil. If you have already received Gardasil, please think back to when you were 
contemplating getting the vaccine and answer the questions according to your thoughts 
and perceptions at that time. If you have not received the Gardasil, please answer the 
questions according to your current thoughts and perceptions. Please answer these 
questions regardless of whether or not you are currently sexually active.  
 
1. What are your chances of contracting HPV if you didn’t get Gardasil? 
 
0%  10%  20%   30%   40%   50%   60%   70%   80%   90%  100% 
 
2. How likely is it that the benefits of Gardasil outweigh the potential side effects?  
 
      Unlikely                                                       Likely 
1  2  3  4  5  6 7 
 
3. I would be embarrassed to let others know that I have HPV if I found out that I 
contracted the disease. 
 
Strongly Disagree       Strongly Agree 
1  2  3  4  5  6 7 
 
4. Getting HPV could hinder my ability to become pregnant. 
 
Strongly Disagree       Strongly Agree 
1  2  3  4  5  6 7 
 
5. Gardasil is effective in preventing an HPV infection. 
 
Strongly Disagree       Strongly Agree 
1  2  3  4  5  6 7 
 
6. What are your chances of developing cervical cancer if you didn’t get Gardasil?  
 





7. It would be difficult for me to ask for Gardasil because it’s associated with an 
STD. 
 
Strongly Disagree       Strongly Agree 
1  2  3  4  5  6 7 
 
8. Gardasil is effective in preventing genital warts. 
 
Strongly Disagree       Strongly Agree 
1  2  3  4  5  6 7 
 
9. In your opinion, how expensive is Gardasil? 
 
Very Inexpensive       Very Expensive 
1  2  3  4  5  6 7 
  
10. If I contracted HPV, it could hinder my present relationship. 
 
Strongly Disagree       Strongly Agree 
1  2  3  4  5  6 7 
.  
11. One of the benefits to getting Gardasil, is feeling that I’ve done everything I can 
do to protect myself against HPV. 
 
Strongly Disagree       Strongly Agree 
1  2  3  4  5  6 7 
 
12. Having to get multiple doses of Gardasil is time consuming. 
 
Strongly Disagree       Strongly Agree 
1  2  3  4  5  6 7 
 
13. Gardasil is effective in preventing cervical cancer. 
 
Strongly Disagree       Strongly Agree 
1  2  3  4  5  6 7 
 
14. What are your chances of contracting genital warts if you didn’t get Gardasil? 
 
0%  10%  20%   30%   40%   50%   60%   70%   80%   90%  100% 
 
15. Getting Gardasil is painful. 
 




1  2  3  4  5  6 7 
 
16. Gardasil is effective in preventing some types of oral cancer. 
 
Strongly Disagree       Strongly Agree 
1  2  3  4  5  6 7 
 
17. If I contracted HPV, it could hinder my future relationships. 
 
Strongly Disagree       Strongly Agree 
1  2  3  4  5  6 7 
 
18. In your opinion, how likely is it that Gardasil causes significant side effects? 
 
Very Unlikely         Very Likely 
1  2  3  4  5  6 7 
 
19. What are your chances of contracting genital warts if you didn’t get Gardasil 
compared to other college-aged women? 
 
0%  10%  20%   30%   40%   50%   60%   70%   80%   90%  100% 
 
20. Gardasil is effective in preventing the spread of HPV to partners.  
 
Strongly Disagree       Strongly Agree 
1  2  3  4  5  6 7 
 
21. I would worry about what my partner or future partners would think if I got 
Gardasil. 
 
Strongly Disagree       Strongly Agree 
1  2  3  4  5  6 7 
 
22. Getting Gardasil is important for my health.   
 
Strongly Disagree       Strongly Agree 
1  2  3  4  5  6 7 
 
23. What are your chances of contracting HPV if you didn’t get Gardasil compared 
to other college-aged women? 
 
0%  10%  20%   30%   40%   50%   60%   70%   80%   90%  100% 
 





Strongly Disagree       Strongly Agree 
1  2  3  4  5  6 7 
 
25. If I contracted HPV, it could harm my future health. 
 
Strongly Disagree       Strongly Agree 
1  2  3  4  5  6 7 
 
26. One of the benefits to getting Gardasil is peace of mind about my health. 
 
Strongly Disagree       Strongly Agree 
1  2  3  4  5  6 7 
 
27. What are your chances of developing cervical cancer if you didn’t get Gardasil 
compared to other college-aged women? 
 
0%  10%  20%   30%   40%   50%   60%   70%   80%   90%  100% 
 
28. Getting Gardasil would go against my beliefs. 
 
Strongly Disagree       Strongly Agree 
1  2  3  4  5  6 7 
 
29. If I found out I had contracted HPV, I would be devastated. 
 
Strongly Disagree       Strongly Agree 
1  2  3  4  5  6 7 
 
 
Perceived Severity Items: 3, 4, 10, 17, 25, 29 
 
Perceived Susceptibility Items: 1, 6, 14, 19, 23, 27, 
 
Perceived Benefits: 2, 5, 8, 11, 13, 16, 20, 22, 26 
 

















Given your answer to the above question (#__), how confident are you that you could get 
Gardasil? 
 
Not Confident                          Very Confident 










































Cues to Action 
 
1. Have you ever known anyone who has had HPV?  
 
Never  1 – 2 people  3 – 4 people  5+ people 
 
2. Have you ever known anyone who has had cervical cancer?  
 
Never  1 – 2 people  3 – 4 people  5+ people 
 
3. Has a health care provider ever recommended that you receive the HPV vaccine (Gardasil)? 
 
Never  1 – 2 times   3 – 4 times  5+ times 
 
4. Has a health care provider made you aware of the HPV vaccine’s (Gardasil) availability? 
 
Never  1 – 2 times  3 – 4 times  5+ times 
 
5. Did you learn about HPV in any of your health education classes in either college or high 
school? If so, how many times did you learn about it? 
 
Never  1 – 2 times  3 – 4 times  5+ times 
 
6. Have you ever known anyone who has had negative side effects from a vaccine?    
 
Never  1 – 2 people  3 – 4 people  5+ people 
 
7. Have you ever known anyone who has received the HPV vaccine (Gardasil)?    
 
Never  1 – 2 people  3 – 4 people  5+ people 
 
8. Have family members or friends talked to you about receiving the HPV vaccine (Gardasil)? 
 
Never  1 – 2 times  3 – 4 times  5+ times 
 
9. Have you ever seen an ad on TV about the HPV vaccine (Gardasil)?  
 
Never  1 – 2 times  3 – 4 times  5+ times 
 
10. Have you ever seen an ad in a magazine about the HPV vaccine (Gardasil)? 
 
Never  1 – 2 times  3 – 4 times  5+ times 
 
11. Have you ever seen a brochure about the HPV vaccine (Gardasil)? 
 









1. If they knew about the HPV vaccine (Gardasil), most people whose opinions I value 
would approve/disapprove of me getting vaccinated against HPV.  
 
Strongly Disapprove       Strongly Approve 
1  2  3  4  5  6 7 
 
2. If they knew about the HPV vaccine (Gardasil), my friends would approve/disapprove 
of me getting vaccinated against HPV. 
 
Strongly Disapprove       Strongly Approve 
1  2  3  4  5  6 7 
 
3. If they knew about the HPV vaccine (Gardasil), my parents would approve/disapprove 
of me getting vaccinated against HPV. 
 
Strongly Disapprove       Strongly Approve 
1  2  3  4  5  6 7 
 
4. If they knew about the HPV vaccine (Gardasil), my partner would approve/disapprove 
of me getting vaccinated against HPV. 
 
Strongly Disapprove       Strongly Approve 
1  2  3  4  5  6 7 
  
5. If they knew about the HPV vaccine (Gardasil), my doctor would approve/disapprove 
of me getting vaccinated against HPV 
 
Strongly Disapprove       Strongly Approve 
1  2  3  4  5  6 7 
 
6. If they knew about the HPV vaccine (Gardasil), most women who are important to me 
would get themselves vaccinated against HPV if they were at risk. 
 
Strongly Disagree       Strongly Agree 














Directions: Please answer the following questions about the human papillomavirus 
(HPV) and the HPV vaccine (Gardasil) to the best of your knowledge. 
 
1. Which of the following health issues are related to HPV? (Please select all that 
apply.)  
a. Cervical cancer 
b. Heart disease 
c. HIV 
d. Genital warts  
e. I don’t know 
Answer: a) cervical cancer, d) genital warts 
 
2. How do you think HPV is transmitted or spread? 
a. Coughing or sneezing 
b. Genital skin-to-skin contact 
c. Contact with bodily fluids (blood)  
d. I don’t know 
Answer: b) genital skin-to-skin contact 
 
3. How can HPV infection be prevented? (Please select all that apply.) 
a. By practicing abstinence 
b. By taking antibiotics 
c. By using condoms 
d. By being vaccinated  
e. I don’t know 
Answer: a) by practicing abstinence, d) by being vaccinated 
 
4. The HPV vaccine (Gardasil) may prevent which of the following. (Please select 
all that apply.)  
a. Genital warts 
b. Cervical cancer 
c. AIDS 
d. Herpes  
e. I don’t know 
Answer: a) genital warts, b) cervical cancer 
 
5. What is the main side effect associated with the HPV vaccine (Gardasil)? 
a. Vomiting 
b. Soreness at the site where the shot is given 
c. Headache 




e. I don’t know 
Answer: b) soreness at the site where the shot is given 
 








8. HPV is one of the most common sexually transmitted infections in the United 
States. 
 
TRUE  FALSE 
Answer: TRUE 
 



































Directions: Please answer the following questions according to how you perceive the 
HPV vaccine.  
 
1. What do you view as the greatest benefits of getting the HPV vaccination for 
yourself?  
 
2. What do you view as the greatest drawbacks of getting the HPV vaccination for 
yourself? 
 
Directions: If you have received the HPV vaccine, please answer the following question 
regarding what led you to get vaccinated and select the number that best describes your 
level of satisfaction with your decision.  
 
What factors led you to get vaccinated? 
 
 
How satisfied are you with your decision to receive the HPV vaccine? 
 
Not at all Satisfied        Very Satisfied 
1  2  3  4  5  6 7 
 
Directions: If you have not received the HPV vaccine, please answer the following 
question regarding what keeps you from getting vaccinated and select the number that 
best describes your level of satisfaction with your decision. 
 
What factors keep you from getting vaccinated? 
 
 
How satisfied are you with your decision to not yet receive the HPV vaccine? 
 
Not at all Satisfied        Very Satisfied 















HPV Vaccination Status 
 
Which of the following best describes your current situation? 
 
a. Have completed the series of 3 shots for the HPV vaccine. 
b. Have started, but not completed, the series of 3 shots for the HPV vaccine. 
c. Have scheduled an appointment with my doctor to receive the HPV vaccine. 





If you have received at least one of the HPV vaccine shots, please indicate the 
approximate date of vaccination:  
1
st
 shot ______________ 
2
nd
 shot ______________ 
3
rd
 shot ______________ 
 
 
If you have received only one or two of the HPV vaccine shots, do you plan to complete 
the vaccine series?  
 


























HPV Vaccination Intentions 
 
1. I want to get vaccinated against the human papillomavirus (HPV) within the next year.  
 
Strongly Disagree              Strongly Agree 
1  2  3  4  5  6 7 
 
2. I expect that I will get vaccinated against the human papillomavirus (HPV) within the 
next year. 
 
Strongly Disagree             Strongly Agree 
1  2  3  4  5  6 7 
  
3. I do not intend to get vaccinated against the human papillomavirus (HPV) within the 
next year. 
 
Strongly Disagree              Strongly Agree 
1  2  3  4  5  6 7 
 
4. I plan to make an appointment for an HPV vaccination within the next year. 
 
Strongly Disagree                         Strongly Agree 




























Thank you for your interest in this study, which is being conducted by researchers at the 
University of Maryland, College Park.  Your participation will contribute important knowledge 
regarding people’s attitudes toward a common sexually transmitted disease, HPV, and its 
prevention, the HPV vaccine.  This questionnaire will take most people approximately 15-20 
minutes to complete. It is important that you answer all questions in one sitting so, if you are 
completing this questionnaire on your own, please seek out a quiet place that is free from 
distractions while taking the study. At the end of the study, you will have the opportunity to seek 
additional information about the human papillomavirus (HPV).  
 
In order to better understand the attitudes of people toward this health topic, it will be necessary 
for the researchers to ask questions about perceptions and behaviors of the participants that are 
relevant to the subject of sexually transmitted diseases (STDs). Some of these questions may be 
personal in nature, including items inquiring about sexual behaviors. The responses of 
participants who are sexually active, as well as those who are not currently active or never have 
been, are all vital to the success of this research. Due to the personal nature of some of this 
material, it is important for you to know that the information you give will be kept confidential. 
You will not be asked for your name and if you are submitting the last name of a professor to get 
class credit for taking the study, this information will be stored separately from the rest of your 
questionnaire and will be destroyed as soon as we report your participation. All information will 
be stored in a secure, locked location to which only the investigators have direct access. 
 
Risks associated with this study may include feeling discomfort in response to some content or 
inadvertently disclosing your responses if the survey is not taken in private. However, you do not 
have to answer any questions that make you feel uncomfortable. Benefits include the likelihood 
that you will learn information about a common STD that might help to protect your health now 
or in the future and that you are contributing to research about an important health topic. Your 
participation in this study is voluntary and you may choose not to participate and may stop at any 
time. If you experience any difficulty in submitting your responses please contact the first 
researcher at the email address below. 
 
If you have any questions or comments about the study, please feel free to contact either of the 
researchers (contact information below). If you have questions about your rights as a research 
subject, please contact the Institutional Review Board (also below). This research has been 
reviewed according to the University of Maryland, College Park IRB procedures for research 
involving human subjects. Thank you again for your participation. By giving your consent to 
participate, you indicate that: 1. you are at least 18 years of age, 2. the research has been 
explained to you, 3. your questions have been fully answered and 4. you freely and 
voluntarily choose to participate in this research project. If you agree with these 
statements and consent to participate, please click on the 'Continue' button below. 
 
Kathryn Schaefer     Mary Ann Hoffman, Ph.D. 
Counseling Psychology Program   Professor, Counseling Psychology  
CAPS Department     CAPS Department 
University of Maryland     University of Maryland  





At the beginning of the study, we recommended that you take this survey alone in order 
to ensure that your responses were accurate and not influenced by others who may have 
been with you when you took the survey. You will receive class credit or be entered into 
a gift certificate drawing regardless of how you answer the following question, but we 
ask that you answer honestly.  
Did you consult with anyone while taking this survey or did anyone else influence your 
answers? 
YES  NO 
 
Thank you so much for participating in this study! Please read the following to make 
certain you get class credit, if applicable. This information will be kept separate from the 
rest of your responses. 
If you are participating for class credit, please write the following below. 
1. Your university 
2. The last name of your instructor 
3. A self-generated 4 digit ID number (ex. the last four digits of your cell phone, social 
security number, or student ID number). 
In order to receive credit for participating in this study, please email your 4-digit 
number to the researcher at kschaefe@umd.edu. 
 
If you are not taking this for class credit, please answer the questions below: 
1. University name 
2. Where you learned about this study (ex. ―sorority‖ or ―class 325‖). 
 
 
If you are NOT taking this for class or community service credit and would like to enter a 
raffle for a $40 gift certificate, please email the researcher (AFTER submitting your 
survey with the above information) at kschaefe@umd.edu and put the word ―raffle‖ as 






Links to More HPV Information 
 
1. This link leads to a fact sheet including Frequently Asked Questions about human 




2. This link will connect you with lots of information about the HPV virus and its vaccine 




3. This link to the American Social Health Association’s (ASHA) National HPV and 
Cervical Cancer Prevention Resource Center has information, chat rooms, support 
groups, and publications about HPV, as well as ways to get involved in the prevention 




4. This link leads to information from the International Council on Infertility Information 



















Email to Participants 
 
A research study about attitudes toward the HPV vaccine 
Would you be interested in participating in a study exploring factors that affect a 
person’s attitudes toward a common sexually transmitted disease (HPV) and its 
prevention (the HPV vaccine)? Participation requires completing a one-time online 
survey, which will take approximately 15-20 minutes to complete, on a secure website. In 
order to better understand the attitudes of people toward this health topic, it will be 
necessary for the researchers to ask questions about perceptions and behaviors of the 
participants that are relevant to the subject of sexually transmitted diseases (STDs). Some 
of these questions may be personal in nature, including items inquiring about sexual 
behaviors. The responses of people who are sexually active, as well as those who are not 
currently active or never have been, are all vital to the success of this research. Due to the 
personal nature of some of this material, it is important for you to know that the 
information you give will be kept confidential. Risks associated with this study may 
include feeling discomfort in response to some content or inadvertently disclosing your 
responses if the survey is not taken in private. However, you do not have to answer any 
questions that make you feel uncomfortable. Benefits of participation include the 
likelihood that you will learn information about a common STD that might help to protect 
your health now or in the future and that you are contributing to research about an 
important health topic. The study is being conducted by Ms. Kathryn Schaefer, a doctoral 
student, and Dr. Mary Ann Hoffman, Ph.D., a professor at the University of Maryland, 




Participation in this research is completely voluntary.  If you are interested, visit 
the website below to be taken to PsychData, a secure website that hosts the survey. Once 
you are there you will be able to review a brief description of the survey, and read an 
informed consent form before you decide to participate.  








































 Scree Plot for Perceived Susceptibility 
  
 
Total Variance Explained for Perceived Susceptibility 
 
Factor 
Initial Eigenvalues Extraction Sums of Squared Loadings 
Total % of Variance Cumulative % Total % of Variance Cumulative % 
1 4.334 72.234 72.234 4.031 67.188 67.188 
2 .590 9.834 82.068    
3 .566 9.436 91.503    
4 .277 4.612 96.115    
5 .122 2.030 98.145    













Total Variance Explained for Perceived Severity 
 
Factor 
Initial Eigenvalues Extraction Sums of Squared Loadings 
Total % of Variance Cumulative % Total % of Variance Cumulative % 
1 2.627 43.788 43.788 2.079 34.642 34.642 
2 1.030 17.160 60.948    
3 .752 12.540 73.489    
4 .726 12.098 85.587    
5 .562 9.372 94.958    







Scree Plot for Perceived Benefits 
 
Total Variance Explained for Perceived Benefits 
 
Factor 
Initial Eigenvalues Extraction Sums of Squared Loadings 
Total % of Variance Cumulative % Total % of Variance Cumulative % 
1 3.601 40.010 40.010 3.039 33.762 33.762 
2 1.388 15.417 55.427    
3 .922 10.241 65.667    
4 .849 9.429 75.096    
5 .669 7.438 82.534    
6 .526 5.841 88.376    
7 .471 5.236 93.611    
8 .331 3.674 97.285    





Scree Plot for Perceived Barriers 
 
Total Variance Explained for Perceived Barriers 
 
Factor 
Initial Eigenvalues Extraction Sums of Squared Loadings 
Total % of Variance Cumulative % Total % of Variance Cumulative % 
1 2.206 27.571 27.571 1.574 19.680 19.680 
2 1.414 17.671 45.242    
3 1.206 15.070 60.313    
4 .791 9.882 70.194    
5 .751 9.390 79.584    
6 .679 8.487 88.071    
7 .535 6.693 94.764    
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